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Chapter 1 
 
General introduction  
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Chronic pain 
 
Chronic pain is recognized as a common, persistent problem within the 
community with relatively high incidence and low recovery rates [1]. In 
the Dutch community, for musculoskeletal pain of the general population, 
20 to 27 percent of the population reports continuous or repetitive pain 
from neck, shoulder or back (RIVM). Chronic pain is one of the most 
common reasons why people seek medical care [2, 3]. Pain is a 
multidimensional sensory experience that is intrinsically unpleasant and 
associated with hurting and soreness. Although we tend to think of pain as 
a homogeneous sensory entity, several distinct types exist: nociceptive 
(transient pain in response to a noxious stimulus), inflammatory 
(spontaneous pain and hypersensitivity to pain in response to tissue 
damage and inflammation), neuropathic (spontaneous pain and 
hypersensitivity to pain in association with damage to or a lesion of the 
nervous system) and functional (hypersensitivity to pain resulting from 
abnormal central processing of normal input) [4]. Pain is also associated 
with avoidance motor reflexes and alterations in autonomic output. Pain 
has physical, cognitive and emotional components. Likewise, the 
treatment of chronic pain has a multimodal character and consists of 
medical, psychological and behavioral measures. A frequently applied 
medical therapy in chronic pain is electrical stimulation of structures of the 
nervous system. Examples are spinal cord stimulation [5], motor cortex-
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stimulation [6], and transcutaneous electric nerve stimulation (TENS) [7]. 
In this thesis we concentrate on TENS in patients with chronic pain.  
 
TENS  
 
In the treatment of chronic pain, TENS has the advantage that it is easy to 
administer - after instruction and a short trial period patients can apply 
TENS themselves - and apart from (reversible) skin irritation it has no 
serious side effects. TENS is a method of applying low-voltage electrical 
current through the skin using surface electrodes to achieve pain control 
[8]. The use of electricity for pain control was documented in classical 
medicine by the first century [9]. By the mid 1700s electricity was 
employed to treat a variety of diseases and pain [10]. After the interest in 
electrical stimulation for pain control had dissipated in the early part of 
the nineteenth century, a new interest in stimulation emerged with the 
presentation of the gate control theory [11]. For clinical application, TENS 
was first presented as a screening tool for spinal cord stimulation. Soon it 
became apparent that stimulation of the skin was often sufficient to 
provide pain control. The first data on TENS were presented in 1973 at the 
founding meeting of The International Association for The Study of Pain 
[10]. 
 
Apart from pain relief, TENS has been found to give rise to less pain 
interference with work, home and social activities, increased activity level 
 10 
 
and pain management and decreased use of other therapies including pain 
medication [8]. However the effects of TENS in chronic pain still raise two 
important questions. Firstly, there are no long-term placebo controlled 
studies and the results of short-term controlled studies in the treatment of 
chronic pain are inconclusive [7, 12], thus questioning the specific working 
mechanism of TENS. Secondly, the efficacy of TENS treatment is assumed 
to decrease in time by long-term application of TENS [10, 13], thereby 
endangering the long term use of TENS in chronic pain. 
 
There are several causes that may account for the inconclusive results of 
the studies in the treatment of TENS in patients with chronic pain. 
One problem is the blinding of patients to the assigned treatment; the 
credibility of the sham TENS as a placebo has been challenged because of 
the absence of the typical buzzing or tingling sensation accompanying the 
regular TENS treatment. Because expectancy is considered a critical 
underlying mechanism of the placebo effect [14], patient’s believe in 
receiving an effective treatment [15] - which would be crucial in evoking a 
placebo response - is therefore threatened. Because of the current lack of 
providing evidence on the success of blinding of patients to the assigned 
treatment [16-18], apart from the study of Deyo [16], the credibility of 
sham TENS remains unknown. However, in TENS studies placebo response 
rates range from 40 to more than 60% [19]. So possibly, placebo 
responses in TENS studies are either low or high, depending on the 
credibility of the sham TENS application. Importantly, high placebo 
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responses may contribute to the problem of demonstrating the efficacy of 
(TENS) treatment [19, 20]. Therefore, for clarifying the specific effects of 
TENS compared to sham TENS it might be necessary to explore the 
mechanisms of effect of TENS compared to sham TENS application as well 
as comparing effect sizes, while taking care of using a credible placebo. 
Using quantitative sensory testing (QST), by measuring pain thresholds, 
we may gain insight in the inhibitory and excitatory processes during 
treatment of pain by TENS vs. sham TENS. Quantitative sensory testing 
quantifies nervous system input-response relations, allowing detection and 
quantification of nociceptive neuroplasticity [21]. 
 
Another important cause for the inconclusive results may concern the 
application of TENS itself. Firstly, in the reviewed studies the TENS 
application often was applied intermittently for only short periods with 
stimulation times of less than 10 hours per week [7]; this treatment is of 
shorter duration and stimulation time than recommended treatments [13]. 
Secondly, an underexposed subject is that in animal research results of 
different TENS applications have been found to depend on pain type. In 
animal models, effects of high and low frequency TENS have been 
extensively studied in inflammation [22] and to a lesser extent in nerve 
ligation [23]. High frequency TENS reverses primary and secondary 
hyperalgesia induced by carrageenan inflammation [24-29], but in 
contrary to low frequency TENS, High frequency TENS does not diminish 
mechanical hyperalgesia following chronic constriction injury of the rat 
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sciatic nerve [23]. However, whether these findings in animal research are 
valid for chronic pain in human research, still needs to be explored.  
 
Finally, The use of different pain outcome measures may also account for 
contrary effects; e.g. in patients with chronic low back pain, Moore et al 
[30] found a significant difference in pain relief, for TENS treatment 
compared to placebo measured by a pain relief scale, but documented no 
pain reduction using a visual analogue scale (VAS). So, patients did 
experience pain relief after a short treatment period, although this could 
not be retrieved by diminished VAS scores. Measuring pain intensity by 
VAS [12] and calculating group means is very common to evaluate 
differences between TENS and sham TENS. However, situations might 
arise in which a particular treatment application produces a substantial 
benefit in a moderate proportion of patients, but no change in others. For 
bimodal data, when there is little or no difference in group mean values, it 
is still possible that there might be a statistical significant difference in 
proportions of patients achieving a clinical important benefit, as discussed 
by Farrar et al [31]. A problem may arise, when trying to define “a clinical 
important improvement” for the result of TENS treatment, when TENS is 
applied for short periods. Marchand et al [32] found for patients with low 
back pain, that TENS significantly decreased pain intensity rating in a 
cumulative manner over repeated treatment sessions. So for shorter 
periods of TENS treatment, less pain reduction may be expected than for 
longer treatment periods. After 3 months of TENS treatment, Eriksson et 
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al [33] found 50% pain relief or more in 72% of the patients with chronic 
pain, who were satisfied with treatment result and continued to use TENS 
after an initial short trial period. This outcome measure is more commonly 
used to evaluate TENS treatment effect in daily practice, and is assumed 
to reflect the result of a balance between effort and therapeutic result 
[34].  
 
Aim of this thesis 
 
The aim of this thesis is to explore both quantitative and qualitative 
effects of high frequency TENS compared to sham TENS (placebo) 
application in patients with chronic pain, in which we answer the following 
research questions: 
1) Is there a difference in time course for pain relief between TENS and 
sham-TENS application in patients treated for chronic pain. 
2) Does the pain relief as a result of TENS decrease in time by long-
term TENS application. 
3) Which pain characteristics determine the effect of high frequency 
TENS? 
4) Do the mechanisms of pain relief differ for TENS compared to sham 
TENS application.  
Therefore we performed a prospective randomized placebo controlled trial. 
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In chapter 2 we describe the (short term) results of high frequency TENS 
vs. sham TENS for pain intensity and satisfaction with treatment result 
after ten days of treatment.  
In chapter 3 we show the long-term results of TENS and sham TENS 
application. 
In chapter 4 we describe the results of a literature survey of TENS in 
animal research, to explore the association of TENS characteristics and 
effect on hyperalgesia in nociception, inflammation and nerve ligation. 
In chapter 5 we show the results of pain characteristics predicting effects 
of conventional TENS, in patients with chronic pain. 
In chapter 6 we describe the results of a pilot-study in which we used 
QST to explore the mechanisms of TENS and sham TENS in the treatment 
of chronic pain. 
In chapter 7, the general discussion, we discuss the findings of our 
research questions and the consequences for treatment and further 
research. 
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Introduction 
 
Transcutaneous electrical nerve stimulation (TENS) is an easy to use, non-
invasive intervention that alleviates pain. Although TENS treatment has 
been used since the early 1970s, results of treatment of patients with 
chronic pain are still inconclusive [7, 12]. These unclear results may be 
due to the fact that TENS treatment was applied intermittently for only 
short periods with stimulation time of less than 10 hours per week [7], in 
different poorly defined modalities [12]. This treatment is of shorter 
duration and stimulation time than recommended treatments [13]. 
Furthermore, the use of different pain outcome measures gave contrary 
results, e.g. in patients with chronic low back pain, Moore et al [30] found 
a significant difference in pain relief for TENS treatment as measured by a 
pain relief scale, but documented no pain reduction using a visual 
analogue scale (VAS), both compared with placebo, after two days of 
treatment. So patients did experience relief after this short treatment 
period, although this could not be retrieved by diminished VAS scores. 
In exploring effect of TENS treatment in chronic pain, measuring pain 
intensity by VAS [12] and calculating group means is very common to 
evaluate differences between TENS and sham TENS, assuming continuous 
and normally distributed data. However, situations might arise in which a 
particular treatment application produces a substantial benefit in a 
moderate proportion of patients, but no change in others. In this case, it 
is important to know that in animal research high frequency TENS is 
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effective in reducing hyperalgesia in the inflammatory pain model in rats 
[24], but not in a rat model of peripheral nerve ligation [23]. Also, for 
placebo response it is assumed that patients either do respond or do not 
respond [15]. For bimodal data, when there is little or no difference in 
group mean values, it is still possible that there might be a statistical 
significant difference in proportions of patients achieving a clinical 
important benefit, as proposed by Farrar et al [31]. A problem may arise, 
when trying to define “a clinical important improvement” for the result of 
TENS treatment, when TENS is applied for short periods. A 50% change in 
pain intensity has been used to evaluate TENS treatment effect in patients 
with osteoarthritis; Smith et al [35] found 50% or more relief in pain 
intensity in 67% and 27% of the patients treated with TENS and sham-
TENS respectively; treatment was applied 8 times for 20 minutes in a 
period of 4 weeks. However, Marchand et al [32] found in patients with 
low back pain, that TENS significantly decreased intensity rating in a 
cumulative manner over repeated treatment sessions. So for shorter 
periods of TENS treatment, less pain reduction may be expected than for 
longer treatment periods. 
Willingness to continue TENS is more commonly used to evaluate 
treatment effect in daily practice and is assumed to reflect the result of a 
balance between effort and therapeutic result [34]. After 3 months of 
TENS treatment, Eriksson et al [33] found 50% pain relief or more in 72% 
of the patients with chronic pain, who continued to use TENS after an 
initial short trial period. Therefore, willingness to continue TENS seems to 
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be a preferable and clinical relevant outcome measure to evaluate short-
term effects of TENS.  
The aim of this study is to test the efficacy of short-term TENS treatment 
with respect to these outcome measures. Our primary research question 
is: is there a difference in the proportions of patients with chronic pain, 
satisfied with the initial treatment result and willing to continue TENS or 
sham-TENS, after a short treatment period? Our secondary questions are: 
is there a difference in relief in pain intensity between patients treated 
with TENS or sham-TENS, and do patients treated with TENS or sham-
TENS and who are satisfied with the initial treatment result, differ in relief 
in pain intensity from each other and from those who do not continue 
treatment? 
 
Methods and Materials 
 
Design 
We performed a prospective, randomized and controlled trial comparing 
TENS and sham-TENS. A concealed block-wise randomization procedure 
was used, and patients, therapists and research assistants were blinded 
for treatment allocation. 
 
Subjects  
Patients with chronic pain participating in this study were referred to the 
Pain Centre of the Radboud University Medical Centre Nijmegen by their 
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family doctor (approximately 30%) or by a medical specialist 
(approximately 70%). Anesthesiologists and physiotherapists of the Pain 
Centre screened patients for TENS treatment. 
Patients were eligible for this study if they met the inclusion criteria. 
Inclusion criteria were: 1) patients with chronic pain of benign origin 
referred to the Pain Centre, 2) duration of pain > 6 months, 3) age above 
18 years. Exclusion criteria were 1) previous TENS treatment (because 
this could affect sham TENS credibility [16]), 2) pain in face or head 
(because visible electrode placement might affect compliance, and hair 
could impair optimal electrode placement), 3) several different pain sites 
(because of the limited area TENS electrodes can serve), 4) history of a 
cerebral vascular accident (because possible spinothalamocortical pathway 
damage could affect the outcome of TENS – and possibly sham TENS 
treatment, too), 5) no relatives/friends to help replace electrodes, thus 
jeopardizing optimal TENS use), 6) involvement in ongoing litigation 
because of their pain [34] and 7) psychological intervention proposed by 
the Pain Centre psychologists (this would interact with TENS treatment 
outcome in an unpredictable way, and withholding it would be unethical). 
Eligible patients were included in this study after signing informed 
consent. The Central Committee on Research Involving Human Subjects 
approved this study. 
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Apparatus  
For TENS and sham TENS treatment, identical devices (ELPHA II 1000, 
Danmeter A/S, Denmark) were used which were specially prepared for 
this study. On the devices’ display, the current intensity level was visible 
with a warning indicator for low battery load. Stimulation pulse frequency 
was set to 80 Hz and pulse width to 50 s for both channels (high 
frequency TENS). Pulses were delivered with an asymmetrical biphasic 
waveform in a continuous pattern. Maximum output was 40 mA constant 
current at a minimum of 2.0 kOhm electrode resistance. Sham TENS 
devices showed a maximum of 10 or 20 mA on the display, but no current 
was actually delivered to the electrodes. Duration of actual use of the 
device (referred to as “compliance”) was registered and could be read out 
by pressing a special key combination. Patients were not aware of this 
feature. Disposable 5 cm  6.4 cm self-adhering electrodes were used with 
an active area of 6.5 cm2.  
 
General procedure 
Patients eligible for the TENS treatment received written information in 
which they were asked to participate in the study. In the letter, it was 
explained that TENS seems to be effective at high and low intensities, and 
that treatment would be by one of these two options. There would also be 
a chance of receiving a sham TENS device in which the settings of pulses 
were neither effective nor harmful.  
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After inclusion, baseline measures were carried out and details of the 
TENS treatment procedure were explained. Patients were told that 
“chronic pain is due to changes in the central nerve system, which 
function as an amplifier for pain stimuli, and that TENS would serve as an 
inhibitory control button for this amplifier by using specific mild 
stimulation”. For seven days before planned start of treatment, patients 
had to fill in a visual analogue scale for pain (VAS) at the same time every 
day, starting on Friday.  
The next Friday – when treatment was started – the patient visited the 
physiotherapist for electrode application and for instruction on both TENS 
treatment modalities. Electrodes were applied over the superficial 
cutaneous nerves in the painful segment(s), determined by the 
physiotherapist, who also showed how to replace them accurately if 
necessary [36]. Next the physiotherapist let the patient experience the 
tingling (not pricking) sensation accompanying “high intensity” TENS. 
Stimulation intensity was then decreased to determine the level at which 
the patient did not experience any sensation. This was explained to be 
“low intensity” TENS. This intensity was adjusted to 10 or 20 mA by the 
physiotherapist (but not visible for the patient) if necessary, and the 
setting shown to the patient to make the patient believe that at 10 or 20 
mA, he or she would not experience any sensation. 
Once acquainted with the method of treatment, the patient left the room 
and visited the research assistant whose only task was to deliver the high 
frequency or sham TENS device to the patient, as determined by the 
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randomization list. With a written instruction how to use the device, and 
not to change pain medication the patient left the outpatient clinic. Ten 
days later, the patient returned for evaluation of the treatment effect. 
Before visiting the researcher, the receptionist asked the patient to leave 
the “TENS” device with her, “to check it for proper function”. The reason 
was twofold: the receptionist could register the TENS use, and the 
researcher would not have access to the TENS device.  
 
Outcome measures  
The primary outcome was the proportion of patients satisfied with the 
initial treatment result and willing to continue treatment (yes or no). 
The secondary outcome measure was pain intensity. Pain intensity was 
measured using a 10-centimeter VAS, ranging from no pain at all to the 
most intense pain imaginable [37]. Patients were instructed to rate their 
pain from that particular moment on the same time every day for a period 
of 14 days, starting one week before treatment. Multiple measures of pain 
intensity across time maximize the reliability and validity of pain 
assessment [38]. 
 
Compliance and placebo credibility  
Duration of TENS use served as a measure for compliance. Data collection 
for TENS use was performed by the receptionist while the patient visited 
the researcher for treatment evaluation.  
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During evaluation of short-term effects, patients were asked how certain 
they felt about having a TENS or sham device using a questionnaire 
according to Deyo et al [16]. 
 
Sample size  
Two main evaluations were planned for this study: a short-term 
evaluation after ten days of treatment and a long-term evaluation after 
one year of treatment. The number of patients in each treatment group 
was based on long-term outcome. Assuming that 35% of the patients in 
the TENS group and 15% in the sham-TENS group would be successfully 
treated after one year, then 72 patients per group would be needed to 
show this difference for a power of 80% and a two-sided alpha value of 
P= 0.05 (chi square test). Allowing for dropouts, this suggested the 
inclusion of about 80 patients per group. 
 
Statistical methods  
All analyses were based on the intention-to-treat population, defined as all 
randomized patients that started with treatment. The level of significance 
used was 0.05. The primary outcome parameter was the proportion of 
patients willing to continue (sham) TENS (yes or no). The difference 
between the two treatment groups was tested with the chi square test. 
The second outcome parameter was the difference in the time course of 
the VAS-score during the first treatment week and the mean of the VAS-
score in the baseline week. These were analyzed using a mixed repeated 
 26 
 
measures model, including as fixed factors time (day), treatment (TENS 
and sham TENS), and all their first-order interactions and furthermore a 
random intercept per patient. In addition, we performed secondary, post 
hoc testing for the differences in VAS time courses between patients 
continuing and not continuing treatment in the two treatment groups 
using a mixed repeated measures model, including the fixed factors 
treatment (TENS and sham TENS) and result of treatment (continuing 
treatment or not), the repeated measures factor time (day), and all their 
first-order interactions and furthermore a random intercept per patient. 
Differences in compliance were analyzed using Wilcoxon’s two-sample 
test. Relationship between patients’ opinion about device type and real 
TENS or sham TENS use was analyzed using a chi square test. For the 
strength of the associations, the phi coefficient was calculated. Phi is 
interpreted as a Pearson r and phi squared is the proportion of the total 
distribution of the variables measured, which is explained by the 
relationship. 
 
Results  
 
Subjects  
From January 2000 until January 2003, 406 consecutive patients were 
proposed for TENS treatment. Two hundred and three patients were 
excluded. One hundred and sixty-five patients signed informed consent. 
Two of the included patients withdrew before the actual treatment took 
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place, they were both assigned to the TENS group. Therefore, 163 
patients entered this study, for details see Figure 1.  
 
Patients proposed for TENS treatment and assessed for eligibility (n=406)
Exclusions (n=203):
Formerly treated with TENS (n=77)
Pain in head or face (n=19)
Several unrelated sites of pain (n=37)
Cerebral vascular accident (n=11)
No help to replace electrodes (n=2)
Ongoing litigation (n=5)
Psychological intervention (n=50)
Did not speak Dutch language (n=2)
No informed consent (n=38):
Extra visits (n=20)
Being at risk for placebo (n=9)
Possible delay of treatment (n=8)
Felt uncertain (n=1)
Patients randomized (n=165)
TENS treatment
(n=81)
Sham-TENS
(n=82)
Withdrawal (n=2):
Being at risk for placebo
 
Figure 1. Trial profile. 
 
The main pain diagnosis were: Nerve injury, compression or surgery and 
diabetic neuropathy (n=17); dorsal root injury, compression or surgery 
(n=24); articular degeneration and osteoporosis of the spine (n=47); 
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articular degeneration of hip knee or ankle (n=5); unclassified limb or 
back pain (n=10); bursitis and tendonitis (n=12); post fracture or post 
surgery pain (n=33); visceral pain (n=7); whiplash injury (n=8). 
Demographic data and pain characteristics were similar for the TENS and 
sham-TENS groups (Tables 1 and 2). The baseline week’s time course for 
pain VAS values did not differ between the TENS and sham TENS groups. 
Baseline VAS time course was also similar for patients willing to continue 
treatment or not, see Figure 2.  
 
 
 TENS 
(n=81) 
Sham-TENS 
(n=82) 
Total 
(n=163) 
 
Age  
Mean ± SE years 
 
 
 
48.4 ± 1.6 
 
 
51.6 ± 1.4 
 
 
50.2 ± 1.1 
Gender, n (%) 
Male 
Female 
 
33 (41) 
48 (69) 
 
33 (40) 
49 (60) 
 
66 (40) 
97 (60) 
 
Nationality, n (%) 
Dutch  
Others  
 
 
79 (98) 
2 (2) 
 
81 (99) 
1 (1) 
 
160 (98) 
3 (2) 
Civil state, n (%)  
Single 
Married /partner 
Divorced  
Widow (er) 
 
 
10 (12) 
67 (83) 
1 (1) 
3 (4) 
5 (6) 
71 (87) 
4 (5) 
2 (3) 
15 (9) 
138 (85) 
5 (3) 
5 (3) 
Education, n (%) 
Elementary school 
Secondary education 
Higher education 
University 
 
13 (16) 
54 (67) 
12 (15) 
2 (2) 
 
15 (18) 
59 (72) 
8 (10) 
0 (0) 
 
28 (17) 
113 (69) 
20 (13) 
2 (1) 
    
 
 Table 1. Baseline demographic details  
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Outcome  
The proportion of patients willing to continue treatment differed 
significantly (chi square=3.8, P=0.05) for TENS (58%) compared to sham 
TENS (42.7%). Pain intensity was significantly reduced for factor time (P< 
0.001), but not for treatment modality (P= 0.53), or interaction of time 
and treatment modality (P= 0.52) during the treatment week. With post 
hoc testing, pain intensity for patients willing to continue treatment 
differed significantly (in time and magnitude; P< 0.001) from patients not 
willing to continue treatment, only for the treatment week.  
Mean proportion of relief in pain intensity, for patients willing to continue 
treatment, was 28.5% (SEM=3.9%); 27.0% (SEM=5.0) for the TENS 
group and 30.6% (SEM=6.5) for the sham TENS group. Pain intensity 
increased for 1% (SEM=8.0) in the TENS group and for 10% (SEM=5.0) in 
the sham TENS group, for patients not willing to continue treatment. 
There were however, again no differences according to treatment 
modality. The time course of pain intensities is illustrated in Figure 2. 
 
Compliance and placebo credibility 
Compliance data were missing in two patients, both in the TENS group; 
from one because of a device handling mistake during retrieval of the 
data, and from another due to technical TENS device failure. There was no 
significant difference in compliance, measured via duration of device 
operation, between the TENS and sham TENS groups (P=0.89). However, 
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TENS 
(n=81) 
Sham-TENS 
(n=82) 
Total 
(n=163) 
 
Intensity of pain, VAS 0-100 mm 
Mean ± SE 
 
 
 
62.2 ± 2.1 
 
 
61.5 ± 2.0 
 
 
61.9 ± 1.4 
Duration of pain (years) 
Mean ± SE 
Median (Range) 
 
 
6.2 ± 0.8 
3.6 (0.6 – 42.1) 
 
6.6 ± 0.9 
4.1 (0.2 – 58.7) 
 
6.4 ± 0.6 
3.7 (0.2 – 58.7) 
Variation of pain during the day, 
n (%) 
Almost constant pain 
Not changing 
Increasing during the day  
Decreasing during the day 
Variable pain 
No pain free moments 
With pain free moments 
Other  
 
 
 
 
29 (36) 
30 (37) 
1 (1) 
 
16 (20) 
5 (6) 
0 (0) 
 
 
 
 
18 (22) 
39 (48) 
1 (1) 
 
18 (22) 
4(4) 
2 (2) 
 
 
 
 
47 (29) 
69 (42) 
2 (1) 
 
34 (21) 
9 (5) 
2 (1) 
 
Origin of pain, n (%) 
Accident  
Surgery 
Disease  
Injury  
Long period of overstraining  
Other  
Not known by patient  
 
 
23 (28) 
19 (23) 
6 (7) 
5 (6) 
9 (11) 
2 (2) 
17 (21) 
 
18 (22) 
22 (27) 
11 (13) 
4 (5) 
14 (17) 
0 (0) 
13 (16) 
 
41 (25) 
41 (25) 
17 (10) 
9 (6) 
23 (14) 
2 (1) 
30 (18) 
Pain course, n (%) 
Gradually  
Sudden onset  
 
 
25 (31) 
56 (69) 
 
30 (37) 
52 (63) 
 
55 (34) 
108 (66) 
Recurrent pain, n (%) 
I had these complaints before 
This was the first time  
 
 
38 (47) 
43 (53) 
 
38 (47) 
43 (52) 
 
76 (47) 
86 (52) 
 
Table 2. Baseline pain characteristics  
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in patients not willing to continue treatment, the sham TENS group used 
the device for slightly longer than the TENS group (P=0.04; see Table 3).  
We found a significant relationship between patients’ opinion about having 
a sham or real TENS device and actually having a sham or real TENS 
device (chi square =13.2, P<0.001, phi=0.28). 
 
 
 
Figure 2. Time course of VAS scores (mean±SEM) for satisfied patients 
(+) and not satisfied patients (-) of the TENS and sham TENS group, 
during baseline (day 1-7) and treatment period (day 8-14). 
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Treatment  Satisfied? n Missing Mean  (SD) 
Sham TENS No 47 0 11.6* (4.9) 
TENS No 33 1 9.8* (2.7) 
Sham TENS Yes 35 0 11.0 (3.7) 
TENS Yes 46 1 11.5 (4.4) 
 
Table 3. Sham/TENS use in hours per day (Compliance). 
* P=0.04 for difference in compliance between sham TENS and  
TENS for patients not satisfied with treatment result. 
 
Discussion  
 
The proportion of patients satisfied with treatment result and willing to 
continue treatment was greater in the TENS group compared to the sham 
TENS group. However, we found no difference in pain intensity over time 
between patients receiving TENS or sham TENS. Pain intensity equally 
decreased during both treatment applications, only for patients satisfied 
with treatment result and willing to continue treatment. For patients not 
willing to continue treatment, pain intensities did not differ from baseline 
values. As shown in Figure 2, the results of real/sham TENS appeared to 
be initiated right from the start of treatment and to increase with time, 
during repeated treatment applications. 
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Comparison of our results with those of other TENS studies in chronic pain 
In our study 58% of the patients were willing to continue TENS after an 
initial short trial period, which result is in accord with the results of Köke 
et al [39], who found 56% of the patients willing to continue TENS 
treatment after a trial period of two weeks.  
For those patients willing to continue treatment, pain intensity decreased 
on average, equally for TENS and sham TENS, by 28.5% compared to 
baseline, which is comparable to the results of Köke et al [39], who found 
for patients with a positive assessments an average 33.5% pain reduction, 
after two weeks of TENS treatment. Other reported relative differences in 
percentage change in pain severity from baseline ranged from 11 to 38% 
[40]. For the TENS treatment group as a whole, we found an average pain 
reduction of 16%, which falls within this range. 
Perhaps more important is the fact that our findings clearly show that 
TENS significantly decreased pain intensity ratings in a cumulative manner 
over repeated treatment sessions, in contrast to animal research, where 
repeated TENS administration results in gradual diminution of analgesic 
effect via opioid tolerance [41], but (except for the sham TENS) in line 
with the results of Marchand et al [32]. However, how much the pain 
results will improve when extending the treatment period needs to be 
investigated. These findings may be one reason to explain the 
inconclusive results for TENS in chronic pain [12], as duration and 
frequency of TENS stimulation sessions varies largely between studies, 
and in general, stimulation periods were short and frequency of 
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application was low [7]. Osiri et al [42] found, as a result of reviewing 
TENS studies in osteoarthritis, that a significant difference in pain relief 
was achieved in studies with an intervention period of TENS application of 
at least 4 weeks.  
In our study we applied high frequency TENS with a frequency of 80 Hz, a 
short pulse width of 50 s and low intensity stimulation to selectively 
stimulate A-beta afferent neurons in the segment(s) of pain. This was 
assured by making the patient experience the different sensations of 
tingling (A-beta fibers) and pricking (nociceptive A-fibers) [43]. Patients 
used their device on average from 9.8-11.6 h a day, which is common in 
the treatment of chronic pain [13, 44]. Whether different application 
parameters for TENS would have improved our results is questionable. 
Köke et al [39] used high frequency TENS comparable with our TENS 
application and found no difference in results of either high or low 
intensity stimulation. Nash et al [45] compared continuous and pulsed 
high and low frequency TENS at multiple intensity levels with a maximum 
just tolerated by the patients; they found however no differences in effect 
for the different TENS applications. In both studies, like in our study, 
patients were treated for various pain conditions. Recently, Defrin et al 
[46] found noxious high frequency stimulation to be more effective than 
innocuous stimulation in patients with osteoarthritis. However, they used 
a not portable device with a stimulation frequency of 4000 Hz, which 
makes it less comparable with the standard TENS application. 
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Differences regarding outcomes 
Our results suggest that pain intensity measured by VAS vs. asking the 
patient’s opinion about treatment result represents different, albeit 
related, pain outcome endpoints. Since we found no differences in pain 
improvement by VAS scores between the TENS and sham TENS group, it 
would seem that patient’s opinion about treatment result reflects the 
additional integration of factors apart from pain in assessing the clinical 
success of treatment. However it should be noted that, VAS scores for 
pain intensity were measured once a day at a fixed time, reflecting the 
pain intensity at that particular moment, whereas patient’s opinion about 
treatment result should include all improvements experienced by the 
patient during the whole treatment period. Interestingly, for patients 
satisfied with treatment result and willing to continue treatment, the mean 
pain reduction was 28.5%, a clinically important difference [47], whereas 
for patients not willing to continue treatment there was no improvement 
in pain intensity during treatment period as compared to baseline period. 
Regarding the accuracy of pain integration into this assessment, it is 
interesting to note that Coghill et al [48] found that individuals with 
similar activation patterns of the somatosensory, the anterior cingulate 
and prefrontal cortex provided similar subjective reports of pain 
magnitude. Finally, our findings seem to support the theory that patients 
either do or do not respond to TENS and sham TENS.  
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Specific versus non-specific effects of TENS treatment 
Our results show that, for patients willing to continue treatment, there is 
no difference in relief in pain intensity between TENS and sham TENS; 
suggesting the same working mechanism, possibly a placebo response. 
Placebo effects can be very impressive; Evans found placebo to be as 
effective as a standard dose of morphine in 56% of subjects [49]. Placebo 
response in TENS treatment has been said to range from less than 40% to 
more than 60% [50]. However, Vase et al [51] studying chronic irritable 
bowel syndrome patients found that the addition of a verbal suggestion 
for pain relief could increase the magnitude of placebo analgesia to that of 
an active agent. Therefore, it cannot be excluded that the similar pain 
reductions achieved in the two groups are accomplished by different 
mechanisms. In this case it is interesting to know that in animal research 
high frequency TENS decreased central sensitization induced by 
inflammation in spinal dorsal horn neurons by activating delta-opioid 
receptors (for review see [52]), and in contrast, the placebo response in 
man is accomplished by the activation of mu-opioid receptors [15, 53]. 
However, further research in the underlying working mechanisms of TENS 
compared to sham TENS in man seems warranted. 
 
Placebo credibility  
The credibility of sham TENS has been challenged because patients do not 
feel the typical buzzing sensation of high frequency TENS [7, 12]. In the 
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present study, patient’s belief regarding real vs. sham TENS was related 
to the actual use of real or sham TENS. However, we believe that the 
present results do provide support for the credibility of our version of 
sham TENS. Firstly, the strength of the relation was weak (phi=0.28; 
resulting in a shared variance of approximately 8%). Secondly, there was 
no difference in actual use (compliance) between the real and sham TENS 
devices – and this device use was registered without the knowledge of the 
patient. Furthermore, subgroup analysis demonstrates that, on average, 
patients not willing to continue treatment as a whole used their TENS 
device approximately one hour and 45 minutes less per day than sham 
TENS users. We would therefore suggest that our patients treated sham 
TENS as a credible treatment modality. 
 
Critique of study design 
The strong point of the present study is that we have succeeded in 
completing a large prospective, randomized, controlled and double-blind 
clinical trial of TENS treatment for chronic pain. In particular, a concerted 
effort was made to ensure that the sham TENS used was credible, and 
that the blinding of patients, therapists and researchers was maintained 
throughout the study. The fact that we did not include a natural history 
group might be considered a weak point, because pain improvement 
during treatment could have been attributed to the natural course of the 
pain. However, patients referred to the Pain Centre had to wait for three 
months before being seen, during which time their pain remained stable. 
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Furthermore, pain reduction started promptly with the beginning of 
treatment (see Fig. 2). It should be noted that adding a third natural 
history group to the study design would have reduced the probability of 
benefit for the volunteers. Thus patients would have entered the study 
with low expectations, violating the external validity of the study [54]. 
Our choice of the outcome measures may be considered a weak point, as 
it not fully reflects all dimensions of chronic pain as proposed by the 
IMMPACT recommendations [55]. However, after this short treatment 
period we did not expect to achieve clinical relevant changes in 
disabilities. In this respect it is of importance to mention that Fishbain et 
al [44] found that patients with chronic pain, who continued to use TENS 
after a trial period, improved by less pain interference with work, home, 
and social activities, and increased activity level and pain management, 
after more than 6 months of TENS treatment. Whether these long term 
results of TENS treatment differ from sham TENS still needs to be 
investigated. 
Finally, the results of this study implies that those patients that 
experience relief by daily TENS (or sham TENS) application, expressed by 
willingness to continue treatment, improve by means of a significant pain 
reduction and that this amount of pain reduction is dependent on the 
period of stimulation. These results may have important implications for 
future TENS studies and clinical application, when defining responding to 
treatment by means of a percentage change of pain intensity. 
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Conclusion 
  
After ten days of TENS or sham TENS application, the proportions of 
patients satisfied with treatment result and willing to continue treatment, 
differed significantly in favor of TENS. However, no differences in pain 
intensity were found for patients treated with TENS or sham TENS. Only 
for patients satisfied with treatment result, pain intensity gradually 
decreased equally both for TENS and sham TENS with repeated treatment 
application. In conclusion, we found that the efficacy of short term TENS 
treatment depends on the choice of outcome measure and the period of 
stimulation. 
Further research is needed to explore the mechanisms underlying the 
effects of TENS versus sham TENS in man. 
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Introduction 
 
Transcutaneous electrical nerve stimulation (TENS) is an easy to use non-
invasive analgesic intervention that results in less pain interference with 
work, home and social activities, increased activity level and pain 
management and decreased use of pain medication [1]. Although TENS 
treatment has existed since the early 1970s, short term results are 
inconclusive for chronic pain [2]. Long-term randomized placebo 
controlled studies with treatment periods of more than three months have 
not been executed to date. It is stated that improvements resulting from 
TENS treatment lasting for more than three months cannot be attributed 
to placebo effects [1, 3, 4]. 
Furthermore, patients with chronic pain have reported a decline in TENS 
efficacy during long-term application [5, 6]; this would make TENS less 
suitable for the treatment of chronic pain.  
Therefore, the aim of this study is to explore the long-term time course of 
the treatment effects of TENS compared to placebo (sham TENS) in 
patients with chronic pain. 
We chose a design in which we compared “survival” of patients satisfied 
with treatment (TENS or sham TENS) result, defined as willing to continue 
treatment. In addition, pain intensity, disability because of pain and 
perceived health status were registered repeatedly, as long as patients 
were satisfied with treatment result until one year. 
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Methods  
 
Patients  
All patients with chronic pain participating in this study were referred to 
the multidisciplinary pain centre of our university hospital. Results of 
medical investigations were retrieved from the specialists before the 
patient was invited to the pain centre for the first visit. Patients eligible for 
this study had chronic non-cancer pain with a duration of pain of more 
than 6 months, were aged above 18 years, and did not met the exclusion 
criteria as presented in the flow-chart (Figure 1). Eligible patients were 
included after signing informed consent. The Central Committee on 
Research Involving Human Subjects approved this study (CWOM-9906-
0116). 
 
Design 
We performed a randomized, placebo controlled trial, comparing survival 
curves of patients satisfied with treatment result, which were treated with 
TENS or sham TENS. 
The researcher who assessed outcome, but who was not involved in the 
treatment and had no access to the randomization list, assigned 
consecutive numbers to eligible patients, when they agreed to participate 
in this study. An independent statistician generated the randomization list 
with SAS/STAT® Software, applying block sizes, randomly of 1-3 patients. 
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The research assistant, who had access to the randomization list and who 
was not involved in recruiting, treating or assessing outcome of patients, 
delivered the TENS or sham TENS device to the patient, based on this list 
and the number assigned to the patient. Therefore the research assistant 
was not blinded. However, the researcher, the patients, and the therapists 
were all blinded. To guarantee concealment of allocation, patients were 
asked to leave their treatment device with the receptionist before visiting 
the researcher for evaluating treatment effects. Furthermore, the 
researcher made no inquiries concerning stimulation intensity levels or 
experienced sensations, and patients were explained that questions 
concerning the device should be addressed to the research assistant 
throughout the study.  
 
Apparatus  
For TENS and sham TENS treatment, identical devices (ELPHA II 1000, 
Danmeter A/S, Denmark) were used, which were specially prepared for 
this study to meet the specifications described below. For both channels, 
TENS pulse frequency was set to 80 Hz (optimal stimulation frequency 
according to Sjolund et al [7]) and pulse width to 50 s (mainly 
stimulating A-beta neuron fibers according to Li and Bak [8], consistent 
with the gate control theory [9]). Sham TENS devices showed a maximum 
of 10 mA on the LCD display (current intensity below the level of 
perception) but no current was actually delivered to the electrodes. 
Duration of actual use of the device, further referred to as “compliance”, 
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could be read out by pressing a special key combination, a feature 
patients were not aware of. Disposable 5 cm  6.4 cm self-adhering 
electrodes were used with an active area of 6.5 cm2.  
 
General procedure 
In our pain center, after optimizing pain medication by the 
anesthesiologist/pain physician, further pain treatment was provided in a 
sequential manner. TENS was the first choice if indicated. Patients eligible 
for TENS treatment received written information about this study and 
were asked to participate. It was explained that TENS seems to be 
effective at high and low intensities, and that treatment would be one of 
these two options. There would also be a chance of receiving a sham 
TENS device in which the settings of pulses were neither effective nor 
harmful.  
One week after baseline measures were performed, the patient visited the 
physiotherapist for electrode application and instruction. Electrodes were 
applied on the superficial cutaneous nerves in the painful segment(s) [10] 
[11]. After electrode application the physiotherapist let the patient 
experience the tingling but not pricking sensation of “high intensity” TENS 
and the absence of a stimulus sensation with “low intensity” TENS. Once 
acquainted with the application, the patient left the room and visited the 
research assistant who delivered the sham/TENS device. With the 
instruction to use the TENS device during the whole day, the patient left 
the outpatient clinic. Ten days later, the patient returned for the first 
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evaluation of treatment effect. After this initial treatment period, patients 
in their opinion experiencing sufficient pain reduction and therefore willing 
to continue TENS treatment were evaluated for the long-term effect. They 
were informed that they could cease treatment at any time when they 
were not satisfied anymore with its result. In that case these patients 
would be referred to the anesthesiologist/pain physician to consider other 
types of pain treatment. 
 
Outcome Measures  
The primary outcome measure was the proportion of patients satisfied 
with treatment result. We defined “satisfied with treatment result” as 
“willing to continue treatment” (yes/no). The date of cessation of 
treatment - because the patient was no longer satisfied with treatment 
result - was used for the survival analysis. Patient satisfaction is predictive 
of health-related behaviors as compliance and of switching providers, and 
is related to self-reported improvement in health [12]. This outcome 
measure can be regarded as an index of patient’s assessment of the 
benefits (efficacy) of the treatment versus its side effects (e.g. problems 
in handling the device), providing a patient-based evaluation of treatment 
[13], and has been used to investigate the efficacy of TENS treatment 
[14]. 
After one year patients still satisfied with treatment result judged “overall 
improvement” as a percentage change from baseline; zero percent 
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meaning “no improvement at all” and hundred percent meaning “complete 
recovery”. 
Pain intensity was measured with a 10-centimeter long Visual Analogue 
Scale (VAS). Patients rated their pain at the same time every day for 
seven days [15], starting at Fridays by using a pain diary. The first pain 
diary was filled in one week before treatment, the second time during the 
first treatment week, followed by one week every four weeks as long as 
patients were satisfied with treatment result, with a maximum of twelve 
times. The pain diaries were sent by mail and the date to start the pain 
registration was indicated in the diary. 
Perceived health status was measured by the Sickness Impact Profile 
(SIP). The SIP is able to detect changes or differences in heath status that 
occur over time or between groups [16, 17]. Jacobs et al [18] validated 
the SIP for The Netherlands. 
Disability because of pain was measured with the Dutch version of the 
Pain Disability Index (PDI) [19-21]. The PDI was developed as a brief, 
self-report indicator of pain-related disability [19, 21, 22]. The sum score 
was used in this study. 
Duration of TENS use served as a measure for compliance and was read 
out by the receptionist, who was trained to do so. Perceived health status 
(SIP), disability because of pain (PDI) and compliance (TENS use) were 
assessed during a visit to the pain center at three six and 12 months and 
were analyzed for patients still satisfied after one year.  
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Placebo credibility was assessed only after the initial treatment period by 
asking the patients how certain they felt about having a TENS or placebo 
device, using a questionnaire according to Deyo et al [23], however we 
dichotomized these results.  
Pain medication was registered together with pain intensity using the 
same pain diary. For analysis we used the mean dose of each taken drug 
in one week. We calculated the drug load as published by the World 
Health Organization (http://www.whocc.no/atcddd/). The method was 
introduced by the World Health Organization Drug Utilization Research 
Group as a tool to convert drug consumption data from different sources 
into comparable units [24].The normalized loads of the different drugs 
were added together. 
For reporting adverse effects, patients were instructed to recognize 
symptoms of allergy by electrode materials. A “what to do list” was given 
to the patient after the instruction. A physiotherapist not involved in the 
initial treatment evaluated and resolved the problems if possible, by 
changing the type of electrodes.  
 
Sample size  
The number of patients in each treatment group was based on the 
assumption that 35% of the patients in the TENS group – derived from 
the studies of Lample [3] and Eriksson [4] - and 15% in the sham-TENS 
group would be successfully treated after one year. For a power of 80% to  
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Assessed for eligibility 
(n=406) 
 
Excluded (n= 203) 
 
Formerly treated with TENS (n=77) 
Pain in head or face 
(n=19) 
Several sites of pain (n=37) 
Cerebral vascular accident (n=11) 
No help to replace electrodes (n=2) 
Ongoing litigation (n=5) 
Psychological intervention (n=50) 
Did not speak Dutch language 
(n=2) 
 
Lost to follow-up (n=2)  
Discontinued intervention 
(n=21) 
 Insolvable skin problems (n=2) 
 Other treatment (n=1) 
 Not satisfied with treatment 
result (n=18) 
Satisfied with treatment result 
after one year (n=24) 
 
Discontinued intervention (not 
satisfied with treatment result) 
(n=34) 
Continued intervention 
(n=47) 
 
 
Allocated to TENS 
(n=83) 
Withdrawal 
(n=2) 
 
Received allocated intervention 
(n=81) 
 
 
Discontinued intervention (not 
satisfied with treatment result) 
(n=47) 
Continued intervention 
(n=35) 
 
 
 
Allocated to Sham-TENS 
(n= 82) 
 
Received allocated intervention 
(n=82) 
 
Lost to follow-up (n=0)   
Discontinued intervention 
(n=16) 
 Insolvable skin problems (n=2) 
 Not satisfied with treatment 
result (n=14) 
Satisfied with treatment result 
after one year (n=19) 
 
 
Allocation 
 
Short-term 
result 
(10 days) 
 
Follow-Up 
(One year) 
 
Enrollment 
 
Randomized 
(n=165) 
 
Refused to participate 
(n=38) 
 
 
Figure 1. flowchart of trial profile
 52 
 
show the difference, a two-sided alpha of 5% and allowing for dropouts, 
this suggested the inclusion of about 80 patients per group. 
 
Statistical analysis  
Analyses of the primary outcome measure were done on the intention-to-
treat population, defined as all randomized patients that started with 
treatment (also called modified intention-to-treat population). The time 
course of the proportion of satisfied patients during treatment was 
estimated using Kaplan-Meier survival estimates, while differences 
between treatments were analyzed with the log-rank test.  
The time courses of VAS and drug load (starting with the first week of 
treatment) for the two treatment groups were analyzed using a mixed 
repeated measures model, including as fixed factors follow-up time (day) 
and time squared, treatment, response to treatment after one year and 
furthermore three random coefficients (for intercept, follow-up time and 
time squared) per patient. 
In further exploratory analyses concerning continuous parameters the 
two-sample t-test or Wilcoxon’s two-sample test was used for 
comparisons between groups, while the paired t-test or Wilcoxon’s signed 
rank test was used for comparisons within groups. The chi square test was 
used for comparison of discrete parameters between groups. The p-values 
described are two-sided and for all tests level of significance used was 
0.05. 
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Results  
 
One hundred sixty five patients entered the study. The patient flow of our 
study is presented in the flow-chart (Figure 1). One patient from the TENS 
group withdrew after two months, from two patients, satisfied with short 
term TENS treatment result, follow up data were not available and two 
patients in each group had to stop sham/TENS treatment because of skin 
problems that could not be managed. However, these patients were 
included in the survival analysis by using the date of cessation of 
treatment or the last known date they were satisfied. Baseline 
characteristics are shown in Table 1. 
Survival analysis of time courses of satisfied patients (Figure 2) revealed 
no significant differences (p=0.79; log-rank test) for TENS treatment 
compared to sham TENS. Only after the initial treatment period the 
proportion of satisfied patients differed significantly (chi square=3.8, 
p=0.05) for TENS compared to sham TENS (more details of short-term 
results are described earlier [25]). After one year 30% (24/81) of the 
patients of the TENS group and 23% (19/82) of the sham TENS group 
were satisfied with treatment result. These patients experienced a mean 
overall improvement of 62.7% (n=43). This effect was not significantly 
different (p=0.74) for patients of the TENS group (mean=61.7%, 
SD=20.1, n=24) compared to patients in the sham TENS group 
(mean=63.9%, SD=25.4, n=19).  
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 TENS 
(n = 81) 
Sham-TENS 
(n = 82) 
Gender, n (%) Male, Female 
 
33 (41) 48 (69) 33 (40) 49 (60) 
Age, Mean ± SEM years 
 
48.4 ± 1.6 51.6 ± 1.4 
Pain diagnoses, n (%)  
Peripheral neuropathic pain 
Osteoarthritis and related disorders 
Injury of bone and soft tissue  
 
 
16 (20) 
31 (38) 
34 (42) 
 
25 (30) 
26 (32) 
31 (38) 
Intensity of pain *, (VAS)  
Mean ± SEM mm 
 
 
62.2 ± 2.1 
 
61.5 ± 2.0 
Duration of pain (years) 
Median (Range) 3.6 (0.6 – 42.1) 4.1 (0.5 – 58.7) 
Pain disability (PDI)  
Sum score, Mean ± SEM mm 
 
 
28.0 ± 1.8 
 
 
28.8 ± 2.0 
 
Perceived health status (SIP)  
Sum score, Mean ± SEM mm 
 
12.3 (8.0) 
 
12.9 (0.8) 
   
* Average pain in baseline week. 
Table 1. Baseline prognostic variables of patients who entered treatment 
 
Figure 2. Time course of proportions of patients satisfied with treatment 
result for TENS and sham TENS, starting at initial treatment.  
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For all other outcome measures there were also no significant differences 
between both groups; for details of the results of the SIP and PDI, see 
Figure 3A and 3B, respectively and for compliance see Figure 3C. Results 
of the time courses of pain intensity and pain medication intake are shown 
in Figure 4A and 4B, respectively. As reported earlier [25], we found a 
weak association (Phi=0.28) between the treatment patients believed to 
have received and the actual received treatment. 
 
Fifty percent (40/80) of the patients - 46% (21/45) of the patients in the 
TENS group and 54% (19/35) in the sham TENS group - experienced skin 
problems caused by the electrodes. 
 
Discussion  
 
This is the first study that evaluated the effects of TENS in patients with 
chronic pain, in a randomized placebo controlled study design for a period 
of one year. We found however no differences in survival curves of 
satisfied patients treated with TENS or sham TENS. Furthermore, 
improvements due to treatment did not differ between both groups for 
pain intensity, pain disability and perceived health status or pain 
medication intake for long term satisfied patients. In the TENS group 30% 
of the patients were satisfied after one year, which is similar to long term 
results of uncontrolled studies [3, 4].
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The survival curves of satisfied patients suggest a decline of effect for 
long-term TENS as well as sham TENS application. However, the time 
course of pain intensity - see Figure 4 - does not show a decline in pain 
diminution for TENS. There is, however, a significant difference in degree 
of pain diminution between patients who were still satisfied after one year 
and those who stopped earlier, probably because they were not satisfied 
anymore with the achieved degree of pain relief. 
 
A remarkably stable improvement in pain was achieved over a period of 
one year for 23 % of the patients using sham TENS. However, because we 
did not include a third group to control for regression to the mean or the 
natural course of chronic pain, we cannot claim to have found a true 
placebo effect (see Ernst et al [26]) induced by the sham TENS 
application. For chronic pain in the general population however, annual 
recovery rates are found of 5.4% and 8.7% [27, 28]. 
 
Skin irritation occurred at some time point in half of the patients, but 
could easily be cured by changing the type of electrode, except for 4 
patients who had to stop treatment. Because there was no difference 
between TENS and sham-TENS, we assume there was no interaction of 
the electric current with electrode material, which has been suggested 
[29]. 
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Study limitations 
 
We chose a design in which we compared “survival” of patients satisfied 
with treatment (TENS or sham TENS) result. Our choice was based on the 
fact that patients with chronic pain, especially those patients referred to 
an end-of-line Pain Center are less likely to benefit from any intervention 
[30]. If treatment success fails and patients are unsatisfied with treatment 
result it will be difficult to obtain unbiased outcome results for a long 
period of time or to avoid loss of data, because these patients will seek 
other treatments. We therefore defined “satisfied with treatment result” as 
“willing to continue treatment” (yes/no) as our main outcome instead of 
pain relief. Importantly, the patients decided when to stop treatment 
because they were no longer satisfied with “TENS” treatment results. This 
outcome may therefore be considered clinical meaningful to the chronic 
pain patients. However patients’ pain intensity was evaluated every four 
weeks, for seven consecutive days to explore the magnitude of change in 
pain intensity. We found for patients still satisfied after one year an 
average decrease of more than 50% in pain intensity which reflects 
“substantial improvement” [31], however patients who stopped TENS 
treatment within one year improved ca 28% which is still considered 
“much improved” [31]; these data show the difficulty of choosing an 
(arbitrary) percentage of change in pain intensity as main outcome. 
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In our study TENS pulse frequency (80 Hz) and pulse width (50 s) were 
fixed by the manufacturer on our request, so patients were not able to 
change TENS settings. Patients were instructed to use TENS at an 
intensity that caused a tingling, but not pricking sensation - mainly 
stimulating A-beta neuron fibers – during the whole day, as long as they 
felt necessary. However in healthy subjects, increasing evidence shows a 
dose response for the intensity of TENS with the higher intensities 
producing a superior analgesic effect than the lower intensities [32-34]. 
However, whether the application parameters for TENS, as applied in 
healthy subjects, would have improved our results is questionable. In 
patients treated for chronic pain, Köke et al[14] used high frequency TENS 
(frequency 80 Hz, pulse duration 80 s at sensory threshold intensity) 
comparable with our TENS application and found no differences in results 
compared to high intensity stimulation (frequency 80 Hz, pulse duration 
250 s at maximum tolerated intensity). Nash et al[35] compared 
continuous and pulsed high and low frequency TENS at multiple intensity 
levels with a maximum just tolerated by the patients; they found however 
no differences in effect for the different TENS applications. In both studies, 
like in our study, patients were treated for various pain conditions. 
Furthermore, in our study TENS was applied for several hours a day - 
which is much longer than in studies with healthy volunteers (30-40 
minutes) - but which is in conformance with what is recommended in 
general practice.[6, 36].  
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TENS placement was applied to the superficial cutaneous nerves of the 
painful segment. This method has been used from the start of TENS in the 
treatment of chronic pain [10], and is consistent with results in animal 
research, [37] where the greatest degree of inhibition of spinothalamic 
tract cell activity occurred with electrodes placed within the receptive field 
for the neuron, and only minimal inhibition occurred when placed on the 
same hind limb but outside the receptive field. However the placement of 
electrodes was determined once, and was only reevaluated if patients 
were uncertain about preserving the marks for the electrode positions. 
Inaccurate electrode placements could have occurred in some cases, 
resulting in diminished analgesic effects for TENS but not for sham TENS. 
 
We allowed patients to continue to use their pain medication when they 
entered our study. Therefore the effects of TENS/sham-TENS in our study 
is expected to be additive to the analgesic effects of the pain medication. 
However for satisfied patients in the TENS group, drug load on average 
was less than 0.2 and for the sham TENS group slightly more than 0.2, 
which - in our opinion - is rather low for patients with the chronic pain 
found in our study population.  
Apart from pain medication, patients who entered this study did not 
receive any other treatment arranged by the anesthesiologist/pain 
physician of our pain center, unless the patient was no longer satisfied 
with TENS treatment result and stopped treatment. However, patients 
could have visited other doctors or therapists, outside our pain center. 
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This however seems not very likely, because patients were referred to our 
center because the usual care for their pain complaints, supplied by their 
family doctor, specialists or therapists, had failed. We have however no 
specific data to exclude this possibility. 
 
After the initial treatment period of ten days we found only a weak 
association between the treatment that patients believed to have received 
and the actual received treatment.  
In our study we used a sham/TENS device with a display on which the 
current intensity level was shown. For the sham unit, current intensity was 
maximized at a predetermined level, at which level patients would not 
perceive any sensation, but no current was actually delivered to the 
electrodes. Recently a special sham TENS device - which unit is active for 
the first 30 seconds and then ramps down to zero stimulus over 15 
seconds - was tested to determine the degree of blinding compared to an 
inactive sham device [38]. The authors found that subjects were blinded 
to the new sham device 40% of the time and the inactive sham device 
21% of the time. In our study however, for patients receiving a sham 
TENS device, 70% believed they had a real TENS device. For patients 
receiving a real TENS device, 93 % believed they had a real TENS device.  
We did not repeat the questionnaire during the course of the study; by 
repeating it we expected to undermine patients’ confidence in the applied 
treatment, which would decrease the chance of a positive treatment 
result. However, after the initial treatment period the survival curves of 
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the proportions of patients willing to continue treatment were not different 
for TENS compared to sham TENS, assuming similar belief in real 
treatment. 
 
We are one of the first groups to have succeeded in completing a long-
term, randomized, placebo-controlled trial for TENS treatment in chronic 
pain. However, based on the results of this study we need to question 
whether a placebo-controlled design is appropriate to reveal the specific 
effects of TENS in chronic pain. As suggested by the present study, recent 
research supports the view that placebo effects are genuine 
psychobiological events, which can be robust in both laboratory and 
clinical settings [39]. Indeed, for neuropathic pain it is increasingly 
accepted that long-term placebo effects pose a risk for decreased 
separation of drug effect from placebo effect [40].  
 
Conclusions  
 
TENS and sham TENS show similar effects in patients with chronic pain 
over a period of one year. Patients still satisfied after one year of 
treatment show more pain relief than those who were satisfied for a 
shorter period. We found no evidence for decline of treatment effect over 
time for TENS, but did find support for long-term placebo effects for sham 
TENS. Further research concerning TENS treatment of patients with 
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chronic pain should particularly target the mechanisms underlying pain 
relief. 
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Chapter 4 
 
Basic science mechanisms of transcutaneous electrical nerve 
stimulation (TENS) in animal models of pain  
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Introduction 
 
TENS is a widely used noninvasive treatment for chronic pain. However 
results of reviews for TENS in chronic pain [1] and low back pain [2] are 
inconclusive, whereas authors of reviews for TENS in post-operative pain 
[3], pain in primary dysmenorrhoea [4] and osteoarthritis [5] confirm the 
effectiveness of TENS. These different results may be due to differences in 
the TENS application as well as differences in pain conditions.  
TENS is applied clinically at varying frequencies, intensities and pulse 
durations of stimulation. Frequency of stimulation is broadly classified as 
high-frequency (>50 Hz), low-frequency (<10 Hz), or burst (bursts of 
high-frequency stimulation applied at a 1-4Hz). Intensity is applied at 
sensory level, giving rise to a tingling sensation (stimulating A-beta 
neuron fibers) or a more intensely, pricking sensation (stimulating A-delta 
neuron fibers) and at motor level, inducing muscle contractions. High-
frequency TENS is generally applied at sensory level and is referred to as 
conventional TENS, whereas low-frequency TENS and burst TENS are 
more commonly applied at motor level and are both referred to as 
acupuncture-like TENS. 
Pain is a multidimensional sensory experience that is intrinsically 
unpleasant. Although it is essentially a sensation, pain has strong 
cognitive and emotional components and is associated with avoidance 
motor reflexes and alterations in autonomic output. Several distinct types 
of pain exist: nociceptive, inflammatory, and neuropathic [6].  
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Animal models have been developed, that mimic these clinical conditions, 
to measure effectiveness of medical treatment [7]. Animal models 
minimize the placebo effect, allow for control of the extent of the injury, 
make application of TENS fully controllable, and allow one to assess the 
neurobiological mechanisms by which TENS produces a reduction of pain 
behaviors [8]. TENS has been studied in the acute (nociceptive) pain 
model, the inflammatory pain model and the neuropathic pain model. The 
response to noxious heat and mechanical or electrical stimulation can be 
assessed in the acute pain model [9]. In the inflammatory pain model, 
carrageenan is injected into the paw or knee joint to produce an acute 
inflammatory event resulting in primary and secondary hyperalgesia [10]. 
Injection of complete Freund’s adjuvant (CFA), either systemically or into 
a joint, is a model of chronic inflammation similar to rheumatoid arthritis 
[7]. For neuropathic pain mainly two models are used; the Bennett model 
induced by making loose ligations around the sciatic nerve [11], and the 
Chung model induced by making tight ligations around the spinal nerves 
[12].  
A literature search was performed and the effects and working 
mechanisms of the various TENS applications in these pain models are 
discussed.  
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Methods  
 
For this survey, journal articles published between January 1976 and 
October 2010 from the National Library of Medicine database and EMBASE 
were searched for “TENS”, “animal research” and “pain”. For “TENS” we 
used the following keywords and combinations: TENS, 
transcutaneous/percutaneous electric/electrical/electronic (nerve) 
stimulation, electric/electrical/ electronic/electronical (nerve) stimulation 
(therapy), electrostimulation therapy, electro-stimulation therapy, electro-
acupuncture and electroacupuncture. For “animal research” we used the 
search filter for the NLM databse developed by Hooymans et all [13], and 
for EMBASE we used the filter developed by De Vries [14]. “Pain” was 
searched by using the following keywords: (an)algesia, (an)algesic, 
hyperalgesia, hyperalgesic, allodynia, nociceptive and antinociception. The 
search was constrained to published articles written in English and 
German. Retrieved articles were screened on title for (T)ENS for “pain” in 
animal studies; papers that passed this screening were reviewed against 
the inclusion/exclusion criteria (below). Only full-text available primary 
research studies for (T)ENS for “pain” in animal models for nociceptive 
pain, inflammatory pain or neuropathic pain, were included. Studies which 
explored the effects of TENS additional to other treatments were excluded. 
Papers concerning electro-acupuncture were excluded, when only 
acupuncture needle electrodes were used.  
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Results of the literature search 
 
A total of 72 papers, all written in English, were reviewed and 44 papers 
were included; five papers were not full-text available, three papers 
studied TENS in combination with other therapies (medication), eight 
papers used (T)ENS for other purposes than for “pain” treatment, two 
studies used TENS for visceral pain, eight studies were not regular TENS 
applications and two papers appeared human studies.  
Eleven papers explored the effects of TENS in an animal model for 
nociceptive pain, twenty-six papers explored TENS in an animal model for 
inflammatory pain and seven papers studied effects of TENS in an animal 
model for neuropathic pain. 
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TENS in animal models of pain 
 
The acute (nociceptive) pain model 
 
The results of a literature survey of the effects of TENS, in an animal 
model for acute pain, are shown in table 1. The effects of high-frequency 
TENS, low-frequency TENS and burst TENS were studied on noxious 
stimulation, induced mechanically (pinch), by thermal stimuli (heat) or by 
electrical stimulation. 
 
High-frequency TENS  
High-frequency TENS (100 Hz), with an intensity causing slight fibrillation 
of the tail, delayed the withdrawal response to noxious heat stimuli both 
in intact and spinal rats (smaller effect), with equal results as 7.5 mg/kg 
morphine for 100 Hz and 0.2 ms stimulation [15], naloxone reversed the 
effects of TENS. High-frequency TENS, with 80 Hz low intensity 
stimulation, caused a marked reflex depression, whereas for high-
frequency, high intensity TENS, stimulation at 40-80 Hz had a more 
marked effect than other frequencies on withdrawal response caused by 
noxious electrical stimulation [16]. High-frequency TENS at 100 Hz 
reduced the number of fos-like immunoreactivity neurons in the ipsilateral 
laminae I-II and IV-VII in rats, reflecting an inhibition of spinal 
nociception by TENS [17]. The TENS stimuli in this study primarily 
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activated A-beta neuron fibers and the noxious stimulation (NS) was 
induced by electrical stimulation at 1 Hz on the same tibial nerve.  
 
When comparing high-frequency low intensity TENS to low-frequency high 
intensity TENS in cats, spontaneously firing and noxiously evoked activity 
of high threshold (HT) and wide dynamic range (WDR) dorsal horn 
neurons was more decreased for high-frequency TENS than for low-
frequency TENS [18], similar effects were found for intact cats and cats 
with transacted spinal cord [19], or for ipsilateral, contralateral (smaller 
effect) or simultaneous (both sides) application of TENS [20]. In these 
studies, TENS and noxious stimulation were applied in the same 
dermatome.  
High-frequency (100 Hz, for one second), low intensity stimulation and 
low-frequency (2 Hz, for five seconds), high intensity stimulation induced 
partial inhibition of lumbar spinal cord field potentials for 2 seconds and 
20 seconds, respectively[21]. Field potentials were evoked by laser pulses 
applied on the plantar surface of the hind paw of rats. 
When 2, 5 and 100 Hz TENS is compared to electro-acupuncture using the 
same acupoints, stimulus frequencies and stepwise increasing intensities, 
no differences are found in analgesic effects on thermal hyperalgesia 
between both applications or stimulation frequencies [22]. 
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Low-frequency TENS  
One study explored the effects of low-frequency (2 Hz) TENS using the 
squeak threshold (vocalization to electric shocks delivered to the tail) and 
found an increased squeak threshold for TENS compared to sham-
stimulated rats. A TENS intensity was used that only stimulated A-beta 
afferents [23]. 
 
Burst TENS  
When stimulating skin nerves with Burst TENS, at intensities stimulating 
A-beta and A-delta neuron fibers, only a burst frequency of 1 Hz was 
effective, whereas for muscle nerves, repetition rates of 1 and 5 Hz bursts 
were both effective, with 1 Hz being most effective in depressing 
withdrawal responses [24]. When comparing continuous stimulation at 85 
Hz to 3 Hz bursts of 85 Hz in monkeys at intensities stimulating A-delta 
fibers, burst mode was more effective than continuous mode in decreasing 
activity of WDR neurons in the dorsal horn[25]. TENS applied in the 
receptive field of the WDR neuron was more effective than outside the 
receptive field. Inhibition of activity of WDR neurons by TENS was not 
altered after intravenous injection of naloxone.  
 
Conclusion 
 
In the acute pain model high-frequency (80 Hz and 100 Hz) low intensity 
TENS (primarily activating A-beta neuron fibers) is effective in reducing 
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activity in the spinal cord of WDR and HT neurons, the number of fos-like 
immunoreactivity neurons, in delaying the withdrawal responses and 
suppressing spinal field potentials, during NS (by mechanical, electrical or 
heat stimuli). Furthermore when both A-beta and A-delta fibers are 
stimulated in 1Hz bursts of trains of high-frequency stimuli, effects are 
more prolonged. For all studies TENS stimulation was applied in the 
segment of NS and one study applied TENS also contralateral to the side 
of NS and bilateral. 
It therefore seems that in the spinal cord two different mechanisms of 
segmental inhibition of noxious stimulation are induced by TENS: 1) 
activated by segmental applied high-frequency stimulation of A-beta 
neuron fibers, as described in the gate control theory [26], and 2) 
activated by burst-like stimulation of A-delta fibers; inducing a long term 
depression (LTD) of spinal cord neurons [27]. Both mechanisms are still 
available in transected spinal cord.  
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e
, 
w
it
h
 1
 H
z
 
b
e
in
g
 m
o
s
t 
e
ff
e
c
ti
v
e
 
 
N
o
 s
ig
n
if
ic
a
n
t 
d
if
fe
re
n
c
e
 f
o
r 
8
 
c
o
m
p
a
re
d
 t
o
 1
6
 
p
u
ls
e
s
 p
e
r 
tr
a
in
. 
S
ti
m
u
la
ti
o
n
 
s
tr
e
n
g
th
 r
e
c
ru
it
in
g
 
b
o
th
 G
ro
u
p
 1
-I
I 
a
n
d
 I
II
 f
ib
e
rs
 w
a
s
 
m
o
s
t 
e
ff
e
c
ti
v
e
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S
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H
z
 
µ
s
 
m
A
 
s
ti
m
u
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te
d
 
a
ff
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n
ts
 
c
li
n
ic
a
l 
c
o
n
d
it
io
n
 
T
y
p
e
/L
o
c
a
ti
o
n
 
ti
m
e
  
  
  
  
L
e
e
 e
t 
a
l.
,1
9
8
5
 
8
5
 H
z
 
c
o
n
ti
n
u
o
u
s
 
m
o
d
e
 o
r 
3
 
b
u
rs
ts
/s
e
c
, 
7
 
p
u
ls
e
s
/b
u
rs
t,
 
w
it
h
 i
n
te
rn
a
l 
fr
e
q
u
e
n
c
y
 o
f 
8
5
 H
z
 
8
0
 
 
A
-b
e
ta
  
w
it
h
 a
n
d
 
w
it
h
o
u
t 
 A
-d
e
lt
a
 
n
e
u
ro
n
 
fi
b
e
rs
 
 
S
u
rf
a
c
e
 e
le
c
tr
o
d
e
s
 
(c
a
rb
o
n
 r
u
b
b
e
r,
1
.5
 
x
 1
.7
5
 i
n
.)
 
7
-9
 s
 
e
v
e
ry
  
1
0
 s
 f
o
r 
5
 m
in
 
M
o
n
k
e
y
s
 (
M
a
c
a
c
a
 
fa
s
c
ic
u
la
ri
s
),
 
re
s
p
o
n
s
e
s
 o
f 
s
p
in
o
th
a
la
m
ic
 t
ra
c
t 
c
e
ll
s
 e
v
o
k
e
d
 b
y
 
e
le
c
tr
ic
a
l 
o
r 
n
o
x
io
u
s
 
h
e
a
t 
te
s
t 
s
ti
m
u
li
 
a
p
p
li
e
d
 t
o
 t
h
e
 
c
o
m
m
o
n
 p
e
ro
n
e
a
l 
n
e
rv
e
 
O
n
ly
 T
E
N
S
 a
t 
h
ig
h
 
in
te
n
s
it
ie
s
, 
a
c
ti
v
a
ti
n
g
 A
-b
e
ta
 
a
n
d
 A
-d
e
lt
a
 f
ib
e
rs
, 
p
ro
d
u
c
e
d
 a
 
re
m
a
rk
a
b
le
 
in
h
ib
it
io
n
 o
f 
C
-f
ib
e
r 
e
v
o
k
e
d
 r
e
s
p
o
n
s
e
s
 i
n
 
S
T
T
 c
e
ll
s
 b
o
th
 
d
u
ri
n
g
 a
n
d
 a
ft
e
r 
T
E
N
S
 a
p
p
li
c
a
ti
o
n
 
(e
it
h
e
r 
c
o
n
ti
n
u
o
u
s
 
o
r 
b
u
rs
t 
m
o
d
e
) 
 
w
it
h
in
 t
h
e
 r
e
c
e
p
ti
v
e
 
fi
e
ld
. 
T
h
e
 d
e
g
re
e
 o
f 
in
h
ib
it
io
n
 w
a
s
 
g
re
a
te
r 
w
it
h
 t
h
e
 
lo
w
 r
a
te
 b
u
rs
t 
m
o
d
e
 t
h
a
n
 w
it
h
 
h
ig
h
-f
re
q
u
e
n
c
y
 
T
E
N
S
 a
t 
th
e
 s
a
m
e
 
in
te
n
s
it
y
. 
In
tr
a
v
e
n
o
u
s
 
in
je
c
ti
o
n
 o
f 
n
a
lo
x
o
n
e
 w
a
s
 o
f 
li
tt
le
 e
ff
e
c
t 
Jo
ru
m
 a
n
d
 S
h
y
u
, 
1
9
8
8
 
2
 
2
0
0
 
 
A
-b
e
ta
 
a
ff
e
re
n
ts
, 
b
a
s
e
d
 o
n
 
c
o
n
d
u
c
ti
o
n
 
v
e
lo
c
it
ie
s
 
o
f 
s
ti
m
u
la
te
d
 
a
ff
e
re
n
ts
 
In
te
n
s
it
y
 o
f 
tw
ic
e
 t
h
e
 
th
re
s
h
o
ld
 o
f 
v
is
ib
le
 m
u
s
c
u
la
r 
tw
it
c
h
e
s
. 
 
P
E
N
S
, 
s
ta
in
le
s
s
 
s
te
e
l 
w
ir
e
s
 
im
p
la
n
te
d
 a
ro
u
n
d
 
th
e
 r
ig
h
t 
ra
d
ia
l 
o
r 
s
c
ia
ti
c
 n
e
rv
e
. 
 
3
0
 m
in
 
M
ø
ll
-W
is
ta
r 
ra
ts
, 
th
e
 a
n
a
lg
e
s
ic
 e
ff
e
c
t 
w
a
s
 a
s
s
e
s
s
e
d
 b
y
 
th
e
 s
q
u
e
a
k
 
th
re
s
h
o
ld
 t
e
s
t;
 
v
o
c
a
li
z
a
ti
o
n
 t
o
 
e
le
c
tr
ic
 s
h
o
c
k
s
 
d
e
li
v
e
re
d
 t
o
 t
h
e
 
ta
il
. 
s
 
T
h
e
 s
ti
m
u
la
te
d
 r
a
ts
 
s
h
o
w
e
d
 s
ig
n
if
ic
a
n
tl
y
 
in
c
re
a
s
e
d
 s
q
u
e
a
k
 
th
re
s
h
o
ld
s
 c
o
m
p
a
re
d
 
to
 t
h
e
 s
h
a
m
-
s
ti
m
u
la
te
d
 r
a
ts
. 
S
q
u
e
a
k
 t
h
re
s
h
o
ld
s
 
g
ra
d
u
a
ll
y
 r
e
tu
rn
e
d
 
to
w
a
rd
s
 b
a
s
e
li
n
e
 
le
v
e
ls
 w
it
h
in
 4
5
 m
in
. 
 
T
h
e
 c
u
rr
e
n
t 
in
te
n
s
it
y
 a
t 
w
h
ic
h
 
th
e
 r
a
t 
v
o
c
a
li
z
e
d
 
tw
ic
e
 w
a
s
 
re
g
a
rd
e
d
 a
s
 t
h
e
 
s
q
u
e
a
k
 t
h
re
s
h
o
ld
. 
A
n
a
lg
e
s
ia
 w
a
s
 o
n
ly
 
o
b
ta
in
e
d
 i
n
 c
a
lm
 
ra
ts
, 
w
h
ic
h
 w
e
n
t 
to
 
s
le
e
p
 r
e
g
u
la
rl
y
. 
 
W
a
n
g
 e
t 
a
ll
, 
1
9
9
2
 
2
, 
5
 a
n
d
 1
0
0
  
3
0
0
 
in
te
n
s
it
y
 o
f 
s
ti
m
u
la
ti
o
n
 
w
a
s
 
in
c
re
a
s
e
d
 
s
te
p
w
is
e
 
fr
o
m
 1
 m
A
 
to
 a
 
m
a
x
im
a
l 
o
f 
3
 m
A
 w
it
h
 
s
te
p
s
 o
f 
1
 
m
A
 l
a
s
ti
n
g
 
fo
r 
1
0
 m
in
 
e
a
c
h
 
 
 
T
E
N
S
 e
le
c
tr
o
d
e
s
, 
s
il
v
e
r 
p
la
te
 
e
le
c
tr
o
d
e
s
 (
5
 X
 6
 
m
m
) 
w
e
re
 p
la
c
e
d
 
b
il
a
te
ra
ll
y
 o
n
 b
o
th
 
h
in
d
 l
im
b
s
. 
F
o
r 
E
A
, 
s
ta
in
le
s
s
 
s
te
e
l 
n
e
e
d
le
s
 o
f 
0
.2
5
 m
m
 d
ia
m
e
te
r 
w
e
re
 p
la
c
e
d
, 
a
t 
th
e
 
s
a
m
e
 s
it
e
s
 a
s
 
T
E
N
S
: 
a
c
u
p
o
in
ts
 
S
to
m
a
c
h
 3
6
 a
n
d
 
S
p
le
e
n
 6
. 
3
0
 m
in
, 
3
 
ti
m
e
s
 1
0
 
m
in
 
R
a
ts
, 
a
d
u
lt
 W
is
ta
r 
ra
ts
 o
f 
b
o
th
 s
e
x
e
s
, 
th
e
 n
o
c
ic
e
p
ti
v
e
 
th
re
s
h
o
ld
 w
a
s
 
a
s
s
e
s
s
e
d
 b
y
 
m
e
a
s
u
ri
n
g
 t
h
e
 
la
te
n
c
y
 o
f 
th
e
 t
a
il
 
w
it
h
d
ra
w
a
l 
fr
o
m
 
n
o
x
io
u
s
 t
h
e
rm
a
l 
ir
ra
d
ia
ti
o
n
. 
 
T
h
e
 a
n
a
lg
e
s
ic
 e
ff
e
c
t 
d
e
v
e
lo
p
e
d
 
p
ro
g
re
s
s
iv
e
ly
 a
n
d
 
re
a
c
h
e
d
 a
 
s
ta
ti
s
ti
c
a
ll
y
 
s
ig
n
if
ic
a
n
t 
le
v
e
l 
to
w
a
rd
s
 2
0
 m
in
 o
r 
5
-1
0
 m
in
 a
ft
e
r 
th
e
 
o
n
s
e
t 
o
f 
E
A
 o
r 
T
E
N
S
, 
re
s
p
e
c
ti
v
e
ly
. 
N
o
 
s
ig
n
if
ic
a
n
t 
d
if
fe
re
n
c
e
 
w
a
s
 f
o
u
n
d
 a
m
o
n
g
 
th
re
e
 d
if
fe
re
n
t 
fr
e
q
u
e
n
c
ie
s
 E
A
- 
o
r 
T
E
N
S
-i
n
d
u
c
e
d
 
a
n
ti
n
o
c
ic
e
p
ti
o
n
. 
E
A
 a
n
d
 T
E
N
S
 w
e
re
 
c
o
m
p
a
re
d
 f
o
r 
th
re
e
 
in
te
n
s
it
ie
s
 a
n
d
 
th
re
e
 s
ti
m
u
la
ti
o
n
 
fr
e
q
u
e
n
c
ie
s
. 
S
y
s
te
m
ic
 n
a
lo
x
o
n
e
 
h
y
d
ro
c
h
lo
ri
d
e
 
a
lm
o
s
t 
c
o
m
p
le
te
ly
 
a
n
d
 p
a
rt
ia
ll
y
 
a
n
ta
g
o
n
iz
e
d
 2
 a
n
d
 
1
5
 H
z
 E
A
- 
o
r 
T
E
N
S
-i
n
d
u
c
e
d
 
a
n
a
lg
e
s
ia
, 
re
s
p
e
c
ti
v
e
ly
, 
b
u
t 
n
o
t 
1
0
0
 H
z
 E
A
 o
r 
T
E
N
S
 
S
T
T
, 
s
p
in
o
th
a
la
m
ic
 t
ra
c
t.
 P
E
N
S
, 
p
e
rc
u
ta
n
e
o
u
s
 e
le
c
tr
ic
a
l 
n
e
rv
e
 s
ti
m
u
la
ti
o
n
. 
E
A
, 
e
le
c
tr
o
-a
c
u
p
u
n
c
tu
re
. 
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c
o
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n
 
T
y
p
e
/L
o
c
a
ti
o
n
 
ti
m
e
  
  
  
  
G
a
rr
is
o
n
 a
n
d
 
F
o
re
m
a
n
, 
1
9
9
4
 
5
0
-1
2
5
  
5
-4
5
 
1
0
0
 
5
-4
0
 
5
0
-6
0
 
 
 
P
E
N
S
, 
a
p
p
li
e
d
 i
n
 
th
e
 d
e
rm
a
to
m
e
 
c
o
rr
e
s
p
o
n
d
in
g
 t
o
 
th
e
 s
p
in
a
l 
c
o
rd
 
s
e
g
m
e
n
t 
o
f 
n
o
x
io
u
s
 
s
ti
m
u
la
ti
o
n
 o
f 
 
n
o
x
io
u
s
 
s
ti
m
u
la
ti
o
n
. 
>
2
0
 s
 
C
a
ts
, 
a
n
e
s
th
e
ti
z
e
d
, 
 
n
o
x
io
u
s
 s
ti
m
u
la
ti
o
n
 
b
y
 a
 s
e
lf
 s
u
s
ta
in
in
g
 
c
la
m
p
 o
r 
b
y
 m
a
n
u
a
l 
n
o
x
io
u
s
 p
in
c
h
. 
S
p
o
n
ta
n
e
o
u
s
ly
 f
ir
in
g
 
a
n
d
 n
o
x
io
u
s
ly
 
e
v
o
k
e
d
 a
c
ti
v
it
y
 o
f 
d
o
rs
a
l 
h
o
rn
 c
e
ll
s
 (
H
T
 
a
n
d
 W
D
R
) 
w
a
s
 m
o
re
 
d
e
c
re
a
s
e
d
 f
o
r 
h
ig
h
  
fr
e
q
u
e
n
c
y
 T
E
N
S
 
th
a
n
 f
o
r 
lo
w
-
fr
e
q
u
e
n
c
y
 T
E
N
S
. 
N
o
x
io
u
s
 
s
ti
m
u
la
ti
o
n
 w
a
s
 
s
ta
rt
e
d
 c
a
 2
0
 s
 
b
e
fo
re
 T
E
N
S
 w
a
s
 
a
p
p
li
e
d
 a
n
d
 w
a
s
 
s
u
s
ta
in
e
d
 t
il
l 
c
a
 2
0
 
s
 a
ft
e
r 
T
E
N
S
. 
W
e
i 
a
n
d
 Z
h
a
o
, 
1
9
9
5
 
1
0
0
 
2
0
0
 
2
.5
 V
 
A
-b
e
ta
 
fi
b
e
rs
 a
n
d
 
a
 s
m
a
ll
 
a
m
o
u
n
t 
o
f 
A
-d
e
lt
a
 
fi
b
e
rs
 
 
E
le
c
tr
o
d
e
s
 w
e
re
 
p
la
c
e
d
 o
n
 t
h
e
 
d
is
s
e
c
te
d
 t
ib
ia
l 
n
e
rv
e
. 
3
2
 m
in
 
R
a
ts
, 
a
n
e
s
th
e
ti
z
e
d
, 
n
o
x
io
u
s
 s
ti
m
u
la
ti
o
n
 
b
y
 e
le
c
tr
ic
a
l 
s
ti
m
u
la
ti
o
n
 o
f 
th
e
 
ti
b
ia
l 
n
e
rv
e
 (
1
0
0
 V
, 
0
.2
 m
s
, 
a
t 
1
 H
z
 f
o
r 
3
0
 m
in
).
 
T
E
N
S
 s
ti
m
u
la
ti
o
n
 
re
d
u
c
e
d
 F
L
I 
fo
r 
c
a
 
5
4
%
 i
n
 l
a
m
in
a
e
 I
V
-
V
II
 a
n
d
 c
a
 5
%
 i
n
 
la
m
in
a
e
 I
-I
II
. 
T
E
N
S
 w
a
s
 a
p
p
li
e
d
 
2
 m
in
 b
e
fo
re
 
n
o
x
io
u
s
 
s
ti
m
u
la
ti
o
n
 a
n
d
  
c
o
-a
p
p
li
e
d
 w
it
h
 
n
o
x
io
u
s
 
s
ti
m
u
la
ti
o
n
 f
o
r 
3
0
 
m
in
. 
G
a
rr
is
o
n
 a
n
d
 
F
o
re
m
a
n
, 
1
9
9
6
 
5
-1
2
5
 
1
0
0
 
5
-6
0
 
 
 
P
E
N
S
, 
a
p
p
li
e
d
 i
n
 
th
e
 d
e
rm
a
to
m
e
 
c
o
rr
e
s
p
o
n
d
in
g
 t
o
 
th
e
 s
p
in
a
l 
c
o
rd
 
s
e
g
m
e
n
t 
o
f 
n
o
x
io
u
s
 
s
ti
m
u
la
ti
o
n
. 
2
0
 s
 o
r 
5
 
m
in
 
C
a
ts
, 
a
n
e
s
th
e
ti
z
e
d
, 
tr
a
n
s
e
c
ti
o
n
 o
f 
th
e
 
s
p
in
a
l 
c
o
rd
, 
n
o
x
io
u
s
 
s
ti
m
u
la
ti
o
n
 b
y
 a
 
s
e
lf
 s
u
s
ta
in
in
g
 
c
la
m
p
. 
S
p
o
n
ta
n
e
o
u
s
ly
 f
ir
in
g
 
o
f 
d
o
rs
a
l 
h
o
rn
 c
e
ll
s
 
(H
T
, 
W
D
R
) 
w
a
s
 
d
e
c
re
a
s
e
d
 f
o
r 
c
a
 
6
0
%
, 
n
o
x
io
u
s
ly
 
e
v
o
k
e
d
 a
c
ti
v
it
y
 o
f 
d
o
rs
a
l 
h
o
rn
 c
e
ll
s
 w
a
s
 
d
e
c
re
a
s
e
d
 b
y
 c
a
 
5
6
%
, 
c
h
a
n
g
e
s
 d
id
 
n
o
t 
s
u
s
ta
in
 a
ft
e
r 
c
e
s
s
a
ti
o
n
 o
f 
T
E
N
S
 
tr
e
a
tm
e
n
t.
 
 
T
E
N
S
 w
a
s
 a
p
p
li
e
d
 
w
it
h
o
u
t 
n
o
x
io
u
s
 
s
ti
m
u
la
ti
o
n
, 
a
ft
e
r 
5
 
m
in
 o
f 
a
tt
a
c
h
in
g
 a
 
c
la
m
p
. 
P
E
N
S
, 
p
e
rc
u
ta
n
e
o
u
s
 e
le
c
tr
ic
a
l 
n
e
rv
e
 s
ti
m
u
la
ti
o
n
. 
H
T
, 
h
ig
h
-t
h
re
s
h
o
ld
. 
W
D
R
, 
w
id
e
-d
y
n
a
m
ic
–
ra
n
g
e
. 
F
L
I,
 f
o
s
-l
ik
e
 i
m
m
u
n
o
re
a
c
ti
v
it
y
. 
80 
 
   
 
S
tu
d
y
 
T
E
N
S
 a
p
p
li
c
a
ti
o
n
 
  
  
  
  
  
A
n
im
a
l/
C
o
n
d
it
io
n
 
E
ff
e
c
t 
C
o
m
m
e
n
ts
 
 
P
u
ls
e
 R
a
te
 
P
u
ls
e
 
W
id
th
 
P
u
ls
e
 
In
te
n
s
it
y
 
  
  
E
le
c
tr
o
d
e
s
 
S
ti
m
u
la
ti
o
n
 
 
 
  
H
z
 
µ
s
 
m
A
 
s
ti
m
u
la
te
d
 
a
ff
e
re
n
ts
 
c
li
n
ic
a
l 
c
o
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it
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n
 
T
y
p
e
/L
o
c
a
ti
o
n
 
ti
m
e
  
  
  
  
W
a
n
g
 e
t 
a
l.
, 
1
9
9
7
 
1
0
0
/2
 
5
0
0
 
 
 
T
h
e
 i
n
te
n
s
it
y
 
w
a
s
 s
e
t 
a
t 
5
 
ti
m
e
s
 t
h
e
 
th
re
s
h
o
ld
 o
f 
th
e
 
s
ti
m
u
la
te
d
 n
e
rv
e
 
fo
r 
th
e
 L
-S
 a
n
d
 
L
-T
 m
o
d
e
s
. 
F
o
r 
th
e
 H
-S
 a
n
d
 H
-T
 
m
o
d
e
s
. 
1
0
0
 t
o
 
2
0
0
 t
im
e
s
 t
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The inflammatory pain model 
 
The results of a literature survey of the effects of TENS, in an animal 
model for inflammatory pain, are shown in table 2. 
Inflammation is induced by intra muscular, intra articular or subcutaneous 
injection of carrageenan or complete Freund’s adjuvant, in the hind paw of 
the rat. The effects of high or low-frequency TENS is studied on 
spontaneous behavior or on primary and secondary hyperalgesia in 
response to radiant heat or mechanical stimuli.  
 
Effects of different TENS applications on primary and secondary 
hyperalgesia 
The effect of varying frequency (100 Hz or 4 Hz), intensity and pulse 
duration in TENS is investigated on primary hyperalgesia of the inflamed 
hind paw of rats. TENS electrodes were applied to the inflamed hind paw 
on the site of primary hyperalgesia. Only high-frequency TENS (100 Hz) 
significantly reduces spontaneous pain behaviors and primary 
hyperalgesia, as measured by the paw withdrawal latency (PWL) to 
radiant heat and mechanical stimuli [28].  
Both high- and low-frequency TENS completely reverses primary 
hyperalgesia, measured by the compression withdrawal threshold, when 
applied at 24 hours or 2 weeks after the induction of inflammation of the 
knee, but not when applied at 4 hours after the induction of inflammation; 
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these data suggest that TENS inhibits primary hyperalgesia associated 
with inflammation in a time-dependent manner after inflammation has 
already developed during both acute and chronic stages [29]. 
 
After injection of carrageenan in the plantar surfaces of rat hind paws, 
low- and high-frequency TENS, with stimulation frequencies of 10 Hz and 
130 Hz respectively, inhibited by 100% the primary hyperalgesia but not 
the edema response [30]. However, low-frequency TENS presented longer 
lasting effects as compared with high-frequency TENS. Animals treated 
with an opioid antagonist (Naltrexone) showed a complete reversion of the 
analgesic effect induced by low- but not high-frequency TENS. 
 
Application of high (100 Hz,) and low (4 Hz) frequency TENS on both sides 
of the inflamed knee in rats, results in reversal of the secondary 
hyperalgesia immediately following treatment [31]. Effects of high-
frequency TENS last through at least 24 h while those of low-frequency 
TENS last through 12 h, no effect is found on spontaneous pain behaviors 
or joint circumference.  
In rats with knee joint inflammation there is no difference in effect of 
varying frequency (100 Hz or 4 Hz) and intensity in TENS on secondary 
hyperalgesia [32]; both TENS applications with high or low frequency or 
high or low intensity are equally successful in reducing secondary 
mechanical hyperalgesia. 
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For TENS-induced antihyperalgesia, large diameter primary afferent fibers 
from deep tissue are required; activation of cutaneous afferents alone is 
not sufficient to induce antihyperalgesia in knee inflammation in rats [33]. 
When the skin surrounding the inflamed knee joint is anesthetized using 
an anesthetic cream (EMLA) both low and high frequency TENS completely 
reverses hyperalgesia. Application of EMLA cream to the skin reduces the 
amplitude of the cord dorsum potential by 40% to 70% for both high and 
low frequency TENS, confirming a loss of large diameter primary afferent 
input after EMLA is applied to the skin. However, injection of lidocaine into 
the knee joint prevented antihyperalgesia produced by both low and high 
frequency TENS. 
 
For high-frequency (100 Hz) TENS, there is no difference on inflammatory 
hyperalgesia with different waveforms (asymmetric biphasic square and 
symmetric biphasic square) [34]. TENS treatment with either the 
asymmetric or symmetric waveform significantly increases the PWL when 
compared with sham TENS. 
 
In an animal model of muscle inflammation, either low (4 HZ) or high-
frequency (100 Hz) TENS applied to the rat gastrocnemius muscle 
ipsilateral to the site of muscle inflammation significantly reverses 
mechanical hyperalgesia both ipsilateral and contralateral to the site of 
inflammation [35]. Low- or high-frequency TENS applied to the 
gastrocnemius muscle contralateral to the site of inflammation also 
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significantly reduces mechanical hyperalgesia, both ipsilateral and 
contralateral to the site of inflammation. 
Similar effects are found in an inflammation model, induced by 
subcutaneous injection of carrageenan in rat hind paws. The application of 
both high-frequency (130 Hz) and low-frequency (10 Hs) TENS to the 
contralateral paw reverses the hyperalgesia of the inflamed paw similar to 
that observed when TENS was applied to the inflamed paw [36] However, 
low-frequency TENS presented a longer-lasting analgesic effect than high-
frequency TENS. Pretreatment of animals with intraplantar naltrexone (an 
opioid antagonist) reversed the analgesic effect of the low-frequency TENS 
but did not alter the effect of high-frequency TENS. 
 
In rats, both low- and high-frequency TENS applied to the inflamed paw 
reduces both noxious and innocuous evoked responses of WDR and HT 
dorsal horn neurons to or below baseline levels [37]. However, the 
increased receptive field of WDR neurons was unchanged following 
treatment of both low- and high-frequency TENS.  
 
Receptors in the central nervous system involved in the effects of TENS  
In rats with inflamed knee joints, high-frequency (100 Hz) TENS reduces 
the paw withdrawal latency (PWL) to radiant heat by δ-opioid receptors 
and low-frequency (4 Hz) TENS by μ-opioid receptors in the spinal cord 
[38]. In a similar study, using the same TENS applications, but in rats that 
were morphine-tolerant, the hyperalgesia in morphine-tolerant animals 
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with knee inflammation was unaffected by low-frequency TENS but fully 
reversed by high-frequency TENS [39].  
In high (100 Hz) and low (4 Hz) frequency TENS, in rats with knee 
inflammation, spinal 5-HT receptors mediate low, but not high-frequency 
TENS–induced antihyperalgesia through activation of 5-HT2A and 5-HT3 
receptors, spinal noradrenergic receptors (α2-adrenoreceptors) are not 
involved in either low- or high-frequency TENS antihyperalgesia [40]. 
However α2A-adrenoreceptors expressed in the knee joint, contribute to a 
component of TENS-mediated antihyperalgesia, after induction of 
inflammation [41]. Low (4 Hz) frequency TENS but not high-frequency 
TENS, increases serotonin concentrations in the dorsal horn, in rats with 
knee inflammation, there is no change in noradrenalin levels in the dorsal 
horn with either Low- or high-frequency TENS [42]. 
Results in a similar study show that high- and low-frequency TENS-
induced antihyperalgesia is mediated partially by activation of spinal 
muscarinic (M1 and M3) receptors but not spinal nicotinic receptors [43]. 
In rats with and without joint inflammation, high-frequency (100 Hz), but 
not low-frequency (4 Hz), TENS significantly reduces spinal glutamate and 
aspartate in animals with joint inflammation compared with levels in those 
without joint inflammation [44].  
High-frequency TENS increases extracellular GABA concentrations in the 
spinal cord in animals with and without joint inflammation. The increases 
in GABA do not occur in response to low frequency TENS, and there are no 
increases in glycine in response to low or high frequency TENS. However, 
 87 
 
the reduction in primary hyperalgesia by both high and low frequency 
TENS is prevented by spinal blockade of GABAA receptors with bicuculline 
[45]. TENS applied with 2 an 100 Hz alternately, suppresses the CFA-
induced extracellular signal-regulated kinase-2 activation in the ipsilateral 
spinal dorsal horn, the contralateral S1 area, and the amygdale [46]. 
 
Descending inhibitory pathways and effects of TENS  
Low-frequency (4 HZ) and high-frequency (100 Hz) TENS produces 
antihyperalgesia by activation of μ- and δ -opioid receptors, respectively 
in the rostroventromedial medulla (RVM) [47]; naloxone microinjected into 
the RVM blocked the antihyperalgesia produced by low frequency, but not 
that produced by high-frequency TENS. In contrast, naltrindole injection 
into the RVM blocked the antihyperalgesia produced by high frequency, 
but not that produced by low-frequency TENS. 
The periaqueductal grey (PAG) is involved in the antinociceptive pathway 
activated by stimulation with either high- (100 Hz) or low-frequency (4 
Hz) TENS in rats [48]. The increases in withdrawal thresholds after TENS 
were prevented by microinjection of CoCl2 into the ventrolateral PAG, but 
not the dorsolateral PAG prior to TENS, and were significantly lower than 
controls treated with TENS. 
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Effects of repeated TENS applications and analgesic tolerance 
Repeated application of either low- or high-frequency TENS for 6 days, 
leads to a development of tolerance to its antihyperalgesic effects, with a 
corresponding cross-tolerance to μ- and δ-opioid agonists [49]. 
Diminution in effectiveness of reversing the ipsilateral secondary 
mechanical hyperalgesia appeared on the fourth day.  
In a similar study design, blockade of NMDA receptors in the dorsal horn 
prevents analgesic tolerance to daily high-frequency (100 Hz) or low-
frequency (4 Hz)TENS, by preventing tolerance at spinal opioid receptors 
[50].  
Spinal blockade of CCK-A or CCK-B receptors blocks the development of 
tolerance to high- and low-frequency TENS, respectively [51]. Spinal 
blockade of CCK-A receptors prevents cross-tolerance at spinal δ-opioid 
receptors that normally occurs with high frequency TENS; and blockade of 
CCK-B receptors prevents cross-tolerance at spinal μ-opioid receptors that 
normally occurs with low frequency TENS.  
Repeated administration of TENS with alternating frequency (4 Hz on 1 
day; 100 Hz on the next day) delays the development of analgesic 
tolerance by approximately 5 days, compared with administration of low- 
or high-frequency TENS independently [52].  
For the application of repeated 100 Hz TENS on the acute CFA-induced 
monoarthritis (Weeks 1–3) in rats, the optimal stimulation schedule is 
twice-a-week; while in the stable period (Weeks 4–9), once-a-week 
schedule appears to produce better analgesic effect. TENS with a weaker 
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intensity of stimulation was more effective than with stronger intensities. 
When TENS was administered five-times-a-week, no therapeutic effect 
was observed [53]. 
 
Conclusion  
 
In rats, in an inflammatory pain model, primary and secondary 
hyperalgesia, induced by inflammation, decreases by both high- and low-
frequency TENS application, when it is applied ipsilateral as well as 
contralateral to the side of the inflammation. Effects are independent of 
stimulus intensities - sensory level and at an intensity which provokes a 
muscle contraction, or wave form – symmetrical biphasic or asymmetrical. 
However, stimulation of deep large afferent neuron fibers is required at 
the site of inflammation, or the mirrored site. 
 
The effects of both and high- and low-frequency TENS are explained by 
reduced activity of the WDR and HT neurons in the dorsal horn, the 
involvement of the rostroventromedial medulla and by the activation of 
the ventrolateral periaqueductal grey. 
High-frequency TENS, but not low-frequency TENS increases extracellular 
GABA concentrations in the spinal cord. However, both TENS applications 
reduce primary hyperalgesia by means of GABAA receptors in the dorsal 
horn; thus for high-frequency TENS by increasing extracellular GABA 
concentrations and possibly for low-frequency TENS through descending 
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control – low-frequency but not high frequency TENS uses serotonin 
pathways in the spinal cord. Both TENS applications have no effect on 
glycine concentrations in the spinal cord. 
The antihyperalgesia effects of high- and low-frequency TENS are 
accomplished by means of δ- and μ-opioid receptors, respectively, both in 
the RVM and in the spinal cord.  
 
Repeated administration of low and high frequency TENS leads to a 
development of opioid tolerance. This diminution in its effectiveness in 
reversing hyperalgesia can be delayed with alternating the stimulation 
frequency, every other day, and by reducing the intervention frequency.  
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e
l 
2
x
 m
o
to
r 
th
re
s
h
o
ld
. 
P
re
-g
e
ll
e
d
 r
o
u
n
d
 
e
le
c
tr
o
d
e
s
, 
to
 t
h
e
 
h
in
d
 p
a
w
. 
O
n
e
 
e
le
c
tr
o
d
e
 w
a
s
 
p
la
c
e
d
 d
o
rs
a
ll
y
 j
u
s
t 
d
is
ta
l 
to
 t
h
e
 a
n
k
le
 
jo
in
t.
 T
h
e
 o
th
e
r 
e
le
c
tr
o
d
e
 w
a
s
 
p
la
c
e
d
 o
n
 t
h
e
 
p
la
n
ta
r 
s
u
rf
a
c
e
 o
f 
th
e
 h
in
d
 p
a
w
 o
n
 t
h
e
 
m
id
-p
la
n
ta
r 
re
g
io
n
. 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
C
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
to
 t
h
e
 
p
la
n
ta
r 
s
u
rf
a
c
e
 o
f 
th
e
 p
a
w
 
H
ig
h
-f
re
q
u
e
n
c
y
 T
E
N
S
 
re
d
u
c
e
s
 p
ri
m
a
ry
 
h
y
p
e
ra
lg
e
s
ia
 t
o
 h
e
a
t 
a
n
d
 m
e
c
h
a
n
ic
a
l 
s
ti
m
u
li
 
fo
r 
u
p
 t
o
 1
 d
a
y
 a
ft
e
r 
tr
e
a
tm
e
n
t.
 V
a
ry
in
g
 
in
te
n
s
it
y
 o
r 
p
u
ls
e
 
d
u
ra
ti
o
n
 h
a
d
 n
o
 e
ff
e
c
t 
o
n
 t
h
e
 d
e
g
re
e
 o
f 
a
n
ti
h
y
p
e
ra
lg
e
s
ia
 
p
ro
d
u
c
e
d
 b
y
 h
ig
h
 
fr
e
q
u
e
n
c
y
. 
L
o
w
 
fr
e
q
u
e
n
c
y
 T
E
N
S
 i
s
 
in
e
ff
e
c
ti
v
e
 i
n
 r
e
d
u
c
in
g
 
p
ri
m
a
ry
 h
y
p
e
ra
lg
e
s
ia
. 
 
 
P
W
L
, 
p
a
w
 w
it
h
d
ra
w
a
l 
la
te
n
c
y
. 
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P
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W
id
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P
u
ls
e
 
In
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E
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e
s
 
S
ti
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ti
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n
 
 
 
  
H
z
 
µ
s
 
m
A
 
s
ti
m
u
la
te
d
 
a
ff
e
re
n
ts
 
c
li
n
ic
a
l 
c
o
n
d
it
io
n
 
T
y
p
e
/L
o
c
a
ti
o
n
 
ti
m
e
  
  
  
  
S
lu
k
a
, 
K
.A
. 
a
n
d
 
M
.A
. 
Ju
d
g
e
, 
e
t 
a
l.
 (
2
0
0
0
) 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
S
e
n
s
o
ry
 
in
te
n
s
it
y
; 
ju
s
t 
b
e
lo
w
 m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 
R
o
u
n
d
 p
re
-g
e
ll
e
d
 
e
le
c
tr
o
d
e
s
, o
n
 t
h
e
 
m
e
d
ia
l 
a
n
d
 l
a
te
ra
l 
a
s
p
e
c
t 
o
f 
th
e
 
in
fl
a
m
e
d
 k
n
e
e
 j
o
in
t 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
K
a
o
li
n
 a
n
d
 
C
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
to
 t
h
e
 
jo
in
t 
c
a
v
it
y
 o
f 
o
n
e
 
k
n
e
e
 
B
o
th
 h
ig
h
- 
a
n
d
 l
o
w
-
fr
e
q
u
e
n
c
y
 T
E
N
S
 
c
a
u
s
e
d
 n
e
a
rl
y
 1
0
0
%
 
in
h
ib
it
io
n
 o
f 
s
e
c
o
n
d
a
ry
 
h
y
p
e
ra
lg
e
s
ia
 i
n
 
a
n
im
a
ls
 r
e
c
e
iv
in
g
 
p
la
c
e
b
o
 p
e
ll
e
ts
. 
In
 
c
o
n
tr
a
s
t,
 t
h
e
 
h
y
p
e
ra
lg
e
s
ia
 i
n
 
m
o
rp
h
in
e
-t
o
le
ra
n
t 
a
n
im
a
ls
 w
it
h
 k
n
e
e
 
jo
in
t 
in
fl
a
m
m
a
ti
o
n
 w
a
s
 
u
n
a
ff
e
c
te
d
 b
y
 l
o
w
-
fr
e
q
u
e
n
c
y
 T
E
N
S
 b
u
t 
fu
ll
y
 r
e
v
e
rs
e
d
 b
y
 h
ig
h
-
fr
e
q
u
e
n
c
y
 T
E
N
S
. 
 
M
o
rp
h
in
e
 t
o
le
ra
n
c
e
 w
a
s
 
in
d
u
c
e
d
 b
y
 s
u
b
c
u
ta
n
e
o
u
s
 
im
p
la
n
ta
ti
o
n
 o
f 
m
o
rp
h
in
e
 
p
e
ll
e
ts
 o
v
e
r 
1
0
 d
a
y
s
. 
K
in
g
, 
E
.W
. 
a
n
d
 
K
.A
. 
S
lu
k
a
 
(2
0
0
1
) 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
T
w
o
 i
n
te
n
s
it
y
 
le
v
e
ls
: 
in
te
n
s
it
y
 
le
v
e
l 
ju
s
t 
b
e
lo
w
 
m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 a
n
d
 
in
te
n
s
it
y
 l
e
v
e
l 
2
x
 m
o
to
r 
th
re
s
h
o
ld
. 
P
re
-g
e
ll
e
d
 
e
le
c
tr
o
d
e
s
 2
.5
 c
m
 i
n
 
d
ia
m
e
te
r,
 o
n
e
 
m
e
d
ia
ll
y
 a
n
d
 o
n
e
 
la
te
ra
ll
y
 o
n
 t
h
e
 
in
fl
a
m
e
d
 k
n
e
e
. 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
K
a
o
li
n
 a
n
d
 
C
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
to
 t
h
e
 
jo
in
t 
c
a
v
it
y
 o
f 
o
n
e
 
k
n
e
e
 
E
it
h
e
r 
lo
w
- 
o
r 
h
ig
h
-
fr
e
q
u
e
n
c
y
 T
E
N
S
 i
s
 
e
q
u
a
ll
y
 s
u
c
c
e
s
s
fu
l 
in
 
re
d
u
c
in
g
 s
e
c
o
n
d
a
ry
 
m
e
c
h
a
n
ic
a
l 
(V
o
n
 F
re
y
 
F
il
a
m
e
n
ts
) 
h
y
p
e
ra
lg
e
s
ia
. 
E
it
h
e
r 
s
e
n
s
o
ry
-o
r-
m
o
to
r-
in
te
n
s
it
y
 T
E
N
S
 e
q
u
a
ll
y
 
re
d
u
c
e
s
 s
e
c
o
n
d
a
ry
 
m
e
c
h
a
n
ic
a
l 
h
y
p
e
ra
lg
e
s
ia
. 
 
 
 
M
a
, 
Y
. 
T
. 
a
n
d
 K
. 
A
. 
S
lu
k
a
 (
2
0
0
1
) 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
M
o
to
r 
le
v
e
l;
 t
h
e
 
in
te
n
s
it
y
 t
h
a
t 
fi
rs
t 
p
ro
d
u
c
e
s
 a
 
v
is
ib
le
 m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
. 
P
re
-g
e
ll
e
d
 s
u
rf
a
c
e
 
e
le
c
tr
o
d
e
s
, 
lo
c
a
te
d
 
to
 e
n
c
o
m
p
a
s
s
 t
h
e
 
p
o
rt
io
n
 o
f 
th
e
 
re
c
e
p
ti
v
e
 f
ie
ld
 
lo
c
a
te
d
 o
n
 t
h
e
 p
a
w
. 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
C
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
to
 t
h
e
 
p
la
n
ta
r 
a
s
p
e
c
t 
o
f 
th
e
 p
a
w
. 
 
E
it
h
e
r 
h
ig
h
 o
r 
lo
w
 
fr
e
q
u
e
n
c
y
 T
E
N
S
 
re
d
u
c
e
d
 b
o
th
 
in
n
o
c
u
o
u
s
 a
n
d
 n
o
x
io
u
s
 
e
v
o
k
e
d
 r
e
s
p
o
n
s
e
s
 o
f 
W
D
R
 a
n
d
 H
T
 d
o
rs
a
l 
h
o
rn
 n
e
u
ro
n
s
 
im
m
e
d
ia
te
ly
 a
n
d
 1
 h
 
a
ft
e
r 
tr
e
a
tm
e
n
t 
w
it
h
 
T
E
N
S
. 
T
E
N
S
 h
a
d
 n
o
 
e
ff
e
c
t 
o
n
 r
e
s
p
o
n
s
e
s
 o
f 
L
T
 n
e
u
ro
n
s
. 
E
x
tr
a
c
e
ll
u
la
r 
re
c
o
rd
in
g
s
 
w
e
re
 a
s
s
e
s
s
e
d
 f
ro
m
 
W
D
R
, 
H
T
 a
n
d
 L
T
 d
o
rs
a
l 
h
o
rn
 n
e
u
ro
n
s
. 
C
o
m
p
a
ri
s
o
n
 o
f 
re
s
p
o
n
s
e
s
 
a
ft
e
r 
T
E
N
S
 w
it
h
 b
a
s
e
li
n
e
 
re
s
p
o
n
s
e
s
 s
h
o
w
e
d
 t
h
a
t 
th
e
 e
v
o
k
e
d
 r
e
s
p
o
n
s
e
s
 i
n
 
th
e
 m
a
jo
ri
ty
 o
f 
W
D
R
 a
n
d
 
H
T
 c
e
ll
s
 r
e
tu
rn
e
d
 t
o
 o
r 
fe
ll
 b
e
lo
w
 b
a
s
e
li
n
e
 
re
s
p
o
n
s
e
s
. 
 
 
W
D
R
, 
w
id
e
 d
y
n
a
m
ic
 r
a
n
g
e
. 
H
T
, 
h
ig
h
 t
h
re
s
h
o
ld
. 
L
T
, 
lo
w
 t
h
re
s
h
o
ld
.
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K
a
lr
a
, 
A
. 
a
n
d
 
M
.O
. 
U
rb
a
n
, 
e
t 
a
l.
 (
2
0
0
1
) 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
S
e
n
s
o
ry
 
in
te
n
s
it
y
; 
ju
s
t 
b
e
lo
w
 m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 
R
o
u
n
d
 p
re
-g
e
ll
e
d
 
e
le
c
tr
o
d
e
s
, o
n
 t
h
e
 
m
e
d
ia
l 
a
n
d
 l
a
te
ra
l 
a
s
p
e
c
t 
o
f 
th
e
 
in
fl
a
m
e
d
 k
n
e
e
 j
o
in
t 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
K
a
o
li
n
 a
n
d
 
c
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
 t
h
e
 
le
ft
 k
n
e
e
 j
o
in
t.
 
lo
w
-f
re
q
u
e
n
c
y
 a
n
d
 
h
ig
h
-f
re
q
u
e
n
c
y
 T
E
N
S
 
p
ro
d
u
c
e
s
 
a
n
ti
h
y
p
e
ra
lg
e
s
ia
 b
y
 
a
c
ti
v
a
ti
o
n
 o
f 
µ
-o
p
io
id
 
a
n
d
 δ
-o
p
io
id
 
re
c
e
p
to
rs
, 
re
s
p
e
c
ti
v
e
ly
, 
in
 t
h
e
 
R
V
M
. 
 
P
a
w
 w
it
h
d
ra
w
a
l 
la
te
n
c
y
 
to
 r
a
d
ia
n
t 
h
e
a
t,
 a
s
 a
n
 
in
d
e
x
 o
f 
s
e
c
o
n
d
a
ry
 
h
y
p
e
ra
lg
e
s
ia
, 
w
a
s
 
re
c
o
rd
e
d
 b
e
fo
re
 a
n
d
 a
ft
e
r 
k
n
e
e
 j
o
in
t 
in
fl
a
m
m
a
ti
o
n
  
a
n
d
 a
ft
e
r 
T
E
N
S
/n
o
 T
E
N
S
 
c
o
a
d
m
in
is
te
re
d
 w
it
h
 
n
a
lo
x
o
n
e
, 
n
a
lt
ri
n
d
o
le
, 
o
r 
v
e
h
ic
le
 m
ic
ro
in
je
c
te
d
 i
n
to
 
th
e
 R
V
M
. 
 
R
a
d
h
a
k
ri
s
h
n
a
n
, 
R
. 
a
n
d
 K
. 
A
. 
S
lu
k
a
 (
2
0
0
3
)
 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
S
e
n
s
o
ry
 
in
te
n
s
it
y
; 
ju
s
t 
b
e
lo
w
 m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 
R
o
u
n
d
 p
re
-g
e
ll
e
d
 
e
le
c
tr
o
d
e
s
, o
n
 t
h
e
 
m
e
d
ia
l 
a
n
d
 l
a
te
ra
l 
a
s
p
e
c
t 
o
f 
th
e
 
in
fl
a
m
e
d
 k
n
e
e
 j
o
in
t 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
K
a
o
li
n
 a
n
d
 
c
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
 t
h
e
 
le
ft
 k
n
e
e
 j
o
in
t 
L
o
w
- 
a
n
d
 h
ig
h
-
fr
e
q
u
e
n
c
y
 T
E
N
S
-
in
d
u
c
e
d
 
a
n
ti
h
y
p
e
ra
lg
e
s
ia
 i
s
 
m
e
d
ia
te
d
 p
a
rt
ia
ll
y
 b
y
 
a
c
ti
v
a
ti
o
n
 o
f 
s
p
in
a
l 
m
u
s
c
a
ri
n
ic
 r
e
c
e
p
to
rs
 
b
u
t 
n
o
t 
s
p
in
a
l 
n
ic
o
ti
n
ic
 
re
c
e
p
to
rs
. 
 
P
a
w
 w
it
h
d
ra
w
a
l 
la
te
n
c
y
 
to
 r
a
d
ia
n
t 
h
e
a
t,
 w
a
s
 u
s
e
d
 
a
s
 a
n
 i
n
d
e
x
 o
f 
s
e
c
o
n
d
a
ry
 
h
y
p
e
ra
lg
e
s
ia
. 
S
p
in
a
l 
M
1
 
a
n
d
 M
3
 m
u
s
c
a
ri
n
ic
 
re
c
e
p
to
r 
s
u
b
ty
p
e
s
 
m
e
d
ia
te
 t
h
e
 m
u
s
c
a
ri
n
ic
 
c
o
m
p
o
n
e
n
t 
o
f 
T
E
N
S
 
a
n
ti
h
y
p
e
ra
lg
e
s
ia
. 
R
a
d
h
a
k
ri
s
h
n
a
n
, 
R
. 
a
n
d
 E
.W
. 
K
in
g
, 
e
t 
a
l.
 
(2
0
0
3
) 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
S
e
n
s
o
ry
 
in
te
n
s
it
y
; 
ju
s
t 
b
e
lo
w
 m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 
R
o
u
n
d
 p
re
-g
e
ll
e
d
 
e
le
c
tr
o
d
e
s
, o
n
 t
h
e
 
m
e
d
ia
l 
a
n
d
 l
a
te
ra
l 
a
s
p
e
c
t 
o
f 
th
e
 
in
fl
a
m
e
d
 k
n
e
e
 j
o
in
t 
1
5
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
K
a
o
li
n
 a
n
d
 
c
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
 t
h
e
 
le
ft
 k
n
e
e
 j
o
in
t 
s
p
in
a
l 
5
-H
T
 s
e
ro
to
n
in
 
re
c
e
p
to
rs
 m
e
d
ia
te
 l
o
w
, 
b
u
t 
n
o
t 
h
ig
h
, 
fr
e
q
u
e
n
c
y
 T
E
N
S
-
in
d
u
c
e
d
 
a
n
ti
h
y
p
e
ra
lg
e
s
ia
 
th
ro
u
g
h
 a
c
ti
v
a
ti
o
n
 o
f 
5
-H
T
2
A
 a
n
d
 5
-H
T
3
 
re
c
e
p
to
rs
 i
n
 r
a
ts
. 
S
p
in
a
l 
n
o
ra
d
re
n
e
rg
ic
 
re
c
e
p
to
rs
 a
re
 n
o
t 
in
v
o
lv
e
d
 i
n
 e
it
h
e
r 
lo
w
 
o
r 
h
ig
h
 f
re
q
u
e
n
c
y
 
T
E
N
S
 
a
n
ti
h
y
p
e
ra
lg
e
s
ia
. 
 
P
a
w
 w
it
h
d
ra
w
a
l 
la
te
n
c
y
 
to
 r
a
d
ia
n
t 
h
e
a
t,
 w
a
s
 u
s
e
d
 
a
s
 a
n
 i
n
d
e
x
 o
f 
s
e
c
o
n
d
a
ry
 
h
y
p
e
ra
lg
e
s
ia
. 
 
R
V
M
, 
ro
s
tr
o
v
e
n
tr
o
m
e
d
ia
l 
m
e
d
u
ll
a
. 
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T
y
p
e
/L
o
c
a
ti
o
n
 
ti
m
e
  
  
  
  
C
h
a
n
d
ra
n
, 
P
. 
a
n
d
 K
.A
. 
S
lu
k
a
 
(2
0
0
3
) 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
2
x
 m
o
to
r 
th
re
s
h
o
ld
 
R
o
u
n
d
 p
re
-g
e
ll
e
d
 
e
le
c
tr
o
d
e
s
, o
n
 t
h
e
 
m
e
d
ia
l 
a
n
d
 l
a
te
ra
l 
a
s
p
e
c
t 
o
f 
th
e
 
in
fl
a
m
e
d
 k
n
e
e
 j
o
in
t 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
C
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
 t
h
e
 
le
ft
 k
n
e
e
 j
o
in
t 
R
e
p
e
a
te
d
ly
 
a
d
m
in
is
te
ri
n
g
 e
it
h
e
r 
lo
w
- 
o
r 
h
ig
h
-f
re
q
u
e
n
c
y
 
T
E
N
S
 f
o
r 
6
 d
a
y
s
, 
le
a
d
 
to
 a
 d
im
in
u
ti
o
n
 i
n
 i
ts
 
e
ff
e
c
ti
v
e
n
e
s
s
 i
n
 
re
v
e
rs
in
g
 t
h
e
 
ip
s
il
a
te
ra
l 
s
e
c
o
n
d
a
ry
 
m
e
c
h
a
n
ic
a
l 
h
y
p
e
ra
lg
e
s
ia
 b
y
 t
h
e
 
fo
u
rt
h
 d
a
y
. 
W
it
h
d
ra
w
a
l 
th
re
s
h
o
ld
 t
o
 
m
e
c
h
a
n
ic
a
l 
s
ti
m
u
li
 w
a
s
 
m
e
a
s
u
re
d
 b
e
fo
re
 a
n
d
 
a
ft
e
r 
a
d
m
in
is
tr
a
ti
o
n
 o
f 
T
E
N
S
 o
n
 e
a
c
h
 d
a
y
 a
n
d
 
a
ls
o
 o
n
 t
h
e
 s
ix
th
 d
a
y
. 
R
e
p
e
a
te
d
 a
d
m
in
is
tr
a
ti
o
n
 
o
f 
lo
w
 a
n
d
 h
ig
h
 
fr
e
q
u
e
n
c
y
 T
E
N
S
 l
e
a
d
s
 t
o
 
a
 d
e
v
e
lo
p
m
e
n
t 
o
f 
o
p
io
id
 
to
le
ra
n
c
e
  
 
R
e
s
e
n
d
e
, 
M
.A
. 
a
n
d
 G
.G
. 
S
a
b
in
o
, 
e
t 
a
l.
 
(2
0
0
4
) 
4
 a
n
d
 1
3
0
 
1
3
0
 
 
 
S
e
n
s
o
ry
 
in
te
n
s
it
y
; 
im
m
e
d
ia
te
ly
 
b
e
lo
w
 m
o
to
r 
th
re
s
h
o
ld
. 
S
p
e
c
ia
ll
y
 
c
o
n
s
tr
u
c
te
d
 
e
le
c
tr
o
d
e
s
, 
fi
x
e
d
 i
n
 
th
e
 d
o
rs
a
l 
a
n
d
 
p
la
n
ta
r 
s
u
rf
a
c
e
 o
f 
ra
t 
p
a
w
s
. 
2
0
 m
in
 
F
e
m
a
le
 H
o
lt
z
m
a
n
 
ra
ts
. 
C
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
to
 t
h
e
 
p
la
n
ta
r 
s
u
rf
a
c
e
 o
f 
th
e
 r
a
t 
h
in
d
 p
a
w
s
 
B
o
th
 h
ig
h
- 
a
n
d
 l
o
w
-
fr
e
q
u
e
n
c
y
 T
E
N
S
 
in
h
ib
it
e
d
 b
y
 1
0
0
%
 t
h
e
 
h
y
p
e
ra
lg
e
s
ia
 (
e
s
c
a
p
e
 
o
r 
p
a
w
 w
it
h
d
ra
w
a
l 
to
 
m
e
c
h
a
n
ic
a
l 
p
re
s
s
u
re
),
 
b
u
t 
n
o
t 
th
e
 e
d
e
m
a
 
re
s
p
o
n
s
e
. 
H
o
w
e
v
e
r,
 
lo
w
-f
re
q
u
e
n
c
y
 T
E
N
S
 
p
re
s
e
n
te
d
 l
o
n
g
e
r 
la
s
ti
n
g
 e
ff
e
c
ts
 a
s
 
c
o
m
p
a
re
d
 w
it
h
 h
ig
h
-
fr
e
q
u
e
n
c
y
 T
E
N
S
. 
 
A
n
im
a
ls
 t
re
a
te
d
 w
it
h
 a
n
 
o
p
io
id
 a
n
ta
g
o
n
is
t 
(n
a
lt
re
x
o
n
e
) 
s
h
o
w
e
d
 a
 
c
o
m
p
le
te
 r
e
v
e
rs
io
n
 o
f 
th
e
 
a
n
a
lg
e
s
ic
 e
ff
e
c
t 
in
d
u
c
e
d
 
b
y
 l
o
w
- 
b
u
t 
n
o
t 
h
ig
h
-
fr
e
q
u
e
n
c
y
 T
E
N
S
. 
R
a
d
h
a
k
ri
s
h
n
a
n
, 
R
. 
a
n
d
 K
. 
A
. 
S
lu
k
a
 (
2
0
0
5
)
 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
S
e
n
s
o
ry
 
in
te
n
s
it
y
; 
ju
s
t 
b
e
lo
w
 m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 
R
o
u
n
d
 p
re
-g
e
ll
e
d
 
e
le
c
tr
o
d
e
s
, o
n
 t
h
e
 
m
e
d
ia
l 
a
n
d
 l
a
te
ra
l 
a
s
p
e
c
t 
o
f 
th
e
 
in
fl
a
m
e
d
 k
n
e
e
 j
o
in
t 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
K
a
o
li
n
 a
n
d
 
c
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
 t
h
e
 
le
ft
 k
n
e
e
 j
o
in
t 
In
 c
o
n
tr
o
l 
a
n
d
 E
M
L
A
 
g
ro
u
p
s
, 
b
o
th
 l
o
w
 a
n
d
 
h
ig
h
 f
re
q
u
e
n
c
y
 T
E
N
S
 
c
o
m
p
le
te
ly
 r
e
v
e
rs
e
d
 
h
y
p
e
ra
lg
e
s
ia
. 
H
o
w
e
v
e
r,
 i
n
je
c
ti
o
n
 o
f 
li
d
o
c
a
in
e
 i
n
to
 t
h
e
 k
n
e
e
 
jo
in
t 
p
re
v
e
n
te
d
 
a
n
ti
h
y
p
e
ra
lg
e
s
ia
 
p
ro
d
u
c
e
d
 b
y
 b
o
th
 l
o
w
 
a
n
d
 h
ig
h
 f
re
q
u
e
n
c
y
 
T
E
N
S
 
R
e
c
o
rd
in
g
s
 o
f 
c
o
rd
 
d
o
rs
u
m
 p
o
te
n
ti
a
ls
 
s
h
o
w
e
d
 t
h
a
t 
b
o
th
 l
o
w
 
a
n
d
 h
ig
h
 f
re
q
u
e
n
c
y
 T
E
N
S
 
a
t 
s
e
n
s
o
ry
 i
n
te
n
s
it
y
 
a
c
ti
v
a
te
s
 o
n
ly
 l
a
rg
e
 
d
ia
m
e
te
r 
a
ff
e
re
n
t 
fi
b
e
rs
. 
In
c
re
a
s
in
g
 i
n
te
n
s
it
y
 t
o
 
tw
ic
e
 t
h
e
 m
o
to
r 
th
re
s
h
o
ld
 r
e
c
ru
it
s
 A
-d
e
lt
a
 
a
ff
e
re
n
t 
fi
b
e
rs
. 
A
p
p
li
c
a
ti
o
n
 o
f 
E
M
L
A
 
c
re
a
m
 t
o
 t
h
e
 s
k
in
 
re
d
u
c
e
s
 t
h
e
 a
m
p
li
tu
d
e
 o
f 
th
e
 c
o
rd
 d
o
rs
u
m
 
p
o
te
n
ti
a
l 
b
y
 4
0
%
 t
o
 7
0
%
 
  
E
M
L
A
, 
a
n
 a
n
e
s
th
e
ti
c
 c
re
a
m
. 
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R
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P
u
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P
u
ls
e
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E
le
c
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e
s
 
S
ti
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la
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o
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H
z
 
µ
s
 
m
A
 
s
ti
m
u
la
te
d
 
a
ff
e
re
n
ts
 
c
li
n
ic
a
l 
c
o
n
d
it
io
n
 
T
y
p
e
/L
o
c
a
ti
o
n
 
ti
m
e
  
  
  
  
S
lu
k
a
, 
K
.A
. 
a
n
d
 
C
.G
.T
. 
V
a
n
c
e
, 
e
t 
a
l.
 (
2
0
0
5
) 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
S
e
n
s
o
ry
 
in
te
n
s
it
y
; 
ju
s
t 
b
e
lo
w
 m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 
R
o
u
n
d
 p
re
-g
e
ll
e
d
 
e
le
c
tr
o
d
e
s
, o
n
 t
h
e
 
m
e
d
ia
l 
a
n
d
 l
a
te
ra
l 
a
s
p
e
c
t 
o
f 
b
o
th
 
in
fl
a
m
e
d
 k
n
e
e
 j
o
in
ts
 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
K
a
o
li
n
 a
n
d
 
c
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
 b
o
th
 
k
n
e
e
 j
o
in
ts
 
H
ig
h
-f
re
q
u
e
n
c
y
, 
b
u
t 
n
o
t 
lo
w
-f
re
q
u
e
n
c
y
, 
T
E
N
S
 
s
ig
n
if
ic
a
n
tl
y
 r
e
d
u
c
e
s
 s
p
in
a
l 
g
lu
ta
m
a
te
 a
n
d
 a
s
p
a
rt
a
te
 i
n
 
a
n
im
a
ls
 w
it
h
 j
o
in
t 
in
fl
a
m
m
a
ti
o
n
 c
o
m
p
a
re
d
 
w
it
h
 l
e
v
e
ls
 i
n
 t
h
o
s
e
 w
it
h
o
u
t 
jo
in
t 
in
fl
a
m
m
a
ti
o
n
. 
 
T
h
e
 r
e
d
u
c
e
d
 r
e
le
a
s
e
 
o
f 
g
lu
ta
m
a
te
 a
n
d
 
a
s
p
a
rt
a
te
 b
y
 h
ig
h
-
fr
e
q
u
e
n
c
y
 T
E
N
S
 w
a
s
 
p
re
v
e
n
te
d
 b
y
 s
p
in
a
l 
b
lo
c
k
a
d
e
 o
f 
d
e
lt
a
-
o
p
io
id
 r
e
c
e
p
to
rs
 w
it
h
 
n
a
lt
ri
n
d
o
le
. 
K
in
g
, 
E
W
,e
t 
a
l.
 
(2
0
0
5
) 
4
 a
n
d
 1
0
0
 
1
0
0
 
6
-1
2
 
 
In
te
n
s
it
y
 a
t 
s
e
n
s
o
ry
 l
e
v
e
l;
 
ju
s
t 
b
e
lo
w
 t
h
e
 
m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
. 
M
e
ta
l 
s
n
a
p
 (
4
 m
m
) 
c
o
v
e
re
d
 w
it
h
 
c
o
n
d
u
c
ti
n
g
 g
e
l,
 
m
e
d
ia
l 
a
n
d
 l
a
te
ra
l 
o
n
 
th
e
 k
n
e
e
. 
2
0
 m
in
 
M
ic
e
, 
m
a
le
 a
n
d
 
fe
m
a
le
, 
w
it
h
 a
n
d
 
w
it
h
o
u
t 
a
 g
e
n
e
 
ta
rg
e
te
d
 m
u
ta
ti
o
n
 
th
a
t 
re
n
d
e
rs
 t
h
e
 
α
2
A
A
R
 
d
y
s
fu
n
c
ti
o
n
a
l.
 
K
a
o
li
n
 a
n
d
 
c
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
 t
h
e
 
k
n
e
e
 j
o
in
t.
 
 
A
lp
h
a
2
A
 a
d
re
n
e
rg
ic
 
re
c
e
p
to
rs
 e
x
p
re
s
s
e
d
 w
it
h
in
 
th
e
 k
n
e
e
 j
o
in
t,
 b
u
t 
n
o
t 
s
p
in
a
l 
o
r 
s
u
p
ra
s
p
in
a
l 
lo
c
a
ti
o
n
s
, 
c
o
n
tr
ib
u
te
 t
o
 a
 
c
o
m
p
o
n
e
n
t 
o
f 
T
E
N
S
-
m
e
d
ia
te
d
 (
4
 a
n
d
 1
0
0
 H
z
) 
a
n
ti
h
y
p
e
ra
lg
e
s
ia
, 
a
ft
e
r 
in
d
u
c
ti
o
n
 o
f 
in
fl
a
m
m
a
ti
o
n
. 
P
a
w
 w
it
h
d
ra
w
a
l 
to
 
ra
d
ia
n
t 
h
e
a
t 
w
a
s
 
te
s
te
d
. 
M
ic
e
 w
e
re
 
li
g
h
tl
y
 a
n
e
s
th
e
ti
z
e
d
 
w
it
h
 v
a
p
o
ri
z
e
d
 
is
o
fl
u
ra
n
e
, 
d
u
ri
n
g
 
T
E
N
S
 a
n
d
 d
u
ri
n
g
 
k
n
e
e
 i
n
je
c
ti
o
n
. 
A
in
s
w
o
rt
h
, 
L
 a
n
d
 
K
. 
B
u
d
li
e
r,
 e
t 
a
l.
 
(2
0
0
6
) 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
S
e
n
s
o
ry
 
in
te
n
s
it
y
; 
ju
s
t 
b
e
lo
w
 m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 
R
o
u
n
d
 p
re
-g
e
ll
e
d
 
e
le
c
tr
o
d
e
s
, 
o
n
 t
h
e
 
s
k
in
 o
v
e
rl
y
in
g
 t
h
e
 
g
a
s
tr
o
c
n
e
m
iu
s
 
m
u
s
c
le
, 
o
n
e
 
p
ro
x
im
a
l 
c
lo
s
e
 t
o
 
th
e
 k
n
e
e
 j
o
in
t 
a
n
d
 
o
n
e
 d
is
ta
l 
n
e
a
r 
th
e
 
A
c
h
il
le
s
 t
e
n
d
o
n
. 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
C
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
 L
e
ft
 
g
a
s
tr
o
c
n
e
m
iu
s
 
m
u
s
c
le
. 
E
it
h
e
r 
lo
w
- 
o
r 
h
ig
h
-
fr
e
q
u
e
n
c
y
 T
E
N
S
 a
p
p
li
e
d
 
e
it
h
e
r 
ip
s
il
a
te
ra
l 
o
r 
c
o
n
tr
a
la
te
ra
l 
to
 t
h
e
 s
it
e
 o
f 
in
fl
a
m
m
a
ti
o
n
 s
ig
n
if
ic
a
n
tl
y
 
re
v
e
rs
e
d
 m
e
c
h
a
n
ic
a
l 
h
y
p
e
ra
lg
e
s
ia
, 
b
o
th
 
ip
s
il
a
te
ra
l 
a
n
d
 c
o
n
tr
a
la
te
ra
l 
to
 t
h
e
 s
it
e
 o
f 
in
fl
a
m
m
a
ti
o
n
. 
 
V
o
n
 F
re
y
 f
il
a
m
e
n
ts
 
w
e
re
 u
s
e
d
 t
o
 d
e
te
c
t 
th
e
 m
e
c
h
a
n
ic
a
l 
w
it
h
d
ra
w
a
l 
th
re
s
h
o
ld
. 
U
n
il
a
te
ra
l 
in
je
c
ti
o
n
 o
f 
c
a
rr
a
g
e
e
n
a
n
 t
o
 t
h
e
 
g
a
s
tr
o
c
n
e
m
iu
s
 m
u
s
c
le
 
s
ig
n
if
ic
a
n
tl
y
 r
e
d
u
c
e
d
 
th
e
 m
e
c
h
a
n
ic
a
l 
w
it
h
d
ra
w
a
l 
th
re
s
h
o
ld
 
(m
e
c
h
a
n
ic
a
l 
h
y
p
e
ra
lg
e
s
ia
) 
b
il
a
te
ra
ll
y
 2
 w
e
e
k
s
 
a
ft
e
r 
in
je
c
ti
o
n
. 
 
S
lu
k
a
, 
K
A
, 
T
L
 
L
is
i 
a
n
d
 K
N
 
W
e
s
tl
u
n
d
. 
(2
0
0
6
) 
1
0
0
 a
n
d
 4
 
1
0
0
 
8
-1
5
 
 
In
te
n
s
it
y
 a
t 
s
e
n
s
o
ry
 l
e
v
e
l;
 
ju
s
t 
b
e
lo
w
 t
h
e
 
m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
. 
E
le
c
tr
o
d
e
s
 (
1
.3
-c
m
 
d
ia
m
e
te
r 
ro
u
n
d
 
p
re
g
e
ll
e
d
) 
w
e
re
 
p
la
c
e
d
 m
e
d
ia
l 
a
n
d
 
la
te
ra
l 
o
n
 t
h
e
 k
n
e
e
. 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
, 
K
a
o
li
n
 a
n
d
 
c
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
 t
h
e
 
k
n
e
e
 j
o
in
t.
 
 
L
o
w
-f
re
q
u
e
n
c
y
 T
E
N
S
 
s
ig
n
if
ic
a
n
tl
y
 i
n
c
re
a
s
e
d
 
s
e
ro
to
n
in
 c
o
n
c
e
n
tr
a
ti
o
n
s
 i
n
 
th
e
 d
o
rs
a
l 
h
o
rn
, 
d
u
ri
n
g
 a
n
d
 
im
m
e
d
ia
te
ly
 a
ft
e
r 
tr
e
a
tm
e
n
t.
 T
h
e
re
 w
a
s
 n
o
 
c
h
a
n
g
e
 i
n
 s
e
ro
to
n
in
 w
it
h
 
h
ig
h
-f
re
q
u
e
n
c
y
 T
E
N
S
, 
n
o
r 
w
a
s
 t
h
e
re
 a
 c
h
a
n
g
e
 i
n
 
n
o
ra
d
re
n
a
li
n
e
 w
it
h
 l
o
w
- 
o
r 
h
ig
h
-f
re
q
u
e
n
c
y
 T
E
N
S
. 
 
T
E
N
S
 w
a
s
 a
p
p
li
e
d
 
w
h
il
e
 t
h
e
 r
a
t 
w
a
s
 
a
n
e
s
th
e
ti
z
e
d
 w
it
h
 
h
a
lo
th
a
n
e
. 
R
e
le
a
s
e
 
o
f 
s
e
ro
to
n
in
 a
n
d
 
n
o
ra
d
re
n
a
li
n
e
 i
n
 t
h
e
 
d
o
rs
a
l 
h
o
rn
 w
a
s
 
m
e
a
s
u
re
d
 b
y
 u
s
in
g
 
p
u
s
h
-p
u
ll
 p
e
rf
u
s
io
n
. 
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P
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 R
a
te
 
P
u
ls
e
 
W
id
th
 
P
u
ls
e
 
In
te
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E
le
c
tr
o
d
e
s
 
S
ti
m
u
la
ti
o
n
 
 
 
  
H
z
 
µ
s
 
m
A
 
s
ti
m
u
la
te
d
 
a
ff
e
re
n
ts
 
c
li
n
ic
a
l 
c
o
n
d
it
io
n
 
T
y
p
e
/L
o
c
a
ti
o
n
 
ti
m
e
  
  
  
  
V
a
n
c
e
, 
C
.G
.T
. 
a
n
d
 R
. 
R
a
d
h
a
k
ri
s
h
n
a
n
, 
e
t 
a
l.
 (
2
0
0
7
).
 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
S
e
n
s
o
ry
 
in
te
n
s
it
y
; 
ju
s
t 
b
e
lo
w
 m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 
R
o
u
n
d
 p
re
-g
e
ll
e
d
 
e
le
c
tr
o
d
e
s
, o
n
 t
h
e
 
m
e
d
ia
l 
a
n
d
 l
a
te
ra
l 
a
s
p
e
c
t 
o
f 
th
e
 
in
fl
a
m
e
d
 k
n
e
e
 j
o
in
t 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
K
a
o
li
n
 
a
n
d
 c
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
 t
h
e
 l
e
ft
 
k
n
e
e
 j
o
in
t 
E
it
h
e
r 
h
ig
h
- 
o
r 
lo
w
-
fr
e
q
u
e
n
c
y
 T
E
N
S
 
c
o
m
p
le
te
ly
 r
e
v
e
rs
e
d
 t
h
e
 
c
o
m
p
re
s
s
io
n
 w
it
h
d
ra
w
a
l 
th
re
s
h
o
ld
 w
h
e
n
 a
p
p
li
e
d
 a
t 
2
4
 h
o
u
rs
 o
r 
2
 w
e
e
k
s
 a
ft
e
r 
th
e
 i
n
d
u
c
ti
o
n
 o
f 
in
fl
a
m
m
a
ti
o
n
 b
u
t 
n
o
t 
a
ft
e
r 
4
 h
o
u
rs
. 
 
T
h
e
 c
o
m
p
re
s
s
io
n
 
w
it
h
d
ra
w
a
l 
th
re
s
h
o
ld
 
w
a
s
 s
ig
n
if
ic
a
n
tl
y
 
re
d
u
c
e
d
 a
t 
4
 h
o
u
rs
, 
2
4
 h
o
u
rs
, 
a
n
d
 2
 
w
e
e
k
s
 a
ft
e
r 
th
e
 
in
d
u
c
ti
o
n
 o
f 
in
fl
a
m
m
a
ti
o
n
. 
H
in
g
n
e
, 
P
. 
M
. 
a
n
d
 K
. 
A
. 
S
lu
k
a
 
(2
0
0
7
) 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
S
e
n
s
o
ry
 
in
te
n
s
it
y
; 
ju
s
t 
b
e
lo
w
 m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 
R
o
u
n
d
 p
re
-g
e
ll
e
d
 
E
le
c
tr
o
d
e
s
, o
n
 t
h
e
 
m
e
d
ia
l 
a
n
d
 l
a
te
ra
l 
a
s
p
e
c
t 
o
f 
th
e
 
in
fl
a
m
e
d
 k
n
e
e
 j
o
in
t 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
K
a
o
li
n
 
a
n
d
 c
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
 t
h
e
 
k
n
e
e
 j
o
in
t.
 
T
E
N
S
 t
re
a
tm
e
n
t 
w
it
h
 
e
it
h
e
r 
th
e
 a
s
y
m
m
e
tr
ic
 o
r 
s
y
m
m
e
tr
ic
 w
a
v
e
fo
rm
 
s
ig
n
if
ic
a
n
tl
y
 i
n
c
re
a
s
e
d
 t
h
e
 
P
W
L
 w
h
e
n
 c
o
m
p
a
re
d
 w
it
h
 
s
h
a
m
 T
E
N
S
 
T
E
N
S
 w
it
h
 d
if
fe
re
n
t 
w
a
v
e
fo
rm
s
 -
 
a
s
y
m
m
e
tr
ic
 b
ip
h
a
s
ic
 
s
q
u
a
re
 a
n
d
 s
y
m
m
e
tr
ic
 
b
ip
h
a
s
ic
 s
q
u
a
re
. 
P
W
L
 
to
 r
a
d
ia
n
t 
h
e
a
t,
 w
a
s
 
u
s
e
d
 a
s
 a
n
 i
n
d
e
x
 o
f 
s
e
c
o
n
d
a
ry
 
h
y
p
e
ra
lg
e
s
ia
. 
 
M
a
e
d
a
, 
Y
. 
a
n
d
 
T
.L
. 
L
is
i,
 e
t 
a
l.
 
(2
0
0
7
) 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
S
e
n
s
o
ry
 
in
te
n
s
it
y
; 
ju
s
t 
b
e
lo
w
 m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 
E
le
c
tr
o
d
e
s
, o
n
 t
h
e
 
m
e
d
ia
l 
a
n
d
 l
a
te
ra
l 
a
s
p
e
c
t 
o
f 
th
e
 
in
fl
a
m
e
d
 k
n
e
e
 j
o
in
t 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
K
a
o
li
n
 
a
n
d
 c
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
 t
h
e
 
k
n
e
e
 j
o
in
t.
 
1
0
0
 H
z
 T
E
N
S
 i
n
c
re
a
s
e
s
 
e
x
tr
a
c
e
ll
u
la
r 
G
A
B
A
 
c
o
n
c
e
n
tr
a
ti
o
n
s
 i
n
 t
h
e
 
s
p
in
a
l 
c
o
rd
 i
n
 a
n
im
a
ls
 
w
it
h
 a
n
d
 w
it
h
o
u
t 
jo
in
t 
in
fl
a
m
m
a
ti
o
n
. 
T
h
e
 
in
c
re
a
s
e
s
 i
n
 G
A
B
A
 d
o
 n
o
t 
o
c
c
u
r 
in
 r
e
s
p
o
n
s
e
 t
o
 4
 H
z
 
T
E
N
S
. 
T
h
e
re
 a
re
 n
o
 
in
c
re
a
s
e
s
 i
n
 g
ly
c
in
e
 i
n
 
re
s
p
o
n
s
e
 t
o
 l
o
w
- 
o
r 
h
ig
h
-
fr
e
q
u
e
n
c
y
 T
E
N
S
 
 
th
e
 r
e
d
u
c
ti
o
n
 i
n
 
p
ri
m
a
ry
 h
y
p
e
ra
lg
e
s
ia
 
b
y
 b
o
th
 h
ig
h
- 
a
n
d
 
lo
w
-f
re
q
u
e
n
c
y
 T
E
N
S
 i
s
 
p
re
v
e
n
te
d
 b
y
 s
p
in
a
l 
b
lo
c
k
a
d
e
 o
f 
G
A
B
A
A
 
re
c
e
p
to
rs
 w
it
h
 
b
ic
u
c
u
ll
in
e
. 
 
 
L
iu
, 
H
.X
. 
a
n
d
 
J.
B
. 
T
ia
n
 e
t 
a
l.
 
(2
0
0
7
) 
1
0
0
 
2
0
0
 
1
-4
 
 
 
R
o
u
n
d
 p
la
ti
n
u
m
 
e
le
c
tr
o
d
e
s
 (
5
 m
m
 
d
ia
m
e
te
r)
 w
e
re
 
a
tt
a
c
h
e
d
 t
ig
h
tl
y
 o
n
 
b
o
th
 l
e
g
s
. 
  
3
0
 m
in
 
F
e
m
a
le
 W
is
ta
r 
ra
ts
. 
C
o
m
p
le
te
 F
re
u
n
d
's
 
a
d
ju
v
a
n
t 
in
je
c
te
d
 
in
 t
h
e
 r
ig
h
t 
a
n
k
le
 
jo
in
t 
In
 t
h
e
 a
c
u
te
 p
e
ri
o
d
 
(w
it
h
in
 3
 w
e
e
k
s
) 
o
f 
m
o
n
o
a
rt
h
ri
ti
s
, 
tw
ic
e
-a
-
w
e
e
k
 s
c
h
e
d
u
le
 o
f 
T
E
N
S
 
re
d
u
c
e
d
 t
h
e
 s
w
e
ll
in
g
 o
f 
th
e
 i
n
fl
a
m
e
d
 a
n
k
le
. 
In
 t
h
e
 
s
ta
b
le
 p
e
ri
o
d
 (
4
-9
 
w
e
e
k
s
),
 o
n
c
e
-a
-w
e
e
k
 
s
c
h
e
d
u
le
 p
ro
d
u
c
e
d
 a
 
b
e
tt
e
r 
e
ff
e
c
t 
o
n
 b
o
th
 
in
fl
a
m
m
a
ti
o
n
 a
n
d
 a
rt
h
ri
ti
c
 
h
y
p
e
ra
lg
e
s
ia
 t
h
a
n
 t
h
a
t 
o
f 
tw
ic
e
- 
o
r 
fi
v
e
-t
im
e
s
-a
-
w
e
e
k
 s
c
h
e
d
u
le
. 
U
s
in
g
 t
h
re
e
 l
e
v
e
ls
 o
f 
in
te
n
s
it
y
 o
f 
T
E
N
S
, 
th
e
 
w
e
a
k
e
r 
(1
-1
-2
 m
A
) 
s
ti
m
u
la
ti
o
n
 p
ro
d
u
c
e
d
 
s
ig
n
if
ic
a
n
tl
y
 b
e
tt
e
r 
th
e
ra
p
e
u
ti
c
 e
ff
e
c
ts
. 
R
e
p
e
a
te
d
 T
E
N
S
 
p
ro
d
u
c
e
d
 a
 r
e
d
u
c
ti
o
n
 
o
f 
S
P
 c
o
n
te
n
t 
in
 s
p
in
a
l 
p
e
rf
u
s
a
te
 i
n
 p
a
ra
ll
e
l 
w
it
h
 t
h
e
 p
ro
g
re
s
s
iv
e
 
re
d
u
c
ti
o
n
 o
f 
th
e
 
a
rt
h
ri
ti
c
 p
a
in
 s
c
o
re
s
. 
P
W
L
, 
p
a
w
 w
it
h
d
ra
w
a
l 
la
te
n
c
y
. 
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c
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H
z
 
µ
s
 
m
A
 
s
ti
m
u
la
te
d
 
a
ff
e
re
n
ts
 
c
li
n
ic
a
l 
c
o
n
d
it
io
n
 
T
y
p
e
/L
o
c
a
ti
o
n
 
ti
m
e
  
  
  
  
S
a
b
in
o
, 
G
.S
. 
a
n
d
 C
.M
.F
. 
S
a
n
to
s
 
(2
0
0
8
) 
1
0
 a
n
d
 
1
3
0
 
1
3
0
 
 
 
S
e
n
s
o
ry
 
in
te
n
s
it
y
; 
im
m
e
d
ia
te
ly
 
b
e
lo
w
 m
o
to
r 
th
re
s
h
o
ld
 
S
p
e
c
ia
ll
y
 
c
o
n
s
tr
u
c
te
d
 
e
le
c
tr
o
d
e
, 
(1
c
m
²
),
 f
ix
e
d
 i
n
 
th
e
 d
o
rs
a
l 
a
n
d
 
p
la
n
ta
r 
s
u
rf
a
c
e
 
o
f 
ra
t 
p
a
w
s
. 
 
2
0
 m
in
 
F
e
m
a
le
 H
o
lt
z
m
a
n
 
ra
ts
. 
C
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 
s
u
b
c
u
ta
n
e
o
u
s
 i
n
 
th
e
 r
ig
h
t 
h
in
d
 
p
a
w
. 
1
3
0
 H
z
 a
n
d
 1
0
 H
z
 
T
E
N
S
 i
n
h
ib
it
e
d
 t
h
e
 
c
a
rr
a
g
e
e
n
a
n
-i
n
d
u
c
e
d
 
h
y
p
e
ra
lg
e
s
ia
 b
y
 
1
0
0
%
. 
T
h
e
 a
p
p
li
c
a
ti
o
n
 
o
f 
1
3
0
 H
z
 a
n
d
 1
0
 H
z
 
T
E
N
S
 t
o
 t
h
e
 
c
o
n
tr
a
la
te
ra
l 
p
a
w
 
re
v
e
rs
e
d
 t
h
e
 
h
y
p
e
ra
lg
e
s
ia
 o
f 
th
e
 
in
fl
a
m
e
d
 p
a
w
 s
im
il
a
r 
to
 t
h
a
t 
o
b
s
e
rv
e
d
 w
h
e
n
 
T
E
N
S
 w
a
s
 a
p
p
li
e
d
 t
o
 
th
e
 i
n
fl
a
m
e
d
 p
a
w
. 
 
P
a
w
 w
it
h
d
ra
w
a
l 
th
re
s
h
o
ld
; 
R
a
n
d
a
ll
 a
n
d
 
S
e
li
tt
o
 m
e
th
o
d
. 
u
s
in
g
 a
 
w
e
ig
h
t 
(m
a
x
im
u
m
 l
im
it
 
o
f 
5
0
0
 g
) 
a
p
p
li
e
d
 t
o
 t
h
e
 
p
a
d
s
 o
f 
h
in
d
 p
a
w
s
. 
P
re
tr
e
a
tm
e
n
t 
o
f 
a
n
im
a
ls
 
w
it
h
 i
n
tr
a
p
la
n
ta
r 
n
a
lt
re
x
o
n
e
 r
e
v
e
rs
e
d
 t
h
e
 
a
n
a
lg
e
s
ic
 e
ff
e
c
t 
o
f 
1
0
 H
z
 
T
E
N
S
 b
u
t 
d
id
 n
o
t 
a
lt
e
r 
th
e
 e
ff
e
c
t 
o
f 
1
3
0
 H
z
 
T
E
N
S
. 
H
in
g
n
e
, 
P
. 
M
. 
a
n
d
 K
. 
A
. 
S
lu
k
a
 (
2
0
0
8
)
 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
S
e
n
s
o
ry
 
in
te
n
s
it
y
; 
im
m
e
d
ia
te
ly
 
b
e
lo
w
 m
o
to
r 
th
re
s
h
o
ld
 
R
o
u
n
d
 p
re
-g
e
ll
e
d
 
E
le
c
tr
o
d
e
s
, o
n
 
th
e
 m
e
d
ia
l 
a
n
d
 
la
te
ra
l 
a
s
p
e
c
t 
o
f 
th
e
 i
n
fl
a
m
e
d
 
k
n
e
e
 j
o
in
t 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
K
a
o
li
n
 a
n
d
 
c
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
 t
h
e
 
k
n
e
e
 j
o
in
t.
 
O
n
 d
a
y
 1
, 
T
E
N
S
 
re
v
e
rs
e
d
 t
h
e
 d
e
c
re
a
s
e
d
 
m
e
c
h
a
n
ic
a
l 
w
it
h
d
ra
w
a
l 
th
re
s
h
o
ld
, 
o
n
 d
a
y
 4
, 
T
E
N
S
 h
a
d
 n
o
 e
ff
e
c
t.
 
H
o
w
e
v
e
r,
 i
n
 t
h
e
 g
ro
u
p
 
tr
e
a
te
d
 w
it
h
 N
M
D
A
 
a
n
ta
g
o
n
is
t 
M
K
-8
0
1
, 
T
E
N
S
 s
ig
n
if
ic
a
n
tl
y
 
re
v
e
rs
e
d
 t
h
e
 
m
e
c
h
a
n
ic
a
l 
w
it
h
d
ra
w
a
l 
th
re
s
h
o
ld
s
 o
n
 d
a
y
 4
. 
 
 
V
o
n
 F
re
y
 f
il
a
m
e
n
ts
 w
e
re
 
u
s
e
d
 t
o
 d
e
te
c
t 
th
e
 
m
e
c
h
a
n
ic
a
l 
w
it
h
d
ra
w
a
l 
th
re
s
h
o
ld
. 
T
E
N
S
 w
a
s
 
a
p
p
li
e
d
 f
o
r 
2
0
 m
in
u
te
s
 
d
a
il
y
 (
4
 d
a
y
s
) 
a
t 
h
ig
h
-
fr
e
q
u
e
n
c
y
 o
r 
lo
w
-
fr
e
q
u
e
n
c
y
. 
 
D
e
S
a
n
ta
n
a
, 
J.
M
. 
a
n
d
 V
.J
. 
S
a
n
ta
n
a
-
F
il
h
o
, 
e
t 
a
l.
 
(2
0
0
8
) 
4
 a
n
d
 1
0
0
 
1
0
0
 
 
 
S
e
n
s
o
ry
 
in
te
n
s
it
y
; 
im
m
e
d
ia
te
ly
 
b
e
lo
w
 m
o
to
r 
th
re
s
h
o
ld
 
R
o
u
n
d
 p
re
-g
e
ll
e
d
 
E
le
c
tr
o
d
e
s
, o
n
 
th
e
 m
e
d
ia
l 
a
n
d
 
la
te
ra
l 
a
s
p
e
c
t 
o
f 
th
e
 i
n
fl
a
m
e
d
 
k
n
e
e
 j
o
in
t 
2
0
 m
in
 
M
a
le
 S
p
ra
g
u
e
-
D
a
w
le
y
 r
a
ts
. 
K
a
o
li
n
 a
n
d
 
c
a
rr
a
g
e
e
n
a
n
 
in
je
c
te
d
 i
n
 t
h
e
 
le
ft
 k
n
e
e
 j
o
in
t.
 
F
ro
m
 d
a
y
 1
-9
 T
E
N
S
 
re
v
e
rs
e
d
 t
h
e
 r
e
d
u
c
e
d
 
p
a
w
 a
n
d
 j
o
in
t 
w
it
h
d
ra
w
a
l 
th
re
s
h
o
ld
s
, 
B
y
 t
h
e
 t
e
n
th
 d
a
y
, 
re
p
e
a
te
d
 d
a
il
y
 
a
d
m
in
is
tr
a
ti
o
n
 o
f 
e
it
h
e
r 
m
ix
e
d
- 
o
r 
a
lt
e
rn
a
ti
n
g
-
fr
e
q
u
e
n
c
y
 T
E
N
S
 d
id
 
n
o
t 
re
v
e
rs
e
 t
h
e
 
d
e
c
re
a
s
e
d
 p
a
w
 a
n
d
 
jo
in
t 
w
it
h
d
ra
w
a
l 
th
re
s
h
o
ld
s
. 
  
T
E
N
S
 a
p
p
li
c
a
ti
o
n
: 
m
ix
e
d
- 
(4
H
z
 a
n
d
 1
0
0
H
z
) 
o
r 
a
lt
e
rn
a
ti
n
g
- 
(4
H
z
 o
n
 
1
 d
a
y
; 
1
0
0
H
z
 o
n
 t
h
e
 
n
e
x
t 
d
a
y
) 
fr
e
q
u
e
n
c
y
 
T
E
N
S
, 
fo
r 
1
0
 d
a
y
s
. 
P
a
w
 
(V
o
n
 F
re
y
 f
il
a
m
e
n
ts
) 
a
n
d
 j
o
in
t 
(t
h
e
 f
o
rc
e
p
s
 
a
p
p
li
e
d
 t
o
 t
h
e
 k
n
e
e
 
jo
in
t)
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The neuropathic pain model 
 
The results of a literature survey of the effects of TENS, in an animal 
model for neuropathic pain, are shown in table 3. The effects of TENS on 
mechanical and thermal pain thresholds, on activity of WDR neurons or 
synaptosomal content of neurotransmitters in the dorsal horn were 
explored in rats with nerve ligation.  
 
Effects of high-frequency TENS on mechanical stimuli 
Daily high-frequency (100 Hz) TENS applied ipsilateral to the injured 
sciatic nerve, on the uninvolved skin innervated by the dorsal rami of the 
spinal nerves of L1-6, with an intensity below the level that produces 
muscle contraction, is not able to consistently reduce chronic constriction 
injury-induced mechanical allodynia, regardless of TENS is started 
immediately after induction of the chronic constriction injury (CCI) of the 
sciatic nerve or three days later [54, 55]. However, when this same TENS 
procedure is performed on the contralateral side of the injured nerve, the 
development of CCI-induced mechanical allodynia is blocked by high-
frequency TENS, regardless when TENS is started [56].  
 
Effects of high-frequency TENS on thermal stimuli 
The effects upon thermal allodynia are inconsistent; when high-frequency 
TENS is applied ipsilateral to the injured nerve on the paraspinal skin 
innervated by the dorsal rami of the related spinal nerves, immediately 
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after nerve surgery, it blocks the development of thermal allodynia, but 
not when TENS is started three days after nerve ligation [54, 55]. Neither 
has contralateral application of high-frequency TENS effect on thermal 
allodynia [56, 57].  
 
Effects of low-frequency TENS on mechanical and thermal stimuli 
The results of low-frequency TENS are more divers. In a tight ligation 
model of L5 and L6 spinal nerves, with TENS intensity provoking muscle 
contraction of the muscles overlying the receptive field of the injured 
nerves, TENS application induced a significant depression of brush and 
pinch-evoked responses of WDR neurons in the dorsal horn [58]. In a 
similar study mechanical allodynia like behavior (using monofilaments) 
was attenuated by low-frequency TENS but cold hyperalgesia-like 
behavior was unresponsive to TENS [59]. In a CCI model of loose ligation, 
with TENS intensity provoking severe muscle contraction in the affected 
leg and with the back of the rat extending vigorously, a prolonged 
alleviation of the thermal hyperalgesia was achieved, which lasted up to 7 
days [60], TENS was started 7 days after surgery. When low-frequency 
TENS is applied to acupuncture points on the leg of the rat, with 3 times 
the intensity necessary to produce a visible muscle contraction, only 
contralateral stimulation blocked the CCI-induced lowering of thermal pain 
threshold in one study [56], but not in a following study by the same 
authors [57], furthermore they found no effect on mechanical allodynia 
[56, 57].  
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Receptor agonists in the central nervous system involved in the effects of 
high and low-frequency TENS  
Interestingly, high-frequency TENS elevates dorsal horn synaptosomal 
content of the inhibitory neurotransmitter GABA bilaterally [57]. Rats with 
nerve injury experience a decrease in the extracellular content of GABA in 
the dorsal horn [61] and a similar trend is found at the axon terminal level 
[57]. However, the bilateral GABA content increase cannot fully explain 
the differences in effect on mechanical pain threshold by the ipsilateral 
compared to contralateral application of high-frequency TENS. 
Furthermore, it can also not explain the inconsistent effect on thermal 
allodynia by high-frequency TENS, because intrathecal infusion of GABA 
has been reported to reduce thermal allodynia [62].  
Contralateral application of a combination of daily alternating 100 Hz and 
2 Hz TENS prevents the CCI-induced mean percent reduction in 
mechanical pain threshold, but not in thermal pain threshold [57]. This 
treatment with a combination of 100 Hz- and 2 Hz TENS elevates the 
mean dorsal horn content of aspartate, glutamate and glycine but not of 
GABA when compared with untreated CCI or naïve control rats. Although 
glycine content is not reduced in the dorsal horns of rats with neuropathic 
pain [63], chronic elevation of glycine in the spinal cord prevents the 
development of mechanical allodynia in CCI rats [64]. Therefore it is 
possible that the mechanical pain reducing effect of this TENS combination 
is mediated by the increase of glycine in the dorsal horn. 
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Conclusion 
 
In nerve ligation in rats, the mechanical pain threshold can be increased 
by high-frequency TENS, when it is applied in the paraspinal region of the 
related spinal nerves, contralateral (but not ipsilateral) to the side of the 
injured nerve, with stimulus intensity below the intensity which provokes 
a muscle contraction. This effect is at least partly explained by a bilateral 
dorsal horn synaptosomal GABA content increase. The effects of high-
frequency TENS on thermal allodynia are inconsistent.  
Low-frequency TENS reduces mechanical allodynia and hyperalgesia, and 
thermal hyperalgesia (for heat, but not for cold hyperalgesia) when 
causing contractions of the muscles underlying the receptive field of the 
injured nerve. Contralateral application – using acupuncture points in the 
leg - is not effective in reducing mechanical allodynia, and in thermal 
allodynia results are inconclusive.  
A combination of alternating high and low-frequency TENS, applied 
contralateral to the injured nerve, prevents the induction of mechanical, 
but not of thermal hyperalgesia. 
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s
 p
ro
c
e
s
s
e
s
 o
f 
lu
m
b
a
r 
v
e
rt
e
b
ra
e
. 
 
6
0
 m
in
 
S
p
ra
g
u
e
-D
a
w
le
y
 
ra
ts
, 
m
a
le
s
, 
c
h
ro
n
ic
 
c
o
n
s
tr
ic
ti
o
n
 o
f 
th
e
 
ri
g
h
t 
s
c
ia
ti
c
 
n
e
rv
e
. 
T
h
e
 f
ir
s
t 
g
ro
u
p
 o
f 
li
g
a
te
d
 
ra
ts
 r
e
c
e
iv
e
d
 
T
E
N
S
 b
e
g
in
n
in
g
 
im
m
e
d
ia
te
ly
 a
ft
e
r 
th
e
 C
C
I 
s
u
rg
e
ry
, 
th
e
 s
e
c
o
n
d
 g
ro
u
p
 
b
e
g
in
n
in
g
 2
0
 t
o
 
3
0
 h
o
u
rs
 l
a
te
r,
 
a
n
d
 t
h
e
 t
h
ir
d
 
g
ro
u
p
 r
e
c
e
iv
e
d
 
T
E
N
S
 b
e
g
in
n
in
g
 3
 
d
a
y
s
 a
ft
e
r 
th
e
 
C
C
I 
s
u
rg
e
ry
, 
a
ll
 
fo
ll
o
w
e
d
 b
y
 d
a
il
y
 
a
p
p
li
c
a
ti
o
n
 u
n
ti
l 
d
a
y
 1
4
. 
 
R
e
g
a
rd
le
s
s
 o
f 
w
h
e
n
 i
t 
w
a
s
 s
ta
rt
e
d
, 
d
a
il
y
 
T
E
N
S
 w
a
s
 u
n
a
b
le
 t
o
 
c
o
n
s
is
te
n
tl
y
 r
e
d
u
c
e
 
C
C
I-
in
d
u
c
e
d
 
m
e
c
h
a
n
ic
a
l 
a
ll
o
d
y
n
ia
. 
T
h
e
rm
a
l 
p
a
in
 
th
re
s
h
o
ld
 w
a
s
 
a
s
s
e
s
s
e
d
 b
y
 w
it
h
d
ra
w
 
la
te
n
c
y
 f
ro
m
 a
 r
a
d
ia
n
t 
h
e
a
t 
s
o
u
rc
e
. 
W
h
e
n
 
d
a
il
y
 T
E
N
S
 s
ta
rt
e
d
 
im
m
e
d
ia
te
ly
 a
ft
e
r 
s
u
rg
e
ry
, 
it
 b
lo
c
k
e
d
 t
h
e
 
d
e
v
e
lo
p
m
e
n
t 
o
f 
th
e
rm
a
l 
a
ll
o
d
y
n
ia
. 
 
C
C
I 
a
c
c
o
rd
in
g
 t
o
 t
h
e
 
p
ro
c
e
d
u
re
 o
f 
B
e
n
n
e
tt
 a
n
d
 
X
ie
. 
M
o
n
o
fi
la
m
e
n
ts
 w
e
re
 
u
s
e
d
 t
o
 d
e
te
c
t 
m
e
c
h
a
n
ic
a
l 
w
it
h
d
ra
w
a
l 
th
re
s
h
o
ld
. 
P
o
s
t 
s
u
rg
ic
a
l 
a
s
s
e
s
s
m
e
n
ts
 w
e
re
 m
a
d
e
 
o
n
 d
a
y
 2
, 
7
, 
1
2
 a
n
d
 d
a
y
 
1
4
, 
a
t 
1
2
 t
o
 1
8
 h
o
u
rs
 
a
ft
e
r 
th
e
 l
a
s
t 
T
E
N
S
 
tr
e
a
tm
e
n
t.
 
T
h
e
 T
E
N
S
 g
ro
u
p
 t
h
a
t 
s
ta
rt
e
d
 t
re
a
tm
e
n
ts
 a
t 
d
a
y
 3
 a
ft
e
r 
s
u
rg
e
ry
, 
h
a
d
 
re
d
u
c
e
d
 m
e
c
h
a
n
ic
a
l 
a
ll
o
d
y
n
ia
 a
ft
e
r 
tr
e
a
tm
e
n
t 
o
n
 d
a
y
 1
2
 a
n
d
 1
4
. 
If
 d
a
il
y
 T
E
N
S
 w
a
s
 s
ta
rt
e
d
 
fr
o
m
 d
a
y
 3
, 
th
e
 
tr
e
a
tm
e
n
t 
w
a
s
 u
n
a
b
le
 t
o
 
re
d
u
c
e
 t
h
e
rm
a
l 
a
ll
o
d
y
n
ia
. 
 
  
C
C
I,
 c
h
ro
n
ic
 c
o
n
s
tr
ic
ti
o
n
 i
n
ju
ry
. 
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A
n
im
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l/
P
ro
c
e
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u
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E
ff
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c
t 
C
o
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m
e
n
ts
 
 
P
u
ls
e
 R
a
te
 
P
u
ls
e
 
W
id
th
 
P
u
ls
e
 
In
te
n
s
it
y
 
  
  
E
le
c
tr
o
d
e
s
 
S
ti
m
u
la
ti
o
n
 
 
 
  
H
z
 
µ
s
 
m
A
 
s
ti
m
u
la
te
d
 
a
ff
e
re
n
ts
 
c
li
n
ic
a
l 
c
o
n
d
it
io
n
 
T
y
p
e
/L
o
c
a
ti
o
n
 
ti
m
e
  
  
  
  
N
a
m
, 
T
.S
. 
a
n
d
 
Y
. 
C
h
o
i,
 e
t 
a
l.
 
(2
0
0
1
) 
2
 
 
4
-5
 
 
M
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 
S
e
lf
-a
d
h
e
s
iv
e
 
e
le
c
tr
o
d
e
s
 a
p
p
li
e
d
 
to
 t
h
e
 m
id
d
le
 r
e
g
io
n
 
o
f 
th
e
 p
la
n
ta
r 
s
u
rf
a
c
e
 o
f 
th
e
 l
e
ft
 
h
in
d
 p
a
w
. 
 
2
0
 m
in
 
S
p
ra
g
u
e
-D
a
w
le
y
 
ra
ts
, 
m
a
le
s
, 
ti
g
h
t 
li
g
a
ti
o
n
 o
f 
L
5
 a
n
d
 
L
6
 s
p
in
a
l 
n
e
rv
e
s
. 
E
ff
e
c
ts
 o
f 
T
E
N
S
 
o
n
 m
e
c
h
a
n
ic
a
l 
(P
a
w
 w
it
h
d
ra
w
a
l 
fr
e
q
u
e
n
c
y
) 
a
n
d
 
c
o
ld
 s
e
n
s
it
iv
it
y
 
(P
a
w
 l
if
t 
d
u
ra
ti
o
n
) 
w
a
s
 
te
s
te
d
 o
n
 p
o
s
t-
in
ju
ry
 d
a
y
 3
. 
 
M
e
c
h
a
n
ic
a
l 
a
ll
o
d
y
n
ia
-
li
k
e
 b
e
h
a
v
io
r 
w
a
s
 
a
tt
e
n
u
a
te
d
 i
n
 a
 
n
a
lo
x
o
n
e
 r
e
v
e
rs
ib
le
 
m
a
n
n
e
r 
b
y
 T
E
N
S
. 
T
h
e
 
c
o
ld
 h
y
p
e
ra
lg
e
s
ia
-l
ik
e
 
b
e
h
a
v
io
r 
w
a
s
 
u
n
re
s
p
o
n
s
iv
e
 t
o
 T
E
N
S
, 
T
e
s
ti
n
g
 w
a
s
 p
e
rf
o
rm
e
d
 
3
0
 m
in
 b
e
fo
re
, 
a
n
d
 a
t 
3
0
 
m
in
, 
1
, 
2
, 
3
 a
n
d
 4
 h
 a
ft
e
r 
th
e
 c
o
m
p
le
ti
o
n
 o
f 
th
e
 
T
E
N
S
 o
r 
s
h
a
m
-
s
ti
m
u
la
ti
o
n
. 
In
o
u
e
, 
T
. 
a
n
d
 M
. 
T
a
k
e
n
o
s
h
it
a
, 
e
t 
a
l.
 (
2
0
0
3
) 
1
 
2
0
0
 
1
2
 
 
W
it
h
 1
2
-m
A
 
c
u
rr
e
n
t,
 t
h
e
 
b
a
c
k
 o
f 
th
e
 r
a
t 
e
x
te
n
d
e
d
 
v
ig
o
ro
u
s
ly
. 
W
ir
e
 e
le
c
tr
o
d
e
s
, 
A
ro
u
n
d
 t
h
e
 l
e
g
 j
u
s
t 
a
b
o
v
e
 t
h
e
 a
n
k
le
 o
f 
th
e
 n
e
rv
e
 
c
o
n
s
tr
ic
te
d
 s
id
e
. 
 
 
1
6
.7
 m
in
 
S
p
ra
g
u
e
-D
a
w
le
y
 
ra
ts
, 
m
a
le
s
, 
C
C
I 
o
f 
th
e
 r
ig
h
t 
s
c
ia
ti
c
 
n
e
rv
e
 w
it
h
 f
o
u
r 
lo
o
s
e
 l
ig
a
tu
re
s
 o
f 
th
e
 s
c
ia
ti
c
 n
e
rv
e
, 
a
c
c
o
rd
in
g
 t
o
 
M
a
v
e
s
 e
t 
a
l.
 T
h
e
 
le
ft
 s
c
ia
ti
c
 n
e
v
e
r 
w
a
s
 e
x
p
o
s
e
d
 b
u
t 
n
o
t 
li
g
a
te
d
 a
n
d
 
s
e
rv
e
d
 a
s
 a
 s
h
a
m
 
s
u
rg
e
ry
. 
T
E
N
S
 
w
a
s
 s
ta
rt
e
d
 
7
d
a
y
s
 a
ft
e
r 
s
u
rg
e
ry
. 
 
 
T
h
e
 r
e
s
u
lt
s
 s
h
o
w
 a
 
p
ro
lo
n
g
e
d
 a
ll
e
v
ia
ti
o
n
 
o
f 
th
e
rm
a
l 
h
y
p
e
ra
lg
e
s
ia
 e
ff
e
c
t 
o
f 
re
p
e
a
te
d
 T
E
N
S
, 
w
h
ic
h
 
la
s
te
d
 a
t 
le
a
s
t 
u
p
 t
o
 7
 
d
a
y
s
. 
F
o
r 
T
E
N
S
, 
p
a
ir
e
d
 p
u
ls
e
s
 
a
re
 u
s
e
d
 w
it
h
 a
n
 i
n
te
rv
a
l 
o
f 
5
 m
s
. 
 
T
h
e
rm
a
l 
h
y
p
e
ra
lg
e
s
ia
 
(P
W
L
) 
w
a
s
 m
e
a
s
u
re
d
 
b
e
fo
re
 n
e
rv
e
 c
o
n
s
tr
ic
ti
o
n
 
s
u
rg
e
ry
 a
n
d
 a
ft
e
r 
s
u
rg
e
ry
: 
ju
s
t 
b
e
fo
re
 
T
E
N
S
, 
a
n
d
 1
, 
3
, 
7
, 
a
n
d
 
1
4
 d
a
y
s
 a
ft
e
r 
th
e
 
c
o
m
p
le
ti
o
n
 o
f 
T
E
N
S
. 
T
E
N
S
 w
a
s
 a
p
p
li
e
d
 5
 
ti
m
e
s
 o
n
 5
 c
o
n
s
e
c
u
ti
v
e
 
d
a
y
s
. 
S
o
m
e
rs
, 
D
.L
. 
a
n
d
  
F
.R
. 
C
le
m
e
n
te
 
(2
0
0
3
) 
1
0
0
 
5
0
-2
0
0
 
 
 
8
0
%
 o
f 
th
e
 
c
u
rr
e
n
t 
in
te
n
s
it
y
 
n
e
e
d
e
d
 t
o
 
p
ro
d
u
c
e
 m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 
s
e
lf
-a
d
h
e
s
iv
e
 
s
u
rf
a
c
e
 e
le
c
tr
o
d
e
s
, 
o
n
 t
h
e
 d
e
n
u
d
e
d
 s
k
in
 
o
v
e
rl
y
in
g
 t
h
e
 r
ig
h
t 
p
a
ra
s
p
in
a
l 
m
u
s
c
u
la
tu
re
; 
th
e
 
s
ti
m
u
la
te
d
 s
k
in
 i
s
 
in
n
e
rv
a
te
d
 b
y
 t
h
e
 
d
o
rs
a
l 
ra
m
i 
o
f 
lu
m
b
a
r 
s
p
in
a
l 
c
o
rd
 
s
e
g
m
e
n
ts
 1
 t
o
 6
. 
 
F
ir
s
t 
tr
e
a
tm
e
n
t 
9
0
 m
in
, 
n
e
x
t 
tr
e
a
tm
e
n
ts
 
6
0
 m
in
 
S
p
ra
g
u
e
-D
a
w
le
y
 
ra
ts
, 
m
a
le
s
, 
C
C
I 
s
u
rg
e
ry
 o
f 
th
e
 
ri
g
h
t 
s
c
ia
ti
c
 
n
e
rv
e
. 
T
h
e
 g
ro
u
p
 
o
f 
li
g
a
te
d
 r
a
ts
 
re
c
e
iv
e
d
 T
E
N
S
 
b
e
g
in
n
in
g
 
im
m
e
d
ia
te
ly
 a
ft
e
r 
th
e
 C
C
I 
s
u
rg
e
ry
.  
 
T
h
e
 m
e
a
n
 l
e
v
e
l 
o
f 
th
e
rm
a
l 
a
n
d
 
m
e
c
h
a
n
ic
a
l 
a
ll
o
d
y
n
ia
 
d
id
 n
o
t 
d
if
fe
r 
b
e
tw
e
e
n
 
th
e
 T
E
N
S
-t
re
a
te
d
 a
n
d
 
u
n
tr
e
a
te
d
 r
a
ts
 w
it
h
 
C
C
I.
  
T
E
N
S
 c
o
m
m
e
n
c
e
d
 o
n
 t
h
e
 
d
a
y
 o
f 
s
u
rg
e
ry
 w
h
il
e
 t
h
e
 
ra
ts
 w
e
re
 s
ti
ll
 u
n
d
e
r 
th
e
 
in
fl
u
e
n
c
e
 o
f 
s
o
d
iu
m
 
p
e
n
to
b
a
rb
it
a
l.
 O
n
 t
h
e
 
s
u
b
s
e
q
u
e
n
t 
1
1
 d
a
y
s
, 
T
E
N
S
 w
a
s
 a
d
m
in
is
te
re
d
 
w
h
il
e
 t
h
e
 r
a
ts
 w
e
re
 
li
g
h
tl
y
 a
n
e
s
th
e
ti
z
e
d
 w
it
h
 
h
a
lo
th
a
n
e
. 
C
C
I,
 c
h
ro
n
ic
 c
o
n
s
tr
ic
ti
o
n
 i
n
ju
ry
. 
P
W
L
, 
p
a
w
 w
it
h
d
ra
w
a
l 
la
te
n
c
y
. 
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P
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P
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e
 
W
id
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P
u
ls
e
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E
le
c
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o
d
e
s
 
S
ti
m
u
la
ti
o
n
 
 
 
  
H
z
 
µ
s
 
m
A
 
s
ti
m
u
la
te
d
 
a
ff
e
re
n
ts
 
c
li
n
ic
a
l 
c
o
n
d
it
io
n
 
T
y
p
e
/L
o
c
a
ti
o
n
 
ti
m
e
  
  
  
  
S
o
m
e
rs
, 
D
.L
. 
a
n
d
  
F
.R
. 
C
le
m
e
n
te
 
(2
0
0
6
) 
1
0
0
 o
r 
2
 
 
 
 
8
0
%
 o
f 
th
e
 
c
u
rr
e
n
t 
in
te
n
s
it
y
 
n
e
e
d
e
d
 t
o
 
p
ro
d
u
c
e
 m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 (
1
0
0
 
H
z
 T
E
N
S
).
 F
o
r 
2
 
H
z
 T
E
N
S
, 
3
 
ti
m
e
s
 t
h
e
 
in
te
n
s
it
y
 
n
e
c
e
s
s
a
ry
 t
o
 
p
ro
d
u
c
e
 a
 v
is
ib
le
 
c
o
n
tr
a
c
ti
o
n
 i
n
 
th
e
 t
ib
ia
li
s
 
a
n
te
ri
o
r 
m
u
s
c
le
. 
 
S
u
rf
a
c
e
 e
le
c
tr
o
d
e
s
 
a
p
p
li
e
d
 t
o
 t
h
e
 
lu
m
b
a
r 
p
a
ra
v
e
rt
e
b
ra
l 
(L
1
-6
) 
s
k
in
 o
v
e
rl
y
in
g
 e
it
h
e
r 
th
e
 r
ig
h
t 
o
r 
le
ft
 
p
a
ra
s
p
in
a
l 
m
u
s
c
u
la
tu
re
 (
1
0
0
 
H
z
 T
E
N
S
) 
a
n
d
 t
o
 
a
c
u
p
u
n
c
tu
re
 p
o
in
ts
 
in
 t
h
e
 r
ig
h
t 
o
r 
le
ft
 
h
in
d
 l
im
b
s
 i
n
 c
a
s
e
 o
f 
2
 H
z
 T
E
N
S
. 
 
6
0
 m
in
 
S
p
ra
g
u
e
-D
a
w
le
y
 
ra
ts
, 
m
a
le
s
, 
C
C
I 
to
 t
h
e
 r
ig
h
t 
s
c
ia
ti
c
 n
e
rv
e
. 
T
w
o
 
g
ro
u
p
s
 o
f 
C
C
I 
ra
ts
 r
e
c
e
iv
e
d
 1
0
0
 
H
z
 T
E
N
S
 a
n
d
 t
w
o
 
g
ro
u
p
s
 r
e
c
e
iv
e
d
 2
 
H
z
 T
E
N
S
, 
s
ta
rt
in
g
 
o
n
 t
h
e
 d
a
y
 o
f 
s
u
rg
e
ry
. 
T
E
N
S
, 
o
n
ly
 d
e
li
v
e
re
d
 
c
o
n
tr
a
la
te
ra
l 
to
 t
h
e
 
n
e
rv
e
 i
n
ju
ry
, 
b
lo
c
k
e
d
 
th
e
 C
C
I-
in
d
u
c
e
d
 
lo
w
e
ri
n
g
 o
f 
m
e
c
h
a
n
ic
a
l 
p
a
in
 t
h
re
s
h
o
ld
, 
b
u
t 
o
n
ly
 f
o
r 
h
ig
h
-
fr
e
q
u
e
n
c
y
 T
E
N
S
. 
F
o
r 
th
e
rm
a
l 
p
a
in
 t
h
re
s
h
o
ld
 
th
e
 s
a
m
e
 w
a
s
 t
ru
e
 f
o
r 
lo
w
-f
re
q
u
e
n
c
y
 T
E
N
S
. 
T
h
e
rm
a
l 
(r
a
d
ia
n
t 
h
e
a
t)
 
a
n
d
 m
e
c
h
a
n
ic
a
l 
(m
o
n
o
fi
la
m
e
n
ts
) 
p
a
in
 
th
re
s
h
o
ld
s
 w
e
re
 a
s
s
e
s
s
e
d
 
in
 t
h
e
 r
ig
h
t 
h
in
d
 p
a
w
 
b
e
fo
re
 a
n
d
 1
2
 d
a
y
s
 a
ft
e
r 
th
e
 C
C
I 
s
u
rg
e
ry
. 
T
h
e
 
T
E
N
S
 w
a
s
 d
e
li
v
e
re
d
 1
 
h
o
u
r 
p
e
r 
d
a
y
, 
fo
r 
1
1
 
d
a
y
s
. 
S
o
m
e
rs
, 
D
.L
. 
a
n
d
  
F
.R
. 
C
le
m
e
n
te
 
(2
0
0
9
) 
1
0
0
 o
r 
2
 
 
0
.0
3
-0
.0
4
 
fo
r 
2
 H
z
 
 
8
0
%
 o
f 
th
e
 
c
u
rr
e
n
t 
in
te
n
s
it
y
 
n
e
e
d
e
d
 t
o
 
p
ro
d
u
c
e
 m
u
s
c
le
 
c
o
n
tr
a
c
ti
o
n
 i
n
 
c
a
s
e
 o
f 
1
0
0
 H
z
 
T
E
N
S
. 
F
o
r 
2
 H
z
 
T
E
N
S
;3
 t
im
e
s
 
th
e
 i
n
te
n
s
it
y
 
n
e
c
e
s
s
a
ry
 t
o
 
p
ro
d
u
c
e
 a
 v
is
ib
le
 
c
o
n
tr
a
c
ti
o
n
 i
n
 
th
e
 t
ib
ia
li
s
 
a
n
te
ri
o
r 
m
u
s
c
le
. 
S
u
rf
a
c
e
 e
le
c
tr
o
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Introduction 
 
Transcutaneous electrical nerve stimulation (TENS) is an easy to use non-
invasive analgesic intervention applied for diverse pain states and 
introduced in the early 1970s. However, its effects are still inconclusive for 
chronic pain [1], although a systematic review indicates benefit for pain in 
osteoarthritis of the knee [2].  
A number of causes are considered responsible for inducing or maintaining 
chronic pain, e.g. inflammation and nerve or spinal cord injury [3]. There 
are however significant differences in the underlying peripheral 
mechanisms of nociceptive and neuropathic pain. Damage of deep 
(muscle, joint and viscera) tissue is typically associated with peripheral 
inflammation, while injury of nerves often leads to neural degeneration, 
neuroma formation and generation of spontaneous neural inputs [4]. 
However, both are significantly influenced by changes in the central 
nervous system (i.e. central sensitization/disinhibition). Interestingly, 
long-lasting or intense nociceptive barrage from the periphery has been 
reported to give rise to persistent and self-sustaining central 
hyperexcitability long after all possible tissue healing has occurred [4]. In 
osteoarthritis however, evidence is found that central hyperexcitability is 
maintained by nociceptive barrage [5], probably by peripheral 
sensitization, as a result of neurogenic inflammation [6]. There is growing 
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evidence that the pain in osteoarthritis is at least partly due to 
inflammation [7]. 
In animal models, effects of high and low frequency TENS have been 
extensively studied in inflammation and to a lesser extent in nerve 
ligation, for review see Sluka and Walsh [8]. High-frequency TENS 
reverses primary and secondary hyperalgesia induced by carrageenan 
inflammation [9-14], but does not diminish mechanical allodynia following 
chronic constriction injury of the rat sciatic nerve [15]. However whether 
these results are true for high frequency TENS in chronic pain in human 
research, still needs to be explored. In predicting effect of TENS [16] 
found that patients with intractable, stabbing, pulsating, electrifying, 
paroxysmal and un-modulated pain - suggesting neuropathic pain [17] - 
have less chance to achieve successful treatment outcome.  
Besides mechanisms of peripheral and central hyperexcitability, 
psychological factors also influence chronic pain processing and treatment 
outcome. Cognitive coping strategies appeared to be correlated with pain 
intensity [18] and especially self-efficacy [19] and catastrophizing [20, 
21] are found to predict outcome of treatment in chronic pain. However, 
effects of cognitive copings strategies on results of TENS treatment are 
unknown. Lample et al. [16] found that, marked depression, highly 
stressful conflict situations and ongoing litigation diminished success rate 
of TENS treatment.  
Therefore, the purpose of this study is to explore the effects of the origin 
of pain and cognitive coping strategies and mood on predicting short-term 
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results of high-frequency TENS in the treatment of chronic pain. We 
expect pain in osteoarthritis and related disorders, but not peripheral 
neuropathic pain to be a positive predictor for results of high frequency 
TENS. 
 
Methods  
 
Design 
To predict outcome of TENS treatment, we performed a prospective, 
randomized and controlled trial comparing TENS and sham TENS. A 
concealed block-wise randomization procedure was used, and patients, 
therapists and research assistants were blinded for treatment allocation. 
 
Randomization procedure and concealment of allocation 
The researcher assigned consecutive numbers to eligible patients, when 
they agreed to participate in this study. The research assistant, only 
delivering the TENS or sham TENS devices to the patients, used these 
numbers to determine treatment assignment, as provided by the 
randomization list. This list of sequential numbers, which-block wise refer 
to treatment allocation, was generated with help of a computer by the 
department of Epidemiology & Biostatistics. To further guarantee 
concealment, patients were asked to leave their treatment device with the 
receptionist before visiting the researcher for evaluating treatment after 
the treatment period. 
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Subjects  
Patients with chronic pain participating in this study were referred to the 
Pain Centre of the Radboud University Medical Centre Nijmegen by their 
family doctor or by a medical specialist. Results of medical investigations 
were retrieved from the specialists before the patient was invited for the 
first visit to the Pain centre. Both anesthesiologists and physiotherapists of 
the Pain Centre screened patients for TENS treatment. 
Patients were eligible for this study if they met the inclusion criteria. 
Inclusion criteria were: 1) patients with chronic non-cancer pain referred 
to the Pain Centre, 2) duration of pain > 6 months, 3) age above 18 
years. Exclusion criteria were: 1) previous TENS treatment (because this 
could affect sham TENS credibility [22]), 2) pain in face or head (because 
visible electrode placement might affect compliance, and hair could impair 
optimal electrode placement), 3) several different pain sites (because of 
the limited area TENS electrodes can serve), 4) history of a cerebral 
vascular accident (because possible spinothalamocortical pathway damage 
could affect the outcome of TENS – and possibly sham TENS treatment, 
too), 5) no assistance at home – e.g. relatives or friends - to help replace 
or connect the electrodes, thus jeopardizing optimal TENS use), 6) 
involvement in ongoing litigation because of their pain [16] and 7) 
psychological intervention proposed by the Pain Centre psychologists (this 
would interact with TENS treatment outcome in an unpredictable way, and 
withholding it would be unethical). Eligible patients were included in this 
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study after signing informed consent (Chart 1). The Central Committee on 
Research Involving Human Subjects approved this study. 
 
Patients proposed for TENS treatment and assessed for eligibility (n=406)
Exclusions (n=203):
Formerly treated with TENS (n=77)
Pain in head or face (n=19)
Several unrelated sites of pain (n=37)
Cerebral vascular accident (n=11)
No help to replace electrodes (n=2)
Ongoing litigation (n=5)
Psychological intervention (n=50)
Did not speak Dutch language (n=2)
No informed consent (n=38):
Extra visits (n=20)
Being at risk for placebo (n=9)
Possible delay of treatment (n=8)
Felt uncertain (n=1)
Patients randomized (n=165)
TENS treatment
(n=81)
Sham-TENS
(n=82)
Withdrawal (n=2):
Being at risk for placebo
 
Chart 1. Patients flow of the study. 
 
Apparatus  
For TENS and sham TENS treatment, identical devices (ELPHA II 1000, 
Danmeter A/S, Denmark) were used, which were specially prepared for 
this study. For high frequency TENS, stimulation pulse frequency was set 
to 80 Hz and pulse width to 50 s. Disposable 5 cm  6.4 cm self-adhering 
electrodes were used with an active area of 6.5 cm2. Sham TENS devices 
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showed a maximum of 10 or 20 mA on the display (current intensity 
below the level of perception of the patient; assessed during the visit by 
the physiotherapist), but no current was actually delivered to the 
electrodes.  
 
General procedure 
Patients eligible for the TENS treatment received written information in 
which they were asked to participate in the study. In the letter, it was 
explained that TENS seems to be effective at high and low intensities, and 
that treatment would be by one of these two options. There would also be 
a chance of receiving a sham TENS device in which the settings of pulses 
were neither effective nor harmful.  
 
After inclusion, baseline measures were carried out and one week later 
patients visited the physiotherapist for TENS application and for 
instruction on both TENS treatment modalities. Electrodes were applied 
over the superficial cutaneous nerves in the painful segment(s) [23]. Once 
acquainted with the method of treatment, the patient left the 
physiotherapist and visited the research assistant whose only task was to 
deliver the high frequency or sham TENS device to the patient, as 
determined by the randomization list. “With the assignment to apply TENS 
treatment continuously during the day, and the written instruction how to 
use the device and not to change pain medication”, the patient left the 
outpatient clinic. Ten days later, the patient returned for evaluation of the 
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treatment effect. More details of the methods are described elsewhere 
[24]. 
 
Outcome measures 
Two outcome measures were used to predict result of TENS treatment. 
The primary outcome measure was the proportion of patients satisfied 
with the initial treatment result and willing to continue treatment (yes or 
no). This outcome measure can be regarded as an index of patient’s 
assessment of the benefits (efficacy) of the treatment versus its side 
effects (e.g. problems in handling the device), providing a patient-based 
evaluation of treatment [25]. The secondary outcome measure was pain 
intensity. Pain intensity was measured using a 10-centimeter VAS, 
ranging from no pain at all to the most intense pain imaginable [26]. 
Patients were instructed to rate their pain from that particular moment on 
the same time every day, for a period of 14 consecutive days, starting one 
week before treatment. For this purpose a pain diary was used. 
 
Predictors  
Based on medical causes of pain, patients were classified in three pain 
diagnoses groups: “Osteoarthritis and related disorders” (ORD) - 
assuming peripheral sensitization by neurogenic inflammation [6, 7] - 
“Peripheral neuropathic pain (PNP) as a result of lesions of the peripheral 
nervous system and finally, the remainder of patients was classified as 
“Injury of bone and soft tissue and visceral pain disorders” (IBST) - 
 119 
 
assuming self-sustaining central hyperexcitability [4], as there were no 
signs of inflammation or peripheral nerve lesions, for visceral pain 
disorders it is suggested that central sensitization may contribute to the 
pain hypersensitivity [27]. “ORD” was specified as pain related to 
osteoarthritis, osteoporosis, bursitis and tendonitis - both osteoarthritis 
and bursitis and tendonitis share mechanisms of peripheral sensitization; 
the number of nerve fibers immunoreactive to substance P are increased 
around the vessels of the tissue related to the site of pain [28, 29], which 
also applies for the number of vessels in that area [28, 30]. The diagnosis 
of PNP was established when symptoms for neuropathic pain (e.g. 
allodynia, hyperalgesia, hyperpathia, dysesthesia, paroxysms) were 
accompanied by a pain related neurological dysfunction, caused by nerve 
or root injury or compression and because of diabetic neuropathy.  
According to [16] factors describing severity of pain adversely affect the 
outcome of TENS treatment. We therefore added the following pain 
characteristics as possible predictors: intensity of pain, duration of pain, 
variation in pain, and disability because of pain. 
For pain intensity, the average pain level (VAS) of the base-line week was 
calculated. The standard deviation (SD) was used as a measure of 
variation of pain. Disability because of pain was measured with the Dutch 
version of the Pain Disability Index (PDI) [31-33] questionnaire, which is 
scored on a scale of 0 (no disability) to 10 (total disability). The items ask 
for the level of limitations in the total range of role functioning: 
family/home responsibilities, recreation, social activities, occupation, 
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sexual behavior, self-care and life-supporting activities. Reliability and 
validity were judged as satisfactory [33, 34]. The sum of levels of the 
items scored was used to calculate the disability index.  
For psychological factors we selected cognitive coping strategies and 
perceived control over pain and finally depression as possible predictors 
for result of TENS treatment. 
Pain coping was measured with the Pain Coping Inventory (PCI) [35, 36], 
which measures 3 passive cognitive and behavioral coping strategies when 
dealing with pain. The PCI is rated on a 4-point Likert scale (1: rarely or 
never to 4: very frequently). Cognitive passive coping is assessed by 
means of worrying (9 items). Behavioral passive coping is assessed with 
two scales, retreating and resting (7 and 5 items, respectively). A priori, 
based on face validity we expected questions 10-13 of retreating (avoid 
upsetting events, seeking restful environment, avoid annoying sound and 
avoid light; when in pain) - referring to coping with arousal due to pain- 
would reflect a separate factor within retreating. We therefore performed 
a principal component analysis with retreating, which revealed two 
factors, with only question 14 (Take care of food/drink) loading on a 
different factor. Accordingly we added the modified construct of retreating 
containing questions 10-13 and 32-33 (separate myself and return home 
soon; when in pain) as a possible separate predictor. Arousal due to pain 
might reflect ongoing or recurrent nociceptive pain caused by peripheral 
nociceptive stimulation presumably acting in addition to peripheral and 
 121 
 
central (dorsal horn) sensitization; a condition in which TENS is found to 
be effective, for review see [8]. 
Pain cognition was measured with the Pain Cognition List (PCL) [37]. This 
instrument represents a measure for the verbal-cognitive response system 
of chronic pain and consists of fifty items, each of which is assigned to one 
of five factors (pain impact, catastrophizing, outcome efficacy, 
acquiescence and reliance on health care). Items are scored on a 5-point 
scale (1: highly disagree to 5: totally agree). In our study the scales for 
catastrophizing and negative self-efficacy were used to predict outcome.  
Perceived control over pain was measured by answering the following 
question: “Can you decrease the severity of your pain by performing 
activities; distracting from pain; relaxation exercises; reducing activities 
or resting; or none of these possibilities?” Patients were assigned to one 
of three groups. Group number one comprised of patients perceiving no 
control; group number two consisted of patients only perceiving control by 
decreasing activities or resting and group number three were patients 
perceiving control by activities, distraction or relaxation exercises. 
Depression was measured with the Dutch version of the Beck Depression 
Inventory (BDI) [38]. Validity was judged as satisfactory [39]. 
 
Statistical methods 
All analyses were done on the intention-to-treat population, defined as all 
randomized patients that started with treatment (also called modified 
intention-to-treat population). Level of significance used was 0.05. Apart 
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from the primary parameters, all analyses were exploratory in nature. The 
primary outcome parameter was the proportion of patients satisfied with 
treatment result and willing to continue (sham) TENS treatment (yes or 
no). The difference between the two treatment groups was tested with the 
chi square test. The second outcome parameter was the difference in the 
time course of the VAS-score during the first treatment week and the 
mean of the VAS-score in the baseline week. These were analyzed using a 
mixed repeated measures model. 
To investigate the possible predictive role of given parameters on the 
result outcome (patients’ satisfaction), the following procedure was used. 
Using as criterion the highest likelihood score statistic within a logistic 
model, the best subset of 1, 2, 3, … parameters at a time was 
determined. For each of these best subsets, Akaike’s Information Criterion 
(AIC) was computed, a measure of the goodness of fit, corrected for the 
number of predictors. As final predictor set, that subset was chosen for 
which AIC was smallest (starting with the best subset with 1 predictor), 
before increasing again. 
To investigate the possible predictive role of given parameters on the VAS 
score on day 14 the following procedure was used. Using as criterion the 
highest R2 within a multiple linear regression model, the best subset of 
one, 2, 3, … parameters at a time was determined. As final predictor set, 
that subset was chosen for which R2, compared with the subset with one 
predictor less, still increased with at least 0.01 (starting with the best 
subset with 1 predictor). 
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 TENS 
(n = 81) 
Sham-TENS 
(n = 82) 
TOTAL 
(n = 163) 
Pain diagnoses a, n (%)  
Peripheral neuropathic pain 
Osteoarthritis and related disorders 
Injury of bone and soft tissue and 
visceral pain  
 
 
16 (20) 
31 (38) 
34 (42) 
 
25 (30) 
26 (32) 
31 (38) 
 
41 (25) 
57 (35) 
  65 (40) 
Intensity of pain, Mean ± SE mm 
Average pain in baseline week (VAS)b  
 
 
62.2 ± 2.1 
 
61.5 ± 2.0 
 
61.9 ± 1.4 
Variation of pain, Mean ± SE mm 
 SD of pain intensity in baseline week 
 
 
11.4 ± 0.8 
 
11.1 ± 0.7 
 
11.2 ± 0.6 
Perceived control of pain, n (%) 
By decreasing activities or resting 
By performing activities or distraction 
None  
 
 
43 (53) 
16 (20) 
22 (27) 
 
42 (51) 
20 (24) 
20 (24) 
 
85 (52) 
36 (22) 
  42 (26) 
Pain disability (PDI) c 
Sum score, Mean ± SE mm 
 
 
28.0 ± 1.8 
 
 
28.8 ± 2.0 
 
 
28.4 ± 1.34 
 
PCI d, Mean ± SE mm 
Resting (5-20) 
Retreating (7-28) 
Worrying (9-36) 
 
12.8 ± 0.4 (n=77) 
11.2 ± 0.5 (n=77) 
17.6 ± 0.7 (n=77) 
 
 
12.4 ± 0.4 (n=77) 
11.9 ± 0.5 (n=77) 
17.3 ± 0.6 (n=77) 
 
 
12.6 ± 0.3 (n=154)  
11.6 ± 0.3 (n=154) 
17.4 ± 0.5 (n=154)  
 
PCL e, Mean ± SE mm 
Negative self efficacy (17-85) 
Catastrophizing (17-85) 
 
43.4 ± 1.2 (n=78)  
43.6 ± 1.7 (n=78) 
 
44.5 ± 1.4 (n=77) 
44.2 ± 1.7 (n=77) 
 
 
43.9 ± 0.9 (n=155) 
43.9 ± 1.2 (n=155) 
BDI f, Mean ± SE mm 
Depression-score (0-63) 
 
10.2 ± 0.8 (n=77) 
 
10.5 ± 0.8 (n=77) 
 
10.3 ± 0.6 (n=154) 
    
a See table 2 for more details. b Visual analogue scale (0-100). c Pain Disability Index (0-70). d Pain Coping 
Inventory. e Pain Cognition List. f Beck Depression Inventory 
 
Table 1.Baseline prognostic variables; pain and psychological characteristics 
 
Results 
 
Subjects 
Two hundred and three patients were included in this study. One hundred 
and sixty-five patients signed informed consent and 38 patients refused. 
Two of the included patients withdrew before the actual treatment took 
place; they were both assigned to the TENS group. Pain diagnoses, pain 
characteristics and psychological assessment revealed no differences 
between TENS and sham TENS groups (Table 1), neither did demographic 
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data or other pain characteristics, as reported previously [24]. The results 
of the classification of pain diagnoses groups are shown in Table 2. 
Because some booklets were not returned or lost, data of the PCL from 
three patients, and data of the PCI and BDI from four patients in the TENS 
group and five patients of the sham TENS group (PCL, PCI and BDI) were 
missing. 
 
Peripheral neuropathic pain 
(n=41) 
Treatment (n) Rate of patients satisfied with 
treatment result 
Nerve injury TENS (0) - 
 Sham (2) 0 
Dorsal root injury TENS (0) - 
 Sham (1) 0 
Nerve compression TENS (5) 3/5 
 Sham (8) 5/8 
Dorsal root compression TENS (10) 6/10 
 Sham (14) 7/14 
Diabetic neuropathy TENS (1) 1/1 
 Sham (0) - 
Osteoarthritis and related disorders  
(n=57) 
  
Osteoarthritis (vertebral column) TENS (21) 6/21 
 Sham (21) 7/21 
Osteoporosis of the spine TENS (3) 2/3 
 Sham (1) 0 
Osteoarthritis (hip, knee, ankle) TENS (2) 2/2 
 Sham (2) 1/2 
Bursitis and tendonitis TENS (5) 2/5 
 Sham (2) 0 
Injury of bone and soft tissue and visceral pain 
(n=65) 
  
Soft tissue lesions TENS (5) 4/5 
 Sham (5) 2/5 
Bone fractures TENS (7) 4/7 
 Sham (2) 1/2 
Whiplash injury TENS (4) 3/4 
 Sham (4) 3/4 
Postsurgical pain * TENS (13) 10/13 
 Sham (12) 4/12 
Visceral pain TENS (5) 4/5 
 Sham (8) 5/8 
* Indicates significant difference between TENS and sham TENS; p=0.047, Fisher’s exact test. 
 
Table 2 Type of pain diagnoses and rate of patients satisfied with treatment 
result for TENS and sham TENS 
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Outcome 
The proportions of patients satisfied with treatment result, differed 
significantly for high frequency TENS compared to sham TENS (58,0% and 
42,7% respectively, chi square=3.8, p=0.05). However, no significant 
differences in pain intensity were found for patients treated with TENS or 
sham TENS (p=0.53). 
 
 Peripheral neuropathic pain 
(PNP) 
(n=41) 
Osteoarthritis and related 
disorders (ORD) 
(n=57) 
Injury of bone and soft tissue 
and visceral pain  
(n=65) 
 TENS Sham TENS Sham TENS Sham 
Satisfied patients,  
% (rate)
 a
 
 
62.5 (10/16) 48.0 (12/25) 38.7 (12/31) 30.8 (8/26) 73.5 (25/34)* 48.4 (15/31) 
PCI b, retreating c  
(6-24) 
 
10.4 (4.5) 9.1 (2.9) 10.0 (3.2) 11.9 (4.8) 8.9 (3.7) 9.4 (2.9) 
Duration of pain  
(years)  
 
6.7 (5.2) 6.7 (6.0) 5.6 (7.8) 9.1 (11.7) 6.4 (6.6) 4.4 (3.7) 
Variation of  
pain intensity d  
9.7 (6.3) 11.3 (6.6) 11.9 (7.7) 10.7 (6.9) 11.7 (8.0) 11.1 (6.4) 
a not corrected for the effects of retreating , duration of pain or variation of pain intensity. 
b Pain Coping Inventory, c modified retreating subscale (see text).  
d SD of VAS scores in baseline week.  
* Indicates significant difference (Х2=4.33, p=0.037) between TENS and sham TENS.  
 
Table 3.Proportions of patients satisfied with treatment result for TENS and sham 
TENS and mean scores (SD) of predictors arranged by type of pain diagnoses 
 
Predicting patients’ satisfaction with treatment result (willingness to 
continue treatment)  
Descriptive data of the predictors are presented in Table 3, arranged by 
type of pain diagnoses. As can be seen by the odds ratios in Table 4, both 
for the ORD-group as for the PNP-group, the chance that patients were 
satisfied and willing to continue treatment was less for high frequency 
TENS. However, for patients with higher sum scores of the modified 
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retreating scale of the PCI the chance for continuing treatment was 
greater for high frequency TENS. As regards patients of the PNP-group, 
longer duration of pain increased the (diminished) chance for willingness 
to continue high frequency TENS. Independent of treatment modality, 
greater variation of pain intensity during the base-line week resulted in a 
greater chance in continuing treatment. 
 
Variable ORs (95% CI) P-value 
Treatment*ORD a 0.12 (0.04-0.43) 0.001 
Treatment*PCI b retreating c 1.18 (1.07-1.31) 0.001 
Treatment*PNP d 0.06 (0.006-0.67) 0.022 
Treatment*duration*PNP d 1.40 (0.94-2.08) 0.099 
Variation of pain intensity e 1.05 (1.0-1.10) 0.066 
Treatment: TENS=1, sham TENS=0. Percentage concordant: 69.5%.  
a Osteoarthritis and related disorders.  
b Pain Coping Inventory.  
c modified retreating subscale (see text). 
d Peripheral neuropathic pain. e SD of VAS scores in baseline week. ORs: odds ratios; 95% CI: 
95% confidence intervals. 
 
Table 4. Logistic regression report predicting willingness to continue treatment. 
 
Predicting pain (VAS) 
Results of predicting pain intensity are shown in Table 5. Treatment 
modality or interactions with treatment modality did not predict intensity 
of pain as a result of treatment. Pain intensity (adjusted for baseline 
values) was predicted by resting (PCI subscale) scores (negative), and 
pain disability (PDI) scores (positive). Perceiving reduction of pain by 
decreasing activities and resting, or with performing activities, relaxation 
exercises and distraction from pain, were positive predictors of pain 
intensity.  
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Variable 
Regression 
Coefficient Standard Error t-value Probability Level 
Mean baseline pain intensity, VAS a 0.80 0.09 8.62 <0.001 
PCI, resting b -2.24 0.56 -3.99 <0.001 
PDI c, total sum score 0.50 0.15 3.22 <0.002 
Perceiving pain reduction by resting 11.31 3.83 2.95 <0.004 
Perceiving pain reduction by activities 10.31 4.67 2.21 0.028 
Model: F(5.146)=26.19. P<0.001. R2=0.47.  
a Visual analogue scale. 
b subscale “resting” of Pain Coping Inventory. 
c Pain Disability Index. 
 
Table 5. Multiple linear regression report predicting VAS score on day 14 (after 
one week of treatment) 
 
Discussion 
 
The results of our study show that predicting the effect of high frequency 
TENS depends on the choice of outcome measure. The chance that 
patients were satisfied with high frequency TENS treatment was reduced, 
both for pain related to osteoarthritis and related disorders as for 
peripheral neuropathic pain, whereas for patients, who retreat more 
because of arousal when in pain (modified retreating scale of the PCI), the 
chance was increased. Only for chronic pain because of bone or soft tissue 
injury the proportion of patients satisfied with treatment result was 
significantly higher for high frequency TENS compared to sham TENS 
(Table 3).  
However, contrary to patient’s satisfaction with treatment result, pain 
intensity as result of treatment was not explained by treatment modality. 
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Furthermore, pain catastrophizing and depressive mood did not predict 
treatment outcome. 
As hypothesized - based on results of animal research [15] - we found 
that peripheral neuropathic pain was a negative predictor for results of 
high frequency TENS. A possible explanation is that high frequency TENS 
as applied in the present study, decreases nociceptive input in the dorsal 
horn by means of selectively stimulating large diameter afferent neuron 
fibers [40], resulting in activating inhibitory interneurons in lamina II. This 
A-fiber mediated inhibition is diminished in rats with sectioned nerves 
[41], probably by apoptosis of inhibitory interneurons as a result of 
peripheral nerve injury [42]. Only for this group we found that with 
increasing duration of the existing pain, the chance of patients to be 
satisfied with treatment result augmented; whether this results from 
adaptive changes in the nervous system in the course of time, or that 
these patients are satisfied with less gain, needs further investigation. 
We expected pain in osteoarthritis and related disorders to be a positive 
predictor for high frequency TENS treatment, but instead, it appeared a 
negative predictor. In a review [2] conclude that high frequency TENS is 
shown to be effective in pain control over sham TENS in the treatment of 
osteoarthritis of the knee. However in our study,  - as can be deduced by 
the data from table 2 – a proportion of 73% of the patients in this group 
suffered from severe osteoarthritis of the vertebral column, with only 6/21 
(29%) and 7/21 (33%) of the patients satisfied with high frequency TENS 
and sham TENS treatment respectively. Accordingly, in a comparable 
 129 
 
group of patients with chronic low back pain, [43] found poor results from 
high frequency TENS treatment as well. A possible explanation is that 
inflammation near to the dorsal root and even a minor lesion of articular 
structures of the vertebral column is found to induce changes in 
neurotrophic factors in the dorsal root neurons [44-46]. These neuropathic 
changes might impair the working mechanisms of high frequency TENS, 
however this needs verification. 
Patients who retreat because of arousal when in pain, benefit from TENS 
treatment (modified retreating scale, PCI). As mentioned before, we 
assume higher scores reflect higher levels of nociceptive pain; in which 
TENS is found to be effective, for review see [8]. However, this modified 
scale needs further validation.  
Independent of treatment modality, baseline variation in pain intensity 
influences patients’ satisfaction in treatment result, with increased pain 
variation resulting in greater chance of success of treatment. This is in 
accordance with the results of [16], who found that TENS in un-modulated 
pain is less effective. We assume that higher rates in fluctuation of pain 
intensity reflect a greater availability of inhibitory controls. Furthermore, 
participating in a study will heighten the sensitivity and vigilance of the 
patients, thereby increasing the detection of beneficial improvements 
[47], especially when pain intensity fluctuates, improvements are more 
likely to be noticed by the patients and attributed to treatment effect. 
Only for chronic pain because of injury of bone and soft tissue (including a 
minor group of visceral pain disorders), the proportion of patients satisfied 
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with treatment result was significantly higher for high frequency TENS 
compared to sham TENS (Table 3). This cannot easily be explained by the 
influence of the other predictors of patients’ satisfaction, as can be seen 
by the data in Table 3. 
 
Predicting pain (VAS) 
For predicting pain intensity (VAS), as a result of high frequency TENS or 
sham TENS application, treatment modality does not show any 
interference. So, in the present study intensity of pain seems not to be 
influenced differently by either TENS or sham TENS treatment. After 
treatment, patients who were more disabled because of pain and those 
perceiving control of pain (by resting, performing activities and distraction 
from pain) have higher pain intensity scores than less disabled patients 
and those not perceiving control. Presumably, those patients already 
experiencing control of their pain seem to tolerate more pain during either 
TENS or Sham TENS treatment or benefit less from either treatment 
modality. Furthermore, patients who seek more rest because of their pain 
manifest less pain, as a result of either Sham TENS or TENS treatment. 
 
Predictors found in other studies 
Other factors predicting less effect of TENS treatment, described in the 
study of Lampl et al, were marked depression, and pain qualities as 
stabbing, pulsating, paroxysmal and electrifying pain. Marked depression, 
as predictor was not found in the present study, which could be due to the 
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low depression score, explained by the exclusion of patients indicated for 
psychological treatment. Whereas for the various pain qualities, this 
agrees with our findings as these symptoms are more common in patients 
with neuropathic pain than those with non-neuropathic pain [48].  
In a previous study in our centre, catastrophizing proved to be a factor 
explaining pain reduction by radiofrequency lesioning of the cervical spinal 
dorsal ganglion [21]. Catastrophizing did not explain pain or patients’ 
satisfaction with treatment result in the present study, although the study 
was performed with the same measure (PCL) and only slightly different 
scores in both studies (mean and (SD): 45.5 (13.9) and 43.9 (14.9)). A 
possible explanation could be that both TENS and sham TENS, stimulated 
a perception of pain control because patients handled their (sham) TENS 
devices themselves, thus diminishing the feeling of helplessness about 
pain, which is a major characteristic of catastrophizing [49].  
 
Predicting pain versus predicting patients’ satisfaction 
Most striking is the fact that predictors for pain intensity differ from those 
who predict patients’ satisfaction with treatment result, both in nature as 
in interaction with treatment modality. Although closely related, these two 
outcome measures differ because patients’ satisfaction comprises the 
considerations of the relevancy of the experienced improvements for the 
patient (e.g. for the pain that was most annoying, threatening, disturbing 
or disabling), whereas the VAS score reflects a measure of pain intensity 
perceived at a fixed time of the day. As described before [24] the satisfied 
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patients exhibited on average a 28.5% pain reduction, which signifies a 
clinical important relief of pain [50]. Patients’ satisfaction might therefore, 
predict clinical important relief of pain.  
 
Strong and weak points of the study  
High frequency TENS was applied in a standardized way and a main 
outcome measure was patients’ satisfaction with result of treatment, 
which would have warranted the relevance for daily practice. Furthermore 
compliance (registered operation time of the device) was not different for 
the TENS or sham TENS group, and there was only a weak correlation 
between the actual and perceived treatment application (i.e. TENS or 
sham TENS), as reported previously [24].  
The main purpose of this study was to explore the effects of the origin of 
pain on the result of high frequency TENS in chronic pain. However the 
classification of the origin of pain may have flaws. Especially, the 
difference between the PNP group and the injury group (IBST) may be 
arguable, as a large proportion of the patients in the latter group 
developed chronic pain after surgery (see Table 2), and it is assumed that 
neuropathic pain is the most common type of post surgical pain [51]. 
Although there were no signs of sensory loss, we cannot fully exclude the 
existence of neuropathic pain in this group, as there is no gold standard 
for defining neuropathic pain [52]. However it would mean that the effect 
of high frequency TENS on PNP is not definite, because contrary to the 
PNP group, in the postsurgical pain group high frequency TENS performed 
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significantly better than sham TENS (see, Table 3 and 2, respectively). 
Interestingly, TENS is found to reduce postoperative analgesic 
consumption [53]. However, there is a need for the development of a 
mechanism-based classification of pain [54, 55].  
 
We conclude that predicting the effect of high frequency TENS in chronic 
pain depends on the choice of outcome measure. Predicting patients’ 
satisfaction with treatment result is related to the origin of pain: both, 
peripheral neuropathic pain and osteoarthritis, especially of the vertebral 
column negatively predict treatment outcome; whereas injury of bone and 
soft tissue (especially postsurgical pain disorder) is a positive predictor. 
Predicting changes in pain intensity following treatment reflects 
mechanisms of pain behavior and perceived control of pain, independent 
of treatment modality. Pain catastrophizing did not predict TENS 
treatment outcome. 
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Introduction 
 
Transcutaneous electrical nerve stimulation (TENS) is an easy to use non-
invasive intervention for the treatment of chronic pain. Although TENS 
treatment has existed since the early 1970s, randomized placebo 
controlled studies show inconclusive results in the treatment of chronic 
pain [1, 2]. Recently, we found no differences in time courses for clinical 
pain relief between patients using real or sham TENS during ten days of 
application - however the proportion of patients willing to continue 
treatment for both groups differed significantly in favor of real TENS [3]. 
These similar time courses for pain relief for real and sham TENS could be 
explained by assuming that TENS operates via a placebo response.  
It is well known that the deceptive administration of a placebo treatment 
leading to expectation of pain relief may result in a significant placebo 
analgesic effect, for review see Price et al [4]. Importantly, placebo 
response in TENS treatment has been said to range from less than 40% to 
more than 60% [5].  
However, in animal research, less subject to placebo effects, TENS effects 
have also been studied and documented extensively, for review see Sluka 
and Walsh [6]. Thus TENS reverses hyperalgesia induced by carrageenan 
inflammation when stimulation is applied in the hyperalgesic segments, as 
expected by the gate control theory postulated by Melzack and Wall [7]. 
In view of these positive animal results we must consider the alternative 
explanation that the pain reductions in patients treated with TENS vs. 
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sham TENS might be achieved by different underlying mechanisms of 
neuroplasticity. Thus pain reduction as a result of a placebo response (i.e. 
sham TENS application) would be initiated through activation of central 
descending inhibitory controls [4], while for real TENS, analgesia would be 
achieved by reversing hyperalgesia via peripheral nerve stimulation in the 
segments of pain: i.e. via spinal gate control[7, 8]. This would result in 
increased pain thresholds in the stimulated spinal segment, whereas in 
case of a placebo response pain thresholds would be expected to increase 
both in and outside the stimulated segment. 
 
The aim of this pilot study is to use quantitative sensory testing to explore 
changes in pain processing during sham vs. real TENS in patients with 
chronic pain; by measuring pain thresholds inside vs. outside the 
stimulated segment for TENS vs. sham TENS. 
 
Methods 
 
Subjects 
Patients with chronic pain referred to the Pain Centre UMC St Radboud 
and who were eligible for TENS treatment were asked to participate in this 
study. Patients were included in this study after giving informed consent. 
Inclusion criteria were: 1) patients with chronic non-cancer pain referred 
to the Pain Centre, 2) duration of pain > 6 months, 3) age above 18 
years. Exclusion criteria were: 1) previous TENS treatment, 2) pain in face 
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or head, 3) several different pain sites, 4) history of a cerebral vascular 
accident (because possible spinothalamocortical pathway damage could 
affect the outcome of TENS – and possibly sham TENS treatment, too), 5) 
no assistance at home – e.g. relatives or friends - to help replace or 
connect the electrodes, thus jeopardizing optimal TENS use), 6) 
involvement in ongoing litigation because of their pain [9]. For this study 
twenty consecutive patients were recruited. The Central Committee on 
Research Involving Human Subjects approved this study. 
 
Design 
We performed a prospective, randomized and controlled study comparing 
real versus sham TENS, for an intervention period of ten days. A 
concealed block-wise randomization procedure was used, and patients, 
therapists and research assistants were blinded for treatment allocation. 
Electrical pain thresholds (EPT) were determined after instruction and the 
delivery of the device, after the first 20 min of the intervention and after a 
period of ten days of daily real/sham TENS application.  
 
Randomization procedure and concealment of allocation 
The researcher assigned consecutive numbers to patients eligible for this 
study when they agreed to participate in this study. An independent 
statistician at the department of Epidemiology & Biostatistics generated 
the randomization list with SAS/STAT® Software, applying block sizes 
randomly of 1-3 patients. A research assistant, whose only task was to 
 143 
 
deliver the TENS or sham TENS devices to the patients, used this list 
together with the numbers assigned to the patients to determine 
treatment allocation. To further guarantee concealment, patients were 
asked to leave their treatment device with the receptionist before visiting 
the researcher for evaluating treatment effect. An experienced research 
assistant not aware of treatment assignment or result of treatment 
performed all electric pain threshold (EPT) measurements. Both the 
researcher and research assistants made no inquiries concerning 
stimulation intensity levels or experienced sensations.  
 
Apparatus 
For real TENS and sham TENS treatment, identical devices (ELPHA II 
1000, Danmeter A/S, Denmark) were used, which were specially prepared 
for this study to meet the specifications described below. For both 
channels, TENS pulse frequency was set to 80 Hz (optimal stimulation 
frequency according to Sjolund et al, 1985 [10]) and pulse width to 50 s 
(mainly stimulating A-beta neuron fibers according to Li and Bak, 1976 
[11], consistent with the gate control theory [7]). TENS stimulation was 
used in continuous mode (no modulation of pulse frequency or pulse width 
and no restricted stimulation duration). Other installed stimulus programs 
were blocked. On the devices’ display, the current intensity level was 
visible. Pulses were delivered with an asymmetrical biphasic waveform in 
a continuous pattern. Maximum output was 40 mA constant current at a 
minimum of 2.0 kOhm electrode resistance. Sham TENS devices showed a 
 144 
 
maximum of 10 mA on the display (under the perception threshold of the 
patients), but no current was actually delivered to the electrodes. 
Duration of actual use of the device (referred to as “compliance”) was 
registered and could be read out by pressing a special key combination; 
patients were not aware of this feature. Disposable 5 cm  6.4 cm self-
adhesive electrodes were used with an active area of 6.5 cm2.  
 
Placebo suggestion 
Patients eligible for TENS treatment received written information in which 
they were asked to participate in the study. In the letter, it was explained 
that TENS seems to be effective in treating chronic pain at high and low 
treatment intensities, and that treatment would be by one of these two 
options. There would also be a chance of receiving a sham TENS device in 
which the settings of pulses were neither effective nor harmful. After 
inclusion, details of the TENS treatment procedure were explained. 
Patients were told that “chronic pain is due to changes in the central 
nervous system, which function as an amplifier for pain stimuli, and that 
TENS would serve as a control button for this amplifier by using specific 
nerve stimulation”. 
 
General procedure 
After application of the electrodes and instruction regarding treatment 
intervention by a pain centre physiotherapist, the patient visited the 
independent research assistant who delivered the real TENS or sham 
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TENS device and briefly demonstrated its application. In case of real TENS 
she let the patient experience the tingling, but not pricking, sensation and 
explained this as “high intensity TENS”. In case of sham TENS she 
demonstrated that the device showed a maximum output of 10 mA on the 
display, which was under the perception threshold of the patient and she 
explained this as “low intensity TENS”. Immediately hereafter in another 
room, the electric pain thresholds were determined by another research 
assistant. Next the research assistant left the room and the patient 
switched on the device, as instructed. After 20 min of treatment 
application (real/sham TENS) the research assistant returned for the 
second pain threshold measurements and subsequently the patient left 
the outpatient clinic. Patients were instructed to use the TENS device 
during the whole day for a period of ten days. After this period patients 
returned for evaluation and final pain threshold measurements. 
 
Outcome measures 
 
Primary outcome measure 
The primary outcome was the electrical pain threshold (EPT). Using a QST 
device (Digistim, Biometer A/S, Copenhagen, Denmark) electric pulses 
(square wave pulses; stimulation rate: 100Hz, pulse duration: 0.2ms) 
were applied to the skin with increasing intensity (ramping at 0.5 mA/s.) 
starting after a pseudorandomized interval, after the device was switched 
on, to prevent anticipation effects. One pair of self-adhesive electrodes 
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(3M, Red Dot; circular stimulation area, diameter: 2 cm) was placed 
within the area of most pain (inside the segment of pain) and another pair 
was placed outside the area of pain (e.g. for pain complaints in the lower 
back and left leg these electrodes were placed on the distal dorsal part of 
the right forearm, and for pain in the upper right part of the body these 
electrodes were placed on the distal ventral part of the left foreleg). The 
first moment when the stimulus intensity became painful, pain threshold 
was detected and the current was stopped. During the test, all subjects 
were seated in a comfortable chair. To familiarize the patients with the 
measurements a trial assessment was conducted first. Subjects were 
trained until they were acquainted with the procedure and variability 
between measurements was smaller than 20%. The sites of 
measurements were marked to ensure the position for the next QST 
measurements.  
 
Secondary outcome measures 
By using a pain diary, pain intensity (VAS, 0-100) was measured on the 
same time every day, during one week (from Friday till Friday) before 
intervention and one week during intervention. Time duration of operation 
of the device at home (compliance) was registered automatically when the 
device was in operation, patients were not aware of this function. 
Furthermore, after the final evaluation patients were asked which 
treatment (real TENS /sham TENS), in their opinion, they had received; 
further called “perceived treatment”.
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Statistical methods 
Baseline characteristics were analyzed using parametric or non-parametric 
tests as appropriate for continuous data and Chi-square tests for 
dichotomous data. Ratings of EPT data were transformed into natural 
logarithmic values to obtain a lognormal distribution. Baseline EPT values 
(measured after device delivery) were analyzed for main effects of gender 
(m/f), received treatment (real TENS/sham TENS), perceived treatment 
(real TENS /sham TENS) and site of EPT measurements (inside vs. outside 
the segment(s) of pain), using ANOVA.  
To explore the differences in the time courses for EPT’s, the first step was 
to perform a RMANOVA with the EPT values (after delivery of the device, 
after 20 min of treatment and after ten days of treatment) as the 
repeated measure and received treatment (real /sham TENS) as fixed 
factor. The second step was to perform RMANOVA separately for EPT’s 
inside and outside the stimulated segments. Post-hoc testing was 
performed to test differences in time per treatment modality (TENS and 
sham TENS) using paired t-tests. 
Differences in compliance were analyzed using ANOVA, with hours of 
device operation at home as dependent, and received treatment and 
perceived treatment as fixed factors.  
Differences in changes in pain intensities for both treatment modalities 
were analyzed using paired t-tests. Differences between both treatments 
were analyzed using an ANOVA with the difference of mean VAS scores of 
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baseline and treatment period as dependent and received treatment or 
perceived treatment as fixed factors.  
 
Results 
 
Subjects (Baseline characteristics) 
Twenty patients (13 men and 7 women), aged 49.1 ± 10.2 years (mean ± 
SD) participated in this study. There were no significant differences 
(P>0.4) in mean VAS baseline scores for pain intensity for real TENS (63 
± 10 mm; mean ± SD) compared to sham TENS (62 ± 13 mm; mean ± 
SD), neither for duration of pain complaints (7.1± 6.5 years; mean ± SD 
and 9.3 ± 8.4 years respectively), disability because of pain (Pain 
Disability Inventory, [12]) (4.1 ± 1.4 (mean ± SD) and 3.5 ± 1.6 
respectively) or age (49.6 ± 9.4 years (mean ± SD) and 48.6 ± 12 years 
respectively). Baseline characteristics per patient are shown in Table 1.  
 
Baseline EPT values 
Baseline EPT-values (ln-transformed) differed significantly for factors 
“received treatment” (1.2 mA ± 0.2 (mean ± SEM) for sham TENS and 
1.9 mA ± 0.2 for real TENS; F=8.1, P=0.007) and gender (1.8 mA ± 0.1 
(mean ± SEM) for male and 1.0 mA ± 0.2 for female; F=12.03, P=0.001), 
but not for site of EPT measurements (1.5 mA ± 0.2; (mean ± SEM) for 
measurements inside the stimulated segment and 1.6 mA ± 0.2 for 
measurements outside the stimulated segment ; F=0.13, P=0.71) or 
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“perceived treatment” (1.4 mA ± 0.5 (mean ± SEM) for sham TENS and 
1.5 mA ± 0.2 for real TENS; F=0.12, P=0.73).  
Baseline EPT-values analyzed separately for measurements inside and 
outside the stimulated segment revealed a significant effect for the factor 
treatment for EPT values outside the stimulated segment (1.2 mA ± 0.2 
(mean ± SEM) for sham TENS and 2.1 ± 0.2 (mean ± SEM) for TENS; 
F=7.0, P=0.016), but not for EPT values inside the stimulated segment of 
pain (P=0.17). For gender there were no significant effects outside the 
stimulated segment of pain (P=0.15), however inside the stimulated 
segment females had significant lower pain thresholds compared to males 
(0.7 mA ± 0.3 (mean ± SEM) for females and 1.9 mA ± 0.2 (mean ± 
SEM) for males; F=12.7, P=0.002). 
 
Effects of treatment and site of measurement 
Differences in time courses of EPT values according to site were analyzed 
for effects of treatment, using the within-subjects effects. The sphericity 
assumption was not met so the Huynh-Feldt correction was applied for 
analysis of the within effects. There was a significant interaction of time 
course of EPT values with treatment (EPT*treatment; F=4.48, P=0.026), 
and a significant between-subjects effect for treatment (F=4.88, 
P=0.033).  
 
Subsequently, RMANOVA was performed separately for measurements 
inside and outside the segments of stimulation. For measurements inside 
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the segment of stimulation it showed no significant interaction of time 
course of EPT values with treatment (EPT*treatment; F=0.06, P=0.89). 
For measurements outside the segment of stimulation there was, 
however, a significant interaction of time course of EPT values with 
treatment (EPT*treatment; F=10.23, P=0.002). Post-hoc testing revealed 
a significant decrease of EPT values over time for TENS patients (time 
point one compared to three; P=0.032 and time point two compared to 
three P=0.02) and a significant increase for sham TENS patients (only for 
time point one compared to three; P=0.039). In addition, there were no 
significant changes in EPT values for TENS or sham TENS inside the 
stimulated segment (P>0.4). Time course of EPT values during TENS and 
sham TENS are shown in Figure 1. 
 
Compliance (hours of device operation during treatment at home) 
There were no differences in use of real TENS vs. sham TENS (132.4 
±23.4 h (mean ± SEM) and 100.7±15.3 h respectively; F=1.28, P=0.27) 
or differences in treatment as perceived by the patients (113.0±11.2 h 
(mean ± SEM) for (perceived) real TENS and 120.0±25.7 h for 
(perceived) sham TENS; F=0.062, P=0.81). 
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Pain intensity 
There was a significant difference in VAS scores for the treatments as 
perceived by the patients (mean VAS baseline–mean VAS perceived treatment: -4.5 
mm ± 5.9 (mean ± SEM) for (perceived) sham TENS and + 11.2 mm ± 
3.1 for (perceived) real TENS; F=6.64, P=0.023), however not for the 
actual received treatments (F=0.38, P=0.54).  
 
Discussion 
 
This study revealed evidence for different mechanisms of analgesic effects 
for real TENS compared to sham TENS in patients with chronic pain. 
Strikingly, in the real TENS group baseline EPT values were significantly 
higher outside the segment of stimulation compared to the sham TENS 
group. For real TENS, EPT values subsequently decreased significantly 
outside the segment of stimulation, whereas for sham TENS these values 
increased. For both treatment modalities there were no differences or 
changes in time for EPT values inside the segment of stimulation.  
 
Our results suggest that not finding a difference in clinical effect size (i.e. 
pain intensity) between TENS and sham TENS does not necessarily mean 
that the experimental treatment is merely the result of a placebo effect. In 
the present study we were able to demonstrates differing underlying 
mechanisms via different time courses of pain thresholds for real vs. sham 
TENS application, suggesting different underlying mechanisms of pain 
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modulation. These results underline the importance of studying 
mechanism-reflecting parameters in addition to symptoms in pain 
research.  
 
As already noted, baseline EPT values for the real TENS group were 
significantly higher for measurements outside the segment of stimulation 
compared to the sham TENS group. It seems unlikely that these 
differences are the result of chance, because there were no baseline 
differences between patients in the real and sham TENS group for any of 
the other pain characteristics (pain intensity, pain disability, duration of 
pain complaints) or age. Differences in expectation of pain relief because 
of brief exposure to real TENS during the delivery of the device and 
possibly resulting in unmasking treatment allocation, also seems unlikely 
because there were no differences in baseline EPT values for perceived 
treatment – i.e. what patients thought they have been treated with. 
Furthermore, there was no difference in hours of real TENS vs. sham 
TENS use during treatment at home, which would be expected when belief 
in TENS treatment in the real TENS group was greater compared to 
patients in the sham TENS group. Finally, there were no differences in 
pain thresholds for gender outside the segment of stimulation. However, 
short stimuli, both painful [13] and non-painful [14], are able to affect 
pain sensitivity. Moreover, TENS application of only 20-30s decreases 
spontaneously and noxiously evoked cell activity in convergent dorsal horn 
cells [15, 16]. Therefore we postulate that the difference in baseline EPT 
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values for the real vs. sham TENS group is the result of the short 
demonstration stimulation period during delivery of the device, 
immediately after which baseline measures were carried out, resulting in 
an increase of EPT’s only found in the area outside the segment of 
stimulation  
 
The subsequent increase in pain thresholds in the sham TENS group for 
measurements outside the segment of stimulation is compatible with the 
concept of central descending inhibitory control induced by expectation of 
pain relief in placebo application. However, the lack of segmental increase 
of the pain threshold in the segment of stimulation for the TENS group is 
not in keeping with the concept of induced spinal segmental inhibitory 
control as hypothesized in the gate control theory[7, 8]. Whether the 
initially increased pain thresholds outside the segments of pain for TENS, 
which decreased in time, are the result of increased inhibitory control in 
the segments of pain, is not clear. In animal research evidence for central 
descending inhibitory effects of high frequency TENS is inconclusive 
[17],[18]; this issue needs further exploration.  
 
In this study we performed pain threshold measurements by 
transcutaneous electrical stimulation to explore the time courses of 
excitatory or inhibitory processes during real/sham TENS application. 
Quantitative sensory testing has been used to evaluate differences in pain 
sensitivity between defined clinical populations and healthy controls, and 
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is considered useful in formulating mechanism-based diagnostic categories 
for pain disorders [19]. Transcutaneous electrical stimulation is a well-
established and easy to use technique in human quantitative sensory 
testing, whose stability, controllability, reliability and simplicity of use 
makes it well suited for patients in the clinical context [20, 21]. It has 
been shown that human thresholds to transcutaneous electrical 
stimulation are sensitive to central excitatory as well as inhibitory 
phenomena, both clinically and experimentally [22, 23]. Every effort was 
made in this study to ensure the validity and reproducibility of the 
threshold measures, including careful instruction and training.  
Because of the small sample size, restrictions must be kept in mind when 
applying our results to more general populations. The restricted statistical 
power may be responsible for the negative results; especially finding no 
significant difference between TENS and sham TENS for pain threshold 
values inside the stimulated segments, which showed a trend for a mean 
difference of approximately 30%. Therefore a larger study is needed to 
permit definitive conclusions. 
 
In this study females reported significantly lower baseline EPT values than 
males, indicating sex differences in pain perception consistent with 
previous studies [19]. Improvements in perceived pain intensity were not 
different for patients receiving real compared to sham TENS, but were 
different according to what patients thought they had received; patients 
who thought they were treated with TENS reported improved pain 
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intensity, whereas patients who questioned the authenticity of the TENS 
treatment showed a small, non-significant increase in pain intensity. 
 
Conclusion 
 
Although subjective pain relief did not differ significantly for real vs. sham 
TENS in the treatment of chronic pain, our study revealed evidence for 
different underlying analgesic mechanisms. By comparing time courses of 
EPTs, we found that measurements outside the stimulated segment 
increased EPT values with sham TENS, whereas for real TENS these values 
decreased. There were, however, no differences for measurements inside 
the stimulated segment. Our results illustrate the importance of including 
mechanism-reflecting parameters in addition to symptoms when 
conducting pain research. Clearly, the results of our pilot study need to be 
confirmed and elaborated by larger studies. 
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Chapter 7 
 
General discussion  
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Introduction  
 
Transcutaneous electric nerve stimulation (TENS) is an easy to use 
application for the treatment of patients with chronic pain. Apart from pain 
relief, TENS has been found to give rise to less pain interference with 
work, home and social activities, increased activity level and pain 
management and decreased use of other therapies including pain 
medication [1]. However the effects of TENS in chronic pain raise two 
important questions. Firstly, the results of randomized placebo controlled 
studies in the treatment of chronic pain are inconclusive [2, 3], therefore 
questioning the specific working mechanism of TENS. Secondly, repeated 
application of TENS would diminish the efficacy of treatment in time, 
thereby endangering the long term use of TENS in chronic pain [4, 5]. 
Here we will discuss our main findings concerning our main thesis 
questions. 
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Main results 
 
Is there a difference in time course or mechanism for pain relief 
between TENS and sham-TENS application in patients treated for 
chronic pain? 
The short-term results of our randomized placebo controlled clinical trial, 
comparing TENS and sham TENS, showed a small but significant 
difference in the proportions of patients willing to continue treatment after 
an initial treatment period, in favor of the TENS group. There were 
however no differences in the time courses of pain intensities between 
TENS and sham TENS.  
For the long term results we found no differences between TENS and 
sham TENS, during one year; neither in the proportions of patients willing 
to continue treatment, nor in the time courses of pain intensity.  
For both groups the largest improvements occurred within the first three 
months and these results remained stable thereafter, while little 
medication was used by the patients, especially in the TENS group. 
Contrary to our results, Johnson and Martinson[6] recently found, in 
reviewing the efficacy of electrical nerve stimulation for chronic 
musculoskeletal pain, a highly significant reduction in pain intensity for 
electrical nerve stimulation compared to placebo. They stated that 
previous equivocal results may have been due to underpowered studies 
(and reviews). Our study possibly lacked statistical power. We assumed 
that 35% of the patients of the TENS group and 15% of the sham TENS 
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group would be satisfied after one year, however after one year we found 
that 30% and 23% of the patients were satisfied with TENS and sham 
TENS respectively. By enlarging the study, the difference in proportions of 
patients might reach the level of significance, however, if we consider the 
similar time courses of pain intensity for TENS and sham TENS in our 
study, we may not expect to find a significant difference, suggesting the 
same working mechanisms for TENS and sham TENS - i.e. a placebo 
response.  
The short term differences in the proportion of patients willing to continue 
treatment could then be attributed to a stronger suggestion through TENS 
- or unmasking of the allocation - because of the tingling sensation 
experienced during operation of the TENS device compared to the absence 
of any sensation during sham TENS application [7]. However, this 
assumption is not in accordance with our findings. 
 
Considering unmasking of the treatment allocation; we only found a weak 
correlation between the received treatment application and the application 
as it was perceived by the patients (i.e. TENS or sham TENS). Although 
we have little comparable data – blinding is rarely tested in placebo 
controlled trials [8, 9] – our data seem comparable to the results of the 
TENS study of Deyo [7]; the only TENS study in which blinding of patients 
was tested. Furthermore, we found no difference in operation time of the 
device between the TENS and sham TENS group. Therefore we assume 
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that our data indicate that for the patients sham TENS was a trustworthy 
treatment application and unmasking does not seem to be an issue. 
Importantly, by comparing the time courses of electrical pain thresholds in 
our pilot study, we found qualitative different processes, revealing 
evidence for different underlying analgesic mechanisms for real TENS vs. 
sham TENS in the treatment of chronic pain. Compared to sham TENS, the 
pain thresholds were increased for TENS immediately after the first short 
stimulation period (during the delivery of the TENS device), which findings 
are in accordance with results of TENS in animal research [10] – TENS 
results in an immediate depression of activity of high threshold and wide 
dynamic range neurons in the dorsal horn. In contrast, the time courses of 
pain thresholds in sham TENS increased gradually over time. To discuss 
an alternative hypothesis we first describe the state of the art of the 
placebo mechanisms. 
 
Placebo mechanisms 
The placebo effect has evolved from being thought of as a nuisance in 
clinical research [11, 12], to a biological phenomenon worthy of scientific 
investigation in its own right [13]. Based on results of brain imaging 
studies [14-16], Wager [17] proposed that placebo is an active brain 
process with a substantial cognitive and evaluative component, not simply 
a reporting bias or passive adaptation. Moreover, there is now direct 
evidence that placebos activate endogenous opioids [18]. Also direct 
biochemical evidence now exists supporting the involvement of reward 
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circuitry and dopamine in the placebo effect in patients with Parkinson’s 
disease [19, 20]. De la Fuente-Fernandez [21-23] proposed that 
expectation of benefit is equivalent to the expectation of reward, which 
triggers placebo responses by activating reward mechanisms in which 
dopamine plays a central role. 
The placebo response may be driven by many different environmental 
factors involved in the context of a patient, factors that influence patients’ 
expectations, desires and emotions [24]. Environmental and psychosocial 
determinants of placebo response include verbal suggestion, conditioning 
and behaviors manifested by healthcare providers [24]. Verbal 
suggestions that induce certain expectations of analgesia induce larger 
placebo responses than those inducing uncertain expectations; the study 
of Pollo et all [25] showed that subtle differences in the verbal context of 
the patient may have a significant impact on the magnitude of the 
response. Expectancy theory [25-29] and conditioning [30-33] have 
become the most popular theories of the placebo effect. Placebo 
responses are mediated by expectation when conscious physiological 
processes such as pain and motor performance are involved, whereas 
they are mediated by conditioning when unconscious physiological 
functions are involved [34]. Although expectancy seems to be an 
important psychological mediator of placebo effects, desire (e.g. desire to 
reduce ongoing pain), is also likely to be involved in placebo phenomena 
[24]. Based on the studies of Geers et al [35] and Vase et al [36], Price et 
al [24] proposed a model of placebo mechanism wherein goals, desire, 
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expectation, and consequent emotional feelings [28, 37, 38], e.g. 
decrease of state anxiety [38] , codetermine the placebo response. In 
addition there is evidence that the degree of somatic focus has a 
moderating influence on these psychological factors [35, 39]. Lundh [39] 
proposed a cognitive-emotional model of the placebo effect in which 
placebo suggestions for improvements in physical health lead individuals 
to attend selectively to signs of improvements. 
Before discussing our hypothesis concerning the mechanisms of effect in 
our study, it is important to distinguish between the true placebo response 
and other mechanisms commonly attributed to the placebo effect.  
 
Placebo mechanisms vs. a specific effects of TENS treatment 
Patients receiving placebos may have improved, for a variety of reasons 
other than a causal connection between the placebo and the outcome [24, 
40, 41]. These may include natural history, regression to the mean in 
repeated measurements and biased patients reports ( to “please” the 
physician or investigator) which occur in controlled trials independent 
whether a placebo group is involved [41-44]. In our study we expect the 
effects of natural history and regression to the mean to be small, as 
patients referred to the Pain Centre had to wait for three months before 
being seen, during which time their pain remained stable [45]. 
Furthermore, pain reduction started promptly with the beginning of 
treatment. Especially in the short term results these effects may therefore 
be negligible. Whether we succeeded in preventing biased patients reports 
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is more difficult to evaluate, but these would have occurred in both group 
of patients. However patient-reported outcome measures are considered 
objective and congruent with laboratory measures [46].  
 
An alternative hypothesis for the effects of TENS and sham TENS  
Although it is assumed that in double-blind, placebo-controlled trials the 
placebo effects are reduced, as compared with placebo effects in 
treatments in clinical practice, because patients know there is a chance of 
receiving a sham treatment and therefore reducing the expectation of 
benefit [25, 47], 43% of the patients receiving sham TENS experienced 
sufficient pain relief to continue treatment. Therefore we may assume that 
expectation of pain relief was sufficient to induce a placebo response, 
which then should have occurred in patients in both the sham TENS and 
TENS group. However, this does not explain our findings concerning the 
different time courses of pain thresholds during TENS and sham TENS 
application.  
We may expect that, induced by expectation of pain relief, the pain 
thresholds will have been increased before the start (device delivery) of 
TENS and sham TENS. However, we have no baseline measures of pain 
threshold before TENS or sham TENS delivery to compare with, so we 
cannot confirm nor reject this assumption. The differences in pain 
thresholds in favor of TENS compared to sham TENS immediately after the 
initial application (with the device delivery) could be explained by the 
specific TENS effect – segmental inhibitory control by stimulating large 
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diameter neuron fibers [48, 49], resulting in immediate depression of 
activity of high threshold and wide dynamic range neurons in the dorsal 
horn [10]. The gradual increase of pain thresholds - and the concurrent 
decreasing pain intensity - during the ten days of application of sham 
TENS could be the result of a learning phenomenon [50], in which patients 
learn to control their pain. Because of expectation of pain relief, the 
patient will focus on improvements and in this condition variation in pain 
intensity - a positive predictor for treatment effect in our study - will 
moderate treatment effect by increasing the expectation of a successful 
treatment with every experienced pain diminution, which consequently will 
be attributed to the (sham) TENS application. To put it differently: 
experienced moments of decreased pain intensity - reflecting momentary 
increases of inhibitory control of nociceptive transmission in the central 
nervous system – may, under the circumstances mentioned above, act as 
an unconditioned response, and because of the repeated association with 
the sham TENS device, the application of the device itself will become the 
conditioned stimulus, which then is capable to elicit a conditioned 
response (pain relief, by increasing inhibitory control). This learning 
process is facilitated by an increased dopamine level, induced by the 
reward circuitry. Our findings concerning the short and long term use of 
the sham TENS device is in accordance with this hypothesis. 
In case of the TENS application, expectation of pain relief would facilitate 
the results of the specific effects of TENS (through increased dopamine 
levels), i.e. increasing segmental inhibition of nociception by stimulating 
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large neuron fibers, which increase in inhibitory control is illustrated by 
the increased pain thresholds for TENS compared to sham TENS, after 
device delivery. Furthermore, we suppose that variation in pain intensity 
will amplify the experiences in improvement, enhancing patient’s believe 
in a successful treatment and resulting in a cumulative decrease in 
experienced pain intensity as measured by the VAS.  
Interestingly, after the initial trial period, we no longer found differences 
in pain thresholds, reflecting a similar amount of inhibitory control, albeit 
achieved by different pathways. Not surprisingly, after this period we also 
found no differences in any outcome measure for patients in both groups 
during one year. However, as mentioned before, there was a difference in 
proportion of patients who were satisfied with treatment result in favor of 
TENS compared to sham TENS, after the initial trial period. This 
difference, in our opinion, reflects the availability of optimal conditions for 
the mechanisms of effect of TENS or sham TENS application. This will 
bring us to the subject of the predictors of effect of TENS vs. sham TENS. 
 
Which pain characteristics determine the effect of high-frequency 
TENS? 
For this purpose we explored the effects of the origin of pain (nociceptive, 
inflammatory or neuropathic) and cognitive coping strategies and mood 
on predicting short-term results of high-frequency TENS compared to 
sham TENS in the treatment of chronic pain. We choose the origin of pain 
as predictor, because animal research indicated that high-frequency TENS 
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would be successful in inflammatory and nociceptive pain, but not in 
neuropathic pain.  
For patient’s satisfaction with treatment result the only positive predictor 
we found, in favor of TENS compared to sham TENS, was retreating 
(because of arousal) when in pain. We suppose, based on the increased 
pain thresholds in patients using the TENS application compared to sham 
TENS during the initial treatment period, that TENS resulted in an 
immediately diminished level of arousal. While focusing on relief of 
symptoms, the relief of symptoms of arousal would have been interpreted 
as proof for effect of treatment - thus increasing their believe in an 
effective treatment - which subsequently resulted in a better outcome for 
these patients. However we do not have data, concerning the level of 
arousal measured during and after the initial trial period to confirm or 
reject this hypothesis, so this issue needs further exploration.  
 
As expected, peripheral neuropathic pain appeared to be a negative 
predictor for TENS compared to sham TENS. In rats, as described in 
Chapter 4, in a peripheral neuropathic pain model no evidence was found 
for effect on mechanical pain threshold for high-frequency TENS, when 
applied in the segments of pain, at the side of the nerve ligation. Probably 
because A-fiber mediated inhibition is diminished in rats with sectioned 
nerves [51], as a result of impaired inhibition by GABAergic interneurons 
in the spinal dorsal horn [52]. However, this would mean that for the 
neuropathic pain group the placebo effect was the only effect in both the 
 172 
 
TENS and sham TENS group and therefore the results should not be 
different between both applications. However, neuropathic pain appeared 
to be a negative predictor only in interaction with treatment (TENS 
compared to sham TENS). So, for peripheral neuropathic pain our results 
mean that high-frequency TENS negatively interacts with the pain 
relieving mechanisms of the placebo response. Interestingly, using a 
spinal nerve ligation procedure in rats, Carlson et al [53] demonstrated 
that both on- and off-cells in the rostroventromedial medulla (RVM) are 
sensitized to innocuous (and noxious mechanical) stimuli after nerve 
injury. They stated that RVM pain-modulating neurons, like the dorsal 
horn, are sensitized to tactile stimulation after nerve injury and therefore 
contribute to allodynia (and hyperalgesia) of neuropathic pain states. 
Because TENS stimulates the innocuous, large diameter neuron fibers in 
the area of pain, we suppose that under these circumstances TENS 
therefore negatively interacts with the mechanisms of pain relief induced 
by the placebo response.  
 
Unexpectedly, pain in osteoarthritis and related disorders appeared to be 
a negative predictor for effect of TENS compared to sham TENS. However 
in our study 73% of the patients in this group suffered from severe 
osteoarthritis of the vertebral column, with only 6/21 (29%) and 7/21 
(33%) of the patients satisfied with high-frequency TENS and sham TENS 
treatment respectively. Importantly, inflammation near to the dorsal root 
and minor lesions of articular structures of the vertebral column induce 
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changes in expression of neurotrophic factors in dorsal root neurons [54-
56]. Conditioning stimulation of large diameter neuron fibers (low 
intensity, high-frequency TENS, as used in our study) excites small, 
GABAergic, interneurons in the substantia gelatinosa of the spinal dorsal 
horn that, under normal conditions, exert inhibitory effects on presynaptic 
nerve terminals [49]. This inhibitory effect is the result of a moderate 
depolarization of the terminals of primary afferents, by GABA. However, 
under conditions of inflammation, depolarization at primary afferent C 
fibers may become steeper and stronger and eventually this would cause 
presynaptic excitation, instead of inhibition [52, 57]. In this condition of 
increasing nociceptive transmission TENS would negatively interact with 
the pain relieving effects of “expectations of pain relief”.  
So for both the osteoarthritis group and the neuropathic pain group, the 
pain sensitivity might have been increased by TENS. However, neither of 
these diagnoses groups was a predictor for pain intensity as result of 
treatment. Interestingly, patients not responding to treatment, used their 
devices significantly shorter when allocated to the TENS group compared 
to the sham TENS group, possibly this reflects the experience of an 
unpleasant feeling during electrical stimulation. However, experienced 
sensations during application of the TENS device were not evaluated or 
discussed - to avoid the risk of unmasking treatment allocation - therefore 
we have no data to explore this assumption. 
Importantly, the large number of patients expressing the characteristics of 
neuropathic pain and severe osteoarthritis of the vertebral column - i.e. 
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58% (47/81) of the patients in the TENS group - will have contributed to 
the small differences in effects between TENS compared to sham TENS, 
especially because in neuropathic pain, the placebo response is not 
decreased [58]. Only the results of the third diagnosis group - reflecting 
chronic pain of nociceptive origin – were significant better for TENS 
compared to sham TENS. 
 
Catastrophizing did not explain intensity of pain as a result of treatment or 
patients’ satisfaction with treatment result, in our study. This would mean 
that catastrophizing did not interact with the specific TENS effects nor with 
the specific placebo effects, during the initial trial period. Several reasons 
may have contributed to this result. First of all the procedure to evaluate 
short term effects may have added to this effect. Patients knew that after 
the trial period they had to decide whether pain relief was sufficient to 
continue treatment or not. This will have focused patient’s attention on 
relief of pain, instead of on deterioration of pain, as with catastrophizing 
thoughts, and will have enabled the effects of TENS and expectation of 
pain relief as described above. A second reason involves the feeling of 
control of pain; by handling the TENS device themselves, patients may 
have experienced control over their pain, especially when they experience 
relief, therefore reducing helplessness and fear of pain.  
 
Contrary to the prediction of patients’ satisfaction with treatment result, 
the prediction of pain intensity as a result of treatment was not related to 
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treatment. This is also well illustrated by the time courses of pain 
intensity; patients willing to continue treatment after the initial treatment 
period showed similar curves, regardless whether they were treated with 
TENS or sham TENS [59]. We found that patients satisfied with treatment 
result and willing to continue treatment after the initial treatment period, 
achieved a clinical important relief of pain [59]. Therefore, patients’ 
satisfaction as described in our study yields predictors that express a 
clinical important impact on pain relief. 
 
Does the pain relief as a result of TENS decrease in time by long-
term TENS application? 
The survival curves of satisfied patients suggest a decline of effect for 
long-term TENS as well as sham TENS application. However, our analysis 
of the time course of pain intensity for satisfied and not-satisfied patients 
for both treatment groups does not show a decline of pain diminution for 
patients of the TENS or sham TENS group. Instead, we find a decrease in 
pain intensity for both satisfied and not satisfied patients during the year. 
Furthermore, pain medication did not increase. However the degree in 
which pain intensity decreased, differed significantly for satisfied 
compared to not-satisfied patients. So, it seems that after a certain 
treatment period some patients judged their pain improvement as not 
sufficient anymore and were no longer satisfied with treatment result. 
However, these results are not consistent with the results in animal 
research where repeated application of either low- or high-frequency TENS 
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leads to a development of tolerance to its antihyperalgesic effects after 4 
days of daily treatment. Repeated administration of TENS with alternating  
frequency (low frequency on 1 day; high-frequency on the next day) 
delays the development of analgesic tolerance compared with 
administration of low- or high-frequency TENS independently. 
Furthermore a once-a-week schedule was more effective than higher 
frequencies of application. This application is quite contrary to our daily 
schedule of high-frequency TENS. This difference in result may be 
attributed to differences in pain mechanisms between human and animal. 
Especially from a psychological point of view, there is a huge difference for 
an animal compared to a patient concerning the context of the TENS 
application. For an animal the TENS application will be perceived as a 
stressor, in which a repeated application may induce an adaptive 
response, thus suppressing the TENS response i.e. the antihyperalgesic 
effects. However in patients with chronic pain the expectation of pain 
relief may facilitate the inhibitory control induced by TENS and possibly 
decreases tolerance by blocking CCK-receptors in the spinal cord. This 
latter assumption needs to be explored. 
 
Main Conclusions 
We conclude that in chronic pain of nociceptive origin, high-frequency 
TENS is more effective than sham TENS, however this is not true for 
chronic pain of neuropathic origin or in osteoarthritis of the vertebral 
column. 
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The analgesic effects of TENS and sham TENS are accomplished by 
different underlying mechanisms. The optimal pain relief is achieved after 
2-3 months and contrary to animal research, there is no proof for 
decrease in analgesic effects by repeated TENS application. 
A placebo response induced by sham TENS may last for one year and has 
the magnitude of effect similar to a real TENS treatment. 
Catastrophizing does not influence the analgesic effects of TENS or sham 
TENS in patients with chronic pain. 
 
Future pain research 
Future studies in the treatment of pain should aim at the interaction of the 
treatment stimuli and the expectations of the patient. 
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Summary  
 
Chapter 1 
In the general introduction we describe the main thesis questions 
concerning TENS in the treatment of chronic pain.  
TENS treatment has been used since the early 1970s, however, short-
term results of placebo-controlled studies of TENS treatment in patients 
with chronic pain are still inconclusive, and long-term placebo-controlled 
studies have not been executed. Furthermore, patients with chronic pain 
have reported a decline in TENS efficacy during long-term application, 
which would make TENS less suitable for the treatment of chronic pain.  
There are several causes that may account for the inconclusive results: 
the difficulty of blinding of patients to the assigned intervention, high 
placebo responses and inappropriate treatment application, because of 
short stimulation periods or inadequate stimulation parameters.  
The aim of this thesis is to explore the effects of high frequency TENS 
compared to sham TENS (placebo) application in patients with chronic 
pain, in which we answer the following research questions: 1) Is there a 
difference in time course for pain relief between TENS and sham-TENS 
application in patients treated for chronic pain? 2) Does the pain relief as 
a result of TENS decrease in time by long-term TENS application? 3) 
Which pain characteristics determine the effect of high frequency TENS? 
4) Do the mechanisms of pain relief differ for TENS compared to sham 
TENS application.  
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To answer these questions we performed a randomized placebo-controlled 
trial (N=165) in which we compared the results of high-frequency TENS 
and sham TENS, for a maximum period of one year.  
 
Chapter 2 
In this chapter we describe the (short term) results of high frequency 
TENS vs. sham TENS for pain intensity and satisfaction with treatment 
result after ten days of treatment. One hundred and sixty three patients 
with chronic pain, referred to the Pain Centre, entered the study. 
Conventional (high-frequency) TENS and sham TENS were applied in the 
segments of pain, for a period of ten days. Outcome measures were pain 
intensity (VAS) and the proportion of patients satisfied with treatment 
result and willing to continue treatment (yes or no). The proportions of 
patients satisfied with treatment result, differed significantly for TENS 
compared to sham TENS (58% and 42,7% respectively, chi square=3.8, 
p=0.05). However, no differences in pain intensity were found for patients 
treated with TENS or sham TENS. Only for patients satisfied with 
treatment result pain intensity gradually decreased equally both for TENS 
and sham TENS with repeated treatment application. Mean proportion of 
relief in pain intensity, for patients willing to continue treatment, was 
28.5%. We found a significant (chi square =13.2, p<0.001) but weak 
association (phi=0.28) between the applied treatment and the perceived 
treatment. 
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Conclusions: the efficacy of short-term TENS treatment depends on the 
choice of outcome measure. Effects on pain improve in time with repeated 
daily application of TENS or sham TENS. 
 
Chapter 3 
Here we show the long-term results of our study comparing TENS and 
sham TENS application in the treatment of chronic pain. Main outcome 
measures are the proportion of patients satisfied with treatment result 
and willing to continue treatment, pain intensity, pain disability and 
perceived health status.  
Survival analysis of time courses of proportions of satisfied patients 
revealed no significant differences (p=0.79; log-rank test) for TENS 
treatment compared to sham TENS. After one year, 30% (24/81) of the 
patients of the TENS group and 23% (19/82) of the sham TENS group 
were satisfied with treatment result. These patients experienced a mean 
overall improvement of 62.7% (n=43). This effect was not significantly 
different between both groups. For satisfied patients, there were no 
differences in pain intensity or disability and perceived health status 
between the TENS and sham TENS group. TENS/sham TENS use, 
expressed in the cumulative hours of device operation, was also not 
different between both groups, during one year.  
Conclusions: TENS and sham TENS show similar effects in patients with 
chronic pain over a period of one year. We found no evidence for decline 
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of treatment effect over time for TENS, but we did find support for long-
term placebo effects for sham TENS. 
 
Chapter 4 
Here we describe the results of a literature survey of TENS in animal 
research, to explore the effects of TENS characteristics on hyperalgesia in 
nociception, inflammation and nerve ligation. 
The conclusions of this survey are that for the acute pain model high-
frequency (80 Hz and 100 Hz) low intensity TENS (primarily activating A-
beta neuron fibers) is effective in reducing activity in the spinal cord of 
wide dynamic range (WDR) and high threshold (HT) neurons, the number 
of fos-like immunoreactivity neurons, in delaying the withdrawal 
responses and suppressing spinal field potentials, during noxious 
stimulation (NS) by mechanical, electrical or heat stimuli. When both A-
beta and A-delta fibers are stimulated in 1Hz bursts of high-frequency 
stimuli trains, effects are more prolonged. For all studies TENS stimulation 
was applied in the segment of NS.  
The results for the inflammatory pain model show that primary and 
secondary hyperalgesia, induced by inflammation, decreases by both 
high- and low-frequency TENS application, when it is applied ipsilateral as 
well as contralateral to the side of the inflammation. Effects are 
independent of stimulus intensities, however, stimulation of deep large 
afferent neuron fibers is required. Repeated administration of both low 
and high frequency TENS leads to a development of opioid tolerance. 
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The effects of both and high- and low-frequency TENS are explained by 
reduced activity of the WDR and HT neurons in the dorsal horn, the 
involvement of the rostroventromedial medulla and by the activation of 
the ventrolateral periaqueductal grey. 
High-frequency TENS, but not low-frequency TENS increases extracellular 
GABA concentrations in the spinal cord. Both TENS applications have no 
effect on glycine concentrations in the spinal cord. 
In nerve ligation in rats, the mechanical pain threshold can be increased 
by high-frequency TENS, when it is applied in the paraspinal region of the 
related spinal nerves, contralateral (but not ipsilateral) to the side of the 
injured nerve, with stimulus intensity below the intensity which provokes 
a muscle contraction. Low-frequency TENS reduces mechanical allodynia 
and hyperalgesia, and thermal hyperalgesia (for heat, but not for cold 
hyperalgesia) when causing contractions of the muscles underlying the 
receptive field of the injured nerve. 
 
Chapter 5 
In this chapter we show the results of pain characteristics predicting 
effects of conventional TENS, in patients with chronic pain. The purpose of 
this study was to explore the effects of the origin of pain, cognitive coping 
strategies and mood on predicting short-term results of high-frequency 
TENS compared to sham TENS in the treatment of chronic pain.  
The results show that predicting the effect of high frequency TENS 
depends on the choice of outcome measure. The chance that patients 
were satisfied with high frequency TENS treatment was reduced, both for 
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pain related to osteoarthritis and related disorders - especially 
osteoarthritis of the vertebral column - as for peripheral neuropathic pain, 
whereas for patients who retreat more because of arousal when in pain 
(modified retreating scale of the PCI), the chance was increased. Only for 
chronic pain because of bone or soft tissue injury the proportion of 
patients satisfied with treatment result was significantly higher for high 
frequency TENS compared to sham TENS.  
However, contrary to patient’s satisfaction with treatment result, pain 
intensity as result of treatment was not explained by treatment modality. 
Furthermore, pain catastrophizing and depressive mood did not predict 
treatment outcome.  
 
Chapter 6 
Here we describe the results of a pilot-study (N=20) in which we used 
quantitative sensory testing to explore the mechanisms of TENS and sham 
TENS in the treatment of chronic pain, by measuring electrical pain 
thresholds (EPT) inside vs. outside the stimulated segment for TENS vs. 
sham TENS. Although subjective pain relief did not differ significantly for 
real vs. sham TENS in the treatment of chronic pain, by comparing time 
courses of EPTs we found for measurements outside the stimulated 
segment increased EPT values with sham TENS, whereas for real TENS 
these values decreased. There were, however, no differences for 
measurements inside the stimulated segment. Our study revealed 
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evidence for different underlying analgesic mechanisms for TENS 
compared to sham TENS. 
 
Chapter 7 
In the general discussion we discuss the findings of our research questions 
and the consequences for treatment and future research. We put 
emphasis on the recent research developments in the area of the placebo 
response, and the consequences of these developments for our study 
results. 
The main findings are that in chronic pain of nociceptive origin, high-
frequency TENS is more effective than sham TENS, however high-
frequency TENS does not outperform sham TENS in chronic pain of 
neuropathic origin or in osteoarthritis of the vertebral column. We found 
proof for the facts that the analgesic effects of TENS and sham TENS are 
accomplished by different underlying mechanisms, and that a placebo 
response induced by sham TENS may last for one year and may have the 
magnitude of effect similar to a real TENS treatment. 
The optimal pain relief during TENS/sham TENS treatment is achieved 
after 2-3 months, and contrary to animal research, there is no proof for 
decrease in analgesic effects by repeated TENS application. 
Finally, we found that catastrophizing does not influence the analgesic 
effects of TENS or sham TENS in patients with chronic pain. 
Future studies in the treatment of pain should aim at the interaction of the 
treatment stimuli and the expectations of the patient. 
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Samenvatting  
 
Hoofdstuk 1 
In de introductie beschrijven we de belangrijkste vragen met betrekking 
tot de behandeling van chronische pijn door middel van transcutane 
elektrische zenuwstimulatie (TENS).  
Hoewel TENS al sinds de beginjaren zeventig wordt toegepast voor de 
behandeling van patiënten met chronische pijn, zijn de behandelresultaten 
van placebo gecontroleerde studies op de korte termijn niet eenduidig en 
zijn er geen lange termijn studies uitgevoerd. Bovendien rapporteren 
patiënten met chronische pijn een afname van het effect bij langdurig 
TENS gebruik, wat de TENS-behandeling minder geschikt maakt voor de 
behandeling van chronische pijn.  
Er zijn verschillende oorzaken aan te wijzen die een verklaring kunnen 
geven voor de niet eenduidige resultaten: de moeilijkheid van het 
blinderen van de patiënt voor de toegewezen behandeling, de hoge 
placeboresponse en een inadequate behandeling, door te korte 
behandeltijd of niet-optimale stimulatieparameters. 
Het doel van dit proefschrift is om de effecten te onderzoeken van de 
behandeling van patiënten met chronische pijn door Conventional-TENS 
(high-frequency TENS) in vergelijking met sham-TENS (placebo), waarbij 
we de volgende vragen beantwoorden: is er een verschil in het beloop van 
de pijnvermindering tussen Conventional-TENS en sham-TENS bij 
patiënten die behandeld worden voor de chronische pijn? 2) neemt bij 
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langdurig TENS gebruik in de loop van de tijd de pijnvermindering af? 3) 
welke pijnkenmerken bepalen het effect van Conventional-TENS? 4) 
verschillen de werkingsmechanismen van de pijnvermindering tussen 
Conventional-TENS en sham-TENS van elkaar.  
Om deze vragen te beantwoorden voerden we een gerandomiseerd, 
placebogecontroleerd onderzoek uit (N=165), waarbij we de resultaten 
vergelijken tussen Conventional-TENS en sham-TENS over een maximale 
periode van een jaar. 
 
Hoofdstuk 2 
In dit hoofdstuk beschrijven we het kortetermijneffect van Conventional-
TENS t.o.v. sham-TENS. Honderd drie en zestig patiënten, die naar het 
pijncentrum verwezen waren, deden mee aan het onderzoek.  
Conventional-TENS and sham-TENS werden toegepast in de pijnlijke 
segmenten, gedurende tien dagen. De uitkomstmaten waren de 
pijnintensiteit (VAS), en het percentage patiënten dat tevreden is met het 
resultaat en door wil gaan met de behandeling. Het percentage tevreden 
patiënten was significant hoger voor TENS t.o.v. sham-TENS; 
respectievelijk 58% en 42,7% (Chi-kwadraat= 3,8; p=0,05). Maar wat 
betreft de pijnintensiteit waren er geen verschillen tussen TENS en sham-
TENS. Alleen bij patiënten die tevreden waren met het behandelresultaat 
nam de intensiteit van de pijn tijdens het dagelijkse behandelen geleidelijk 
en in gelijke mate af, voor zowel TENS als sham-TENS. Het gemiddelde 
percentage pijnvermindering voor deze patiënten was 28,5%. Verder 
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vonden we een significante, maar zwakke relatie (chi square =13.2, 
p<0.001; phi=0,28) tussen de daadwerkelijk uitgevoerde behandeling en 
de behandeling zoals de patiënt die ervaren heeft (TENS of placebo). 
Conclusie: de keuze van de uitkomstmaat heeft invloed op de effectiviteit 
van de kortdurende TENS-behandeling. Door het dagelijks behandelen 
neemt het pijnverminderend effect van TENS en sham-TENS toe. 
 
Hoofdstuk 3 
In hoofdstuk drie tonen we de resultaten van het langetermijneffect van 
onze studie, waarin we de effecten van de behandeling van chronische 
pijn met TENS en sham-TENS met elkaar vergelijken. De belangrijkste 
uitkomstmaten zijn: het percentage patiënten dat tevreden is met het 
resultaat van de behandeling en door wil gaan met de behandeling, de 
intensiteit van de pijn, de beperkingen als gevolg van de pijn en de 
ervaren gezondheid. Survival analyses van het beloop van de pijn liet 
geen significant verschil zien tussen TENS en sham-TENS (p=0.79; log-
rank test). Na een jaar waren 30% (24/81) van de patiënten van de 
TENS-groep en 23% (19/82) van de sham-TENS-groep tevreden met het 
resultaat. Deze patiënten ervoeren een overall verbetering van 62.7% 
(n=43). Dit effect verschilde niet significant tussen de beide groepen. 
Voor de patiënten die tevreden waren met het behandelresultaat, waren 
er geen significante verschillen tussen TENS en sham-TENS wat betreft de 
intensiteit van de pijn, de beperkingen als gevolg van de pijn en de 
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ervaren gezondheid. Het gebruik van het TENS-apparaat, uitgedrukt in het 
cumulatief aantal uren, verschilde ook niet gedurende het jaar. 
Conclusie: over een periode van een jaar zijn de resultaten van TENS en 
sham-TENS bij patiënten met chronische pijn gelijkwaardig. We vonden 
geen bewijs voor een afname van de pijnvermindering in de tijd, maar we 
vonden wel aanwijzingen voor een langdurig placebo-effect voor sham-
TENS. 
 
Hoofdstuk 4 
Hier beschrijven we de resultaten van een literatuurstudie over 
dierenexperimenteel onderzoek om de effecten te bestuderen van de 
TENS-variabelen op de hyperalgesie als gevolg van nocicepsis, ontsteking 
of het afbinden van een zenuw.  
De resultaten voor het nociceptive pijnmodel tonen dat high frequency (80 
Hz and 100 Hz) TENS met een lage stimulusintensiteit (waarbij 
voornamelijk A-beta zenuwvezels worden geactiveerd) effectief is: in het 
verminderen van de activiteit van wide dynamic range (WDR) en high 
threshold (HT) neuronen en het aantal fos-like immunoreactivity 
neuronen; in het vertragen van de terugtrekreactie en het onderdrukken 
van spinale field potentials, tijdens nocicepsis (door mechanische, 
elektrische of warmteprikkels). De effecten houden langer aan als er zowel 
A-beta als A-delta zenuwvezels worden gestimuleerd door middel van 1 Hz 
bursts van treintjes pulsen met een hoge interne frequentie. Bij alle 
studies werd TENS toegepast in het segment van de nociceptieve prikkel.  
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De resultaten van het ontstekingsmodel laten zien dat de primaire en 
secundaire hyperalgesie als gevolg van een ontstekingreactie, afnemen 
door zowel TENS met een hoge als lage frequentie, zowel als het wordt 
toegepast aan de ipsilaterale zijde als aan de contralaterale zijde van de 
ontsteking. De effecten zijn onafhankelijk van de intensiteit van de TENS, 
maar stimulatie van de diepe zenuwvezels is een vereiste. De herhaalde 
toepassing van TENS, zowel met een hoge als lage frequente, leidt tot 
opioïdtolerantie.  
De effecten van TENS, met een hoge en met een lage frequentie, zijn te 
verklaren door de verminderde activiteit van de van WDR en HT neuronen 
in de achterhoorn van het ruggenmerg en de invloed van de 
rostroventromediale medulla en het peri-aquaductale grijs.  
Door TENS met een hoge frequentie, maar niet met een lage frequentie 
neemt de extracellulaire concentratie van GABA in het ruggenmerg toe. 
Bij het neuropathische pijnmodel (door het afbinden van een zenuw) bij 
ratten neemt de pijnprikkeldrempel voor mechanische prikkels toe, t.o.v. 
een controlegroep, wanneer TENS met een hoge frequentie wordt 
toegepast aan de contralaterale (maar niet de ipsilaterale) zijde van de 
paravertebrale regio die gerelateerd is aan de aangedane zenuw. De 
gebruikte TENS-intensiteit ligt hierbij onder het niveau waarbij een 
spiercontractie optreedt. TENS met een lage frequentie, wanneer die 
wordt toegepast in het receptieve veld van de aangedane zenuwvezels 
met een intensiteit waarbij spiercontracties optreden, vermindert de 
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allodynia en hyperalgesie voor mechanische prikkels en de hyperalgesie 
voor warmte- maar niet voor koudeprikkels.  
 
Hoofdstuk 5 
In dit hoofdstuk beschrijven we de resultaten met betrekking tot de 
pijnkenmerken die het effect voorspellen van Conventional TENS, bij 
patiënten met chronische pijn. Het doel van dit onderzoek was de invloed 
van de oorzaak van de pijn naast cognitieve copingstrategieën en 
stemming te onderzoeken op het voorspellen van de kortetermijneffecten 
van Conventional-TENS bij de behandeling van chronische pijn. 
De resultaten laten zien dat het voorspellen van het effect afhangt van de 
keuze van de uitkomstmaat. De kans dat patiënten tevreden waren met 
het behandelresultaat door Conventional-TENS , was zowel kleiner voor 
pijnklachten samenhangend met artrose en gerelateerde aandoeningen – 
in het bijzonder artrose van de wervelkolom – als voor perifere 
neuropathische pijn, terwijl de kans dat ze tevreden waren groter was 
voor patiënten die zich meer terugtrekken vanwege pijngerelateerde 
arousal (een gemodificeerde schaal voor “terugreken” van de PCI). Alleen 
voor chronische pijn als gevolg van bot- en gewrichtsletsels was het 
percentage patiënten dat tevreden was met het resultaat significant hoger 
voor Conventional-TENS dan voor sham-TENS.  
In tegenstelling tot de patiëntentevredenheid over het resultaat, werd de 
pijnintensiteit als uitkomstmaat van de behandeling niet verklaard door de 
behandeling (TENS of sham-TENS). Voor beide uitkomstmaten werd het 
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resultaat van de behandeling niet voorspeld door de mate van 
catastroferen of depressieve stemming. 
 
Hoofdstuk 6 
In dit hoofdstuk bespreken we de resultaten van een pilotstudy, waarbij 
we quantitative sensory testing toepassen door elektrische 
pijnprikkeldrempels  te meten binnen ten opzichte van buiten het segment 
van stimulatie, voor Conventional-TENS ten opzichte van sham-TENS, om 
de mechanismen van beide interventies te onderzoeken. Hoewel de 
subjectieve pijnbeleving door de behandeling niet significant verschilde 
tussen Conventional-TENS en sham-TENS, vonden we door het vergelijken 
van het beloop van de pijnprikkeldrempels voor de metingen buiten het 
gestimuleerde segment, bij de sham-TENS groep een toename van de 
waardes van de pijnprikkeldrempel. Terwijl bij de patiënten die behandeld 
werden met Conventional-TENS deze waardes afnamen. Er waren echter 
geen verschillen in het beloop tussen TENS en sham-TENS voor de 
metingen binnen het segment van de stimulatie. Onze studie draagt 
hiermee bewijs aan voor een verschil in het onderliggende analgetische 
mechanisme tussen TENS en sham-TENS.  
 
Hoofdstuk 7 
In deze “General Discussion” bespreken we de bevindingen van onze 
onderzoeksvragen en de consequenties voor de behandeling en 
toekomstig onderzoek. We besteden aandacht aan de resultaten van 
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recente onderzoeken op het gebied van het placebo-effect en bespreken 
de consequenties van deze ontwikkelingen op onze onderzoeksresultaten.  
De belangrijkste bevindingen zijn dat Conventional-TENS bij de 
behandeling van chronische pijn van nociceptieve oorsprong effectiever is 
dan sham-TENS, maar dat bij chronische neuropathische pijn en 
chronische pijnklachten bij artrose van de wervelkolom TENS het niet 
beter doet dan sham-TENS. We vonden bewijs voor het feit dat de 
analgetische effecten van TENS en sham-TENS door verschillende 
onderliggende mechanismen tot stand komen en dat het placebo-effect 
door het gebruik van sham-TENS een jaar lang kan blijven bestaan. Het 
effect van sham-TENS is in grootte vergelijkbaar met het effect van 
Conventional-TENS. Het optimale effect op de pijnvermindering door 
TENS/sham-TENS wordt bereikt na 2-3 maanden behandelen en, in 
tegenstelling tot de resultaten van dierexperimenteel onderzoek, is er 
geen bewijs gevonden voor een afnemend effect op de pijn door 
regelmatige toepassing. Tot slot vonden we dat catastroferen geen invloed 
heeft op het analgetische effect van TENS dan wel sham-TENS bij 
patiënten met chronische pijn.  
Toekomstig onderzoek met betrekking tot de behandeling van pijn zou 
gericht moeten zijn op de interactie tussen de behandelstimuli (de keuze 
van de prikkels) enerzijds en de verwachting van de patiënt anderzijds. 
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dagen was genaderd. Dit gebeurde (puur toevallig) ook op een 
donderdag. Ik hoop dat je er geen spijt van hebt gekregen dat ik je nog 
gedurende meer dan 5 jaar van jouw emeritaat aan het werk hebt 
gehouden. Maar het is nu zover, ook je laatste promovendus heeft zijn 
boekje af. Ben, ik ben je zeer dankbaar voor alles wat je voor mij hebt 
gedaan. 
Prof. Rob Oostendorp, beste Rob het was voor mij meteen duidelijk dat jij 
er als begeleider van dit promotieonderzoek bij moest komen. Je zorgde 
vooral voor structuur en bewaakte het proces, wat onontbeerlijk was op 
die momenten dat het tegenzat en de vaart eruit dreigde te gaan. Dit 
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bleek ook het laatste halfjaar, waar jouw doortastende inzet er belangrijk 
toe bijdroeg dat de afronding toch ineens in een stroomversnelling 
terechtkwam. Rob, ik ben je daar heel erkentelijk voor. Natuurlijk heb ik 
ook jou langer aan het werk gehouden, maar al heb je nog wel enkele 
promovendi te gaan, mij kun je nu afstrepen.  
Oliver Wilder-Smith, beste Oliver met jouw komst naar ons Pijncentrum 
werd er een dimensie aan het pijnonderzoek toegevoegd en ik heb daar 
de vruchten van geplukt. De discussies over het onderzoek en over pijn 
waren en zijn een verrijking. 
Marianne van Leeuwen, beste Marianne, ik ben je dankbaar voor jouw 
advies en hulp bij het design van mijn studie en natuurlijk voor de 
buitengewoon plezierige samenwerking.  
Theo de Boo, beste Theo het klinkt misschien paradoxaal, maar naarmate 
mijn kennis over de statistiek toenam, leverde de gesprekken met jou mij 
meer op. Jouw onafhankelijke opstelling enerzijds en je interesse in de 
vraagstelling anderzijds heb ik zeer gewaardeerd. Je nuchtere opstelling 
heeft ook het spannendste moment van mijn onderzoek opgeleverd, toen 
je op een vrijdagmiddag na half vijf het mailtje met de eerste resultaten 
stuurde met de opmerking: “kijk er maar eens rustig naar, maandag 
spreken we elkaar wel verder”. Het waren ca 30 pagina’s, maar het leken 
er wel 100 en ergens tussen al die gegevens moest het antwoord staan op 
de vraag of er verschil was tussen de TENS en de placebo; ik heb me 
zelden meer verantwoordelijk gevoeld voor mijn onderzoek en de 
patiënten; een moment dat ik nooit meer zal vergeten. Ik ben jou en Wim 
 201 
 
Lemmens dankbaar voor jullie deskundige hulp en de prettige 
samenwerking.  
Han Samwel jij adviseerde mij over de psychologische vragenlijsten voor 
mijn onderzoek en Ria te Winkel zorgde ervoor dat de dozen vol met 
vragenlijsten die ik haar kwam brengen heel zorgvuldig tot een digitaal 
bestand werden geconverteerd, allebei hartelijk dank hiervoor. 
Al mijn (oud)collega’s van de fysiotherapieafdeling, wil ik heel hartelijk 
bedanken voor hun directe of indirecte hulp en steun bij de uitvoering van 
dit onderzoek, slechts enkelen zal ik hier noemen: 
Marianne Rombouts, jij verving mij bij mijn afwezigheid, met de 
zorgvuldigheid die jouw eigen is. 
Peter Paul Mazure, Michel ten Bokum en Quirine Anderegg jullie waren 
onmisbaar bij de uitvoering van de TENS-behandeling.  
Riet Doppen, samen met Marijke Hankel als jouw vervanger hadden jullie 
de verantwoordelijke taak de patiënten met evenveel overtuiging een 
echte TENS of een “Nepperd” te verstrekken; dit is jullie wonderbaarlijk 
goed gelukt!  
Toos, Murial en Annemarie, bedankt voor jullie hulp bij de logistieke en 
administratieve ondersteuning en het uitlezen van de TENS apparaatjes. 
Jorke de Witte, als toenmalig hoofd van de afdeling nam je het initiatief 
om bij NWO te informeren naar de uitslag van de subsidieaanvraag, 
omdat er maar geen bericht kwam. Bedankt hiervoor en voor je altijd 
warme belangstelling voor Annelies en mij. 
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Verder wil ik de patiënten bedanken die meegedaan hebben aan dit 
onderzoek, die ondanks hun lang bestaande en vaak hevige pijnklachten 
het risico wilden nemen om een placebobehandeling te loten met als veel 
genoemde reden: “als ik er dan geen voordeel van heb, dan hebben 
andere pijnpatiënten dat misschien wel”. 
En tenslotte Annelies: Mijn Liesje, jij hebt er vooral veel last van gehad 
dat “jouw Jan” de ambitie had om te gaan promoveren. Maar jouw 
kwaliteit als “plaatjes-hacker” was onbetaalbaar; als op het laatste 
moment, bij het indienen van een artikel, een figuur door een te lage 
resolutie of verkeerd format werd afgekeurd, dan had jij dat in korte tijd 
“gefixt”. Je bleef er al die tijd vooral nuchter onder en als we van het werk 
naar huis reden en ik belangrijk nieuws over het onderzoek wilde vertellen 
riep jij: “pas op, een fietser van rechts” of “het stoplicht staat op oranje” 
of iets dergelijks. Toen de promotiedatum al vrijwel zeker was, wachtte jij 
nog even om het in je agenda te noteren totdat het helemaal zeker was. 
Maar in vergelijking met de topprestaties die jij elke dag opnieuw moet 
volbrengen stelt mijn prestatie ook niet zoveel voor; want ook al kun je 
door je spierzwakte bijna niets, jij doet toch bijna alles en bij voorkeur 
voor iedereen! Nooit heb ik nog zo iemand ontmoet als jij: jij bent uniek!  
 
Ik heb gezegd, het boek is af, nu is het tijd voor een feestje: steek het 
vuurwerk maar af!  
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